<SEC-DOCUMENT>0001193125-24-012979.txt : 20240123
<SEC-HEADER>0001193125-24-012979.hdr.sgml : 20240123
<ACCEPTANCE-DATETIME>20240123160731
ACCESSION NUMBER:		0001193125-24-012979
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		26
CONFORMED PERIOD OF REPORT:	20240122
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240123
DATE AS OF CHANGE:		20240123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sight Sciences, Inc.
		CENTRAL INDEX KEY:			0001531177
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				800625749
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40587
		FILM NUMBER:		24552555

	BUSINESS ADDRESS:	
		STREET 1:		4040 CAMPBELL AVE,
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		(415) 889-0550

	MAIL ADDRESS:	
		STREET 1:		4040 CAMPBELL AVE,
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d715146d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sght="http://www.sightsciences.com/20240122" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-01-22_to_2024-01-22">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-01-22_to_2024-01-22">0001531177</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="sght-20240122.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2024-01-22_to_2024-01-22"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001531177</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-22</xbrli:startDate> <xbrli:endDate>2024-01-22</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-01-22_to_2024-01-22">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt:datemonthdayyearen">January&#160;22, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-01-22_to_2024-01-22">Sight Sciences, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-01-22_to_2024-01-22">001-40587</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-01-22_to_2024-01-22">80-0625749</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-01-22_to_2024-01-22">4040 Campbell Avenue</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-01-22_to_2024-01-22">Suite 100</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-01-22_to_2024-01-22">Menlo Park</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-01-22_to_2024-01-22">94025</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-01-22_to_2024-01-22">877</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-01-22_to_2024-01-22">266-1144</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-01-22_to_2024-01-22">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-01-22_to_2024-01-22">SGHT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-01-22_to_2024-01-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Entry into Hercules Term Loan Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On January&#160;22, 2024 (the &#8220;Closing Date&#8221;), Sight Sciences, Inc. (&#8220;Company&#8221; and collectively with any Company affiliates that are made party to the Loan Agreement, &#8220;Borrower&#8221;) entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Hercules Capital, Inc (&#8220;Hercules&#8221; or &#8220;Agent&#8221;) and certain affiliates of Hercules (collectively with Hercules, the &#8220;Lender&#8221;), which provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0&#160;million (the &#8220;Term Loan Facility&#8221;). An initial tranche of $35.0&#160;million (the &#8220;Initial Loan&#8221;) was funded under the Term Loan Facility on the Closing Date. In addition to the Initial Loan, the Term Loan Facility includes additional tranches available as follows: $5.0&#160;million available in a single draw through December&#160;15, 2024 (together with the Initial Loan, the &#8220;Tranche I Commitment&#8221;), $10.0&#160;million available to draw between the period commencing on the date that Agent, receives evidence in form and substance reasonably satisfactory to it that Borrower has achieved certain performance milestones, and ending on September&#160;15, 2025, and $15.0&#160;million available for Borrower to draw through the interest only period (an initial period of 30 months from the Closing Date which may be extended to 36 months based on achieving certain performance milestones) in increments of $5.0&#160;million, subject to the sole approval of Lender&#8217;s investment committee (the &#8220;Tranche Loans&#8221;, and together with the Initial Loan, the &#8220;Term Loans&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Each Term Loan draw is subject to standard conditions precedent, including absence of any events of default and Borrower&#8217;s continued compliance with the terms and provisions of the Loan Agreement. The Term Loan Facility has a maturity date of July&#160;1, 2028 (the &#8220;Maturity Date&#8221;). Upon repayment of the Term Loans (whether at Maturity Date or upon earlier prepayment), Borrower is required to pay an exit fee equal to 5.95% of the originally funded Term Loans. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Borrower&#8217;s net proceeds from the Initial Loan were $34.6&#160;million, after deducting estimated debt issuance costs, fees and expenses. On the Closing Date, the Company repaid the Borrower&#8217;s prior term loan from MidCap (as defined in Item 1.02 below) including payment of certain termination fees and other expenses incurred in connection therewith (as described in Item 1.02 below) in the aggregate amount of $37.7&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Rate, Facility Charge, Warrant Coverage and Right to Invest </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Term Loan Facility will accrue interest at a floating annual rate based on the greater of (i) 10.35% or (ii)&#160;the Wall Street Journal prime rate plus 2.35%. Accrued interest on the Term Loans is payable monthly in arrears. Upon an event of default under the Loan Agreement, the interest rate will automatically increase by an additional 3.0% per annum. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Term Loan Facility includes a 0.75% facility charge on the Tranche I Commitment due at Closing Date. A facility charge of 0.75% will be charged on additional Tranche Loans at the time of funding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On the Closing Date, the Company will issue a warrant to Lender to purchase that number of shares of the Company&#8217;s common stock equal to two percent of Initial Loan, or $700,000, divided by the volume-weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s common stock for the <span style="white-space:nowrap">five-day</span> period preceding the Closing Date. The Company will issue additional common stock warrants to Lender at the closing of future Tranche Loans, if any, to purchase that number of shares of common stock equal to two percent of the applicable Tranche Loan divided by the VWAP of the Company&#8217;s common stock for the <span style="white-space:nowrap">five-day</span> period preceding the applicable Tranche Loan closing date. Each warrant shall be exercisable for seven years from date of issuance and shall be tradeable in accordance with the provisions of Rule 144 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">While the Term Loans remain outstanding, Borrower shall use commercially reasonable efforts to grant to Lenders the option to invest up to a total of $3&#160;million in Borrower&#8217;s next round of equity offering, if any, broadly marketed to multiple investors on the same terms, conditions and pricing offered to investors in such subsequent equity financing. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Prepayment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Borrower is entitled to prepay the Term Loans at any time, subject to a prepayment premium equal to (a) 3.0% of the amount so prepaid, if such prepayment occurs during the first twelve months following the Closing Date, (b) 2.0% of the amount so prepaid, if such prepayment occurs during the second twelve months following the Closing Date, (c) 1.0% of the amount so prepaid thereafter. Prepayment is not applicable in circumstances in which Hercules or an affiliate of Hercules refinances its own debt. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Security </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the Loan Agreement, all of Borrower&#8217;s obligations under the Term Loan Facility are secured by a perfected first priority security interest in substantially all of its existing and after-acquired assets, subject to customary exceptions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Representations, Warranties, Covenants, and Events of Default </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Loan Agreement contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, events of default and other provisions and conditions that are customarily required for similar financings. The affirmative covenants, among over things, require Borrower to undertake various reporting and notice requirements and an obligation to maintain and enforce certain rights, approvals and assets. The negative covenants restrict Borrower&#8217;s ability to, among other things and subject to certain exceptions contained in the Loan Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers and acquisitions; change Borrower&#8217;s business activities; and make investments or restricted payments, in each case subject to customary exceptions. The negative covenants also restrict Borrower&#8217;s ability to change its fiscal year, repay certain indebtedness, engage in certain affiliate transactions, or enter into, amend or terminate any other agreements that has the impact of restricting Borrower&#8217;s ability to make loan repayments under the Loan Agreement. In addition, Borrower must meet certain minimum cash and revenue covenants as outlined below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Minimum Cash Covenant: Borrower is required to maintain an unrestricted cash balance (&#8220;Minimum Cash Requirement&#8221;) of at least 85% of total Secured Obligations. Upon Borrower&#8217;s achievement of certain performance milestones, the Minimum Cash Requirement shall be reduced to 35% of the total Secured Obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Minimum Revenue Covenant: Upon achievement of certain performance milestones and tested monthly, Borrower must maintain an amount of trailing <span style="white-space:nowrap">six-month</span> GAAP revenue equal to 80% of the revenue forecast approved by the Company&#8217;s Board of Directors and provided to Lenders. The testing of the Minimum Revenue Covenant shall be waived at any time in which either: a) the Company maintains unrestricted cash equal to 100% of the total Secured Obligations, or b) the Company maintains unrestricted cash equal to 70% of the total Secured Obligations and maintains a market capitalization of at least $400,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing summary of the Term Loan Facility is not complete and is qualified in its entirety by reference to the full text of the form of warrant and the Loan Agreement, copies of which are filed as Exhibit 4.1 and Exhibit 10.1, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> (this &#8220;Current Report&#8221;) and are incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Capitalized terms not otherwise defined in this Current Report shall have the meanings ascribed to them in the Loan Agreement. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Termination of a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Termination of MidCap Term Loan Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">In connection with the entry into the Loan Agreement with Lenders, Borrower&#8217;s Amended and Restated Credit and Security Agreement, dated November&#160;23, 2020 (as amended, the &#8220;Prior Credit Agreement&#8221;), with MidCap Financial Trust (&#8220;MidCap&#8221; and together with certain affiliates of MidCap, the &#8220;Prior Lenders&#8221;) was terminated, effective as of the Closing Date, the payment and other obligations of Borrower under the Prior Agreement were discharged, and Prior Lenders&#8217; security interest in the Company&#8217;s assets and property was released. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;2.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Creation of a Direct Financial Obligation or an Obligation under an <span style="white-space:nowrap">Off-Balance</span> Sheet Arrangement of a Registrant </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Information set forth in Item 1.01 of this Current Report is incorporated by reference into this Item 2.03. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Information set forth in Item 1.01 of this Current Report is incorporated by reference into this Item 3.02. The warrants were issued pursuant to an exemption from the registration requirements under Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On January&#160;23, 2024, the Company issued a press release announcing its entry into the Loan Security Agreement described above. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The information contained under Item 7.01 of this Current Report (including Exhibit 99.1), shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d715146dex41.htm">Form of Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d715146dex101.htm">Loan and Security Agreement, dated January&#160;22, 2024, by and among Sight Sciences, Inc., certain affiliates of Hercules Capital, Inc., and Hercules Capital., Inc.+ </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d715146dex991.htm">Press Release, dated January&#160;23, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Portions of this exhibit are redacted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish an unredacted copy of such exhibit, or a copy of any omitted schedule or exhibit, to the Securities and Exchange Commission upon request. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Sight Sciences, Inc.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Date: January&#160;23, 2024</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">By:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:justify">/s/ Alison Bauerlein</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d715146dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;), OR ANY
STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL)
REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">To Purchase
Shares of the Common Stock of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of January&nbsp;22, 2024 (the &#147;<U>Effective Date</U>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, SIGHT SCIENCES, INC., a Delaware corporation (the &#147;<U>Company</U>&#148;), has entered into a Loan and Security Agreement dated
as of January&nbsp;22, 2024 (as amended and in effect from time to time, the &#147;<U>Loan Agreement</U>&#148;) with [__________]. [__________] (the &#147;<U>Warrantholder</U>&#148;), and the lender parties thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Loan Agreement and as additional consideration to the Warrantholder for, among other things, its agreements in the
Loan Agreement, the Company has agreed to issue to the Warrantholder this Warrant Agreement, evidencing the right to purchase shares of the Company&#146;s Common Stock (this &#147;<U>Warrant</U>&#148;, &#147;<U>Warrant Agreement</U>&#148;, or this
&#147;<U>Agreement</U>&#148;, and together with any additional Warrants issued upon any permitted transfer of this Warrant hereunder, collectively, the &#147;<U>Warrants</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the Warrantholder having executed and delivered the Loan Agreement and provided the financial
accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and the Warrantholder agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. </B>GRANT OF THE RIGHT TO PURCHASE COMMON STOCK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to the number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock equal to the Number of Shares (as defined below). The
Exercise Price (defined below) of such shares is subject to adjustment as provided in Section&nbsp;8. As used herein, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Act</U>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Charter</U>&#148; means the Company&#146;s Certificate of Incorporation or other constitutional document, as may be
amended and in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the Company&#146;s common stock,
$0.001 par value per share, as presently constituted under the Charter, and any class and/or series of Company capital stock for or into which such common stock may be converted or exchanged in a reorganization, recapitalization or similar
transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exercise Price</U>&#148; means $5.159, subject to adjustment from time to time in accordance with
the provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liquid Sale</U>&#148; means the closing of a Merger Event in which the
consideration received by the Company and/or its shareholders, as applicable, consists solely of cash and/or Marketable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Marketable Securities</U>&#148; in connection with a Merger Event means securities meeting all of the following
requirements: (i)&nbsp;the issuer thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), and is then current in its
filing of all required reports and other information under the Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by the Warrantholder in connection with the Merger Event were
the Warrantholder to exercise this Warrant on or prior to the closing thereof is then traded on a national securities exchange or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and
(iii)&nbsp;following the closing of such Merger Event, the Warrantholder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the issuer&#146;s shares and/or other securities that would be received by the
Warrantholder in such Merger Event were the Warrantholder to exercise this Warrant in full on or prior to the closing of such Merger Event, except to the extent that any such restriction (x)&nbsp;arises solely under federal or state securities laws,
rules or regulations, and (y)&nbsp;does not extend beyond six (6)&nbsp;months from the closing of such Merger Event (except for any restrictions as a result of Warrantholder&#146;s status as an Affiliate (as defined in Rule 144 (as defined below))
of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Event</U>&#148; means any of the following: (i)&nbsp;a sale, lease or other transfer of
all or substantially all assets of the Company, (ii)&nbsp;any merger or consolidation involving the Company in which the Company is not the surviving entity or in which the outstanding shares of the Company&#146;s capital stock are otherwise
converted into or exchanged for shares of capital stock or other securities or property of another entity (other than a merger or consolidation effected exclusively to change the Company&#146;s domicile), or (iii)&nbsp;any sale by holders of the
outstanding voting equity securities of the Company in a single transaction or series of related transactions of shares constituting a majority of the outstanding combined voting power of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Number of Shares</U>&#148; means [135,686] shares of Common Stock, subject to adjustment from time to time in
accordance with the provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchase Price</U>&#148; means, with respect to any exercise of
this Warrant, an amount equal to the then-effective Exercise Price multiplied by the number of shares of Common Stock as to which this Warrant is then exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. </B>TERM OF THE AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term of this Agreement and the right to purchase Common Stock as granted herein shall commence on the Effective Date and, subject to
Section&nbsp;8(a) below, shall be exercisable until 5:00 p.m. (Eastern Time) on the seventh (7<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. </B>EXERCISE OF THE PURCHASE RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exercise</U>. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time,
or from time to time, prior to the expiration of the term set forth in Section&nbsp;2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as <U>Exhibit I</U> (the &#147;<U>Notice of
Exercise</U>&#148;), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3)&nbsp;business days thereafter,
the Company or its transfer agent shall either (i)&nbsp;issue to the Warrantholder a certificate for the number of shares of Common Stock purchased or (ii)&nbsp;credit the same via book entry to the Warrantholder, and the Company shall execute the
acknowledgment of exercise in the form attached hereto as <U>Exhibit II</U> (the &#147;<U>Acknowledgment of Exercise</U>&#148;) indicating the number of shares which remain subject to future purchases under this Warrant, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Purchase Price may be paid at the Warrantholder&#146;s election either (i)&nbsp;by cash or check, or (ii)&nbsp;by surrender of all or a
portion of the Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an amended Agreement setting forth the remaining number of shares purchasable hereunder, as determined below (&#147;<U>Net
Issuance</U>&#148;). If the Warrantholder elects the Net Issuance method, the Company will issue shares of Common Stock in accordance with the following formula: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = <U><FONT STYLE="white-space:nowrap">Y(A-B)</FONT></U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">A </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Where:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">X = the number of shares of Common Stock to be issued to the Warrantholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Y = the number of shares of Common Stock requested to be exercised under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">A = the then-current fair market value of one (1)&nbsp;share of Common Stock at the time of exercise of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">B = the then-effective Exercise Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the above calculation, the current fair market value of shares of Common Stock shall mean with respect to each share of Common
Stock: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) at all times when the Common Stock is traded on a national securities exchange, inter-dealer quotation system or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> bulletin board service, the volume weighted average prices over a five (5)&nbsp;day period before the day the current fair market value of the securities is
being determined; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) if the exercise is in connection with a Merger Event, the fair market value of a share of Common Stock shall be
deemed to be the per share value received by the holders of the outstanding shares of Common Stock pursuant to such Merger Event as determined in accordance with the definitive transaction documents executed among the parties in connection
therewith; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) in cases other than as described in the foregoing clauses (i)&nbsp;and (ii), the current fair market value of a share
of Common Stock shall be determined in good faith by the Company&#146;s Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Upon partial exercise by either cash or Net Issuance, prior to the expiration or earlier
termination hereof, the Company shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein,
including, but not limited to the Effective Date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Prior to Expiration</U>. To the extent this Warrant is not
previously exercised as to all shares of Common Stock subject hereto, and if the then-current fair market value of one share of Common Stock is greater than the Exercise Price then in effect, or, in the case of a Liquid Sale, where the value per
share of Common Stock (as determined as of the closing of such Liquid Sale in accordance with the definitive agreements executed by the parties in connection with such Merger Event) to be paid to the holders thereof is greater than the Exercise
Price then in effect, this Agreement shall be deemed automatically exercised on a Net Issuance basis pursuant to Section&nbsp;3(a) (even if not surrendered) as of immediately before its expiration determined in accordance with Section&nbsp;2. For
purposes of such automatic exercise, the fair market value of one share of Common Stock upon such expiration shall be determined pursuant to Section&nbsp;3(a). To the extent this Warrant or any portion hereof is deemed automatically exercised
pursuant to this Section&nbsp;3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Common Stock if any, the Warrantholder is to receive by reason of such automatic exercise, and to issue or cause its transfer
agent to issue a certificate or a book-entry credit to the Warrantholder evidencing such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. </B>RESERVATION OF SHARES.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Common
Stock to provide for the exercise of the rights to purchase Common Stock as provided for herein. If at any time during the term hereof the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this
Warrant in full, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. </B>NO FRACTIONAL SHARES OR SCRIP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such
fractional shares the Company shall round up or down to the nearest whole share upon exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. </B>NO RIGHTS AS
SHAREHOLDER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Without limitation of any provision hereof, the Warrantholder agrees that this Agreement does not entitle the Warrantholder
to any voting rights or other rights as a shareholder of the Company prior to the exercise of any of the purchase rights set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. </B>WARRANTHOLDER REGISTRY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. The Warrantholder&#146;s
initial address, for purposes of such registry, is set forth in Section&nbsp;12(g) below. The Warrantholder may change such address by giving written notice of such changed address to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 8. </B>ADJUSTMENT RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment from time to time, as follows:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Merger Event</U>. In connection with a Merger Event that is a Liquid Sale, this Warrant shall, on and after the closing thereof,
automatically and without further action on the part of any party or other person, represent the right to receive the consideration payable on or in respect of all shares of Common Stock that are issuable hereunder as of immediately prior to the
closing of such Merger Event less the Purchase Price for all such shares of Common Stock (such consideration to include both the consideration payable at the closing of such Merger Event and all deferred consideration payable thereafter, if any,
including, but not limited to, payments of amounts deposited at such closing into escrow and payments in the nature of earn-outs, milestone payments or other performance-based payments), and such Merger Event consideration shall be paid to the
Warrantholder as and when it is paid to the holders of the outstanding shares of Common Stock. In connection with a Merger Event that is not a Liquid Sale, the Company shall cause the successor or surviving entity to assume this Warrant and the
obligations of the Company hereunder on the closing thereof, and thereafter this Warrant shall be exercisable for the same number and type of securities or other property as the Warrantholder would have received in consideration for the shares of
Common Stock issuable hereunder had it exercised this Warrant in full as of immediately prior to such closing, at an aggregate Exercise Price no greater than the aggregate Exercise Price in effect as of immediately prior to such closing, and subject
to further adjustment from time to time in accordance with the provisions of this Warrant. The provisions of this Section&nbsp;8(a) shall similarly apply to successive Merger Events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Reclassification of Shares</U>. Except for Merger Events subject to Section&nbsp;8(a), if the Company at any time shall, by
combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes of
securities, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under
this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section&nbsp;8(b) shall similarly apply to successive combination, reclassification, exchange, subdivision or other
change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Subdivision or Combination of Shares</U>. If the Company at any time shall combine or subdivide its Common Stock,
(i)&nbsp;in the case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares for which this Warrant is exercisable shall be proportionately increased, or (ii)&nbsp;in the case of a combination, the Exercise
Price shall be proportionately increased and the number of shares for which this Warrant is exercisable shall be proportionately decreased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Dividends</U>. If the Company at any time while this Agreement is outstanding and unexpired shall: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) pay a dividend with respect to the Common Stock payable in additional shares of Common Stock, then the Exercise Price shall be adjusted,
from and after the date of determination of shareholders entitled to receive such dividend, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A)&nbsp;the numerator of
which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B)&nbsp;the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such
dividend or distribution, and the number of shares of Common Stock for which this Warrant is exercisable shall be proportionately increased; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) make any other dividend or distribution on or with respect to Common Stock, except any
dividend or distribution (A)&nbsp;in cash, or (B)&nbsp;specifically provided for in any other clause of this Section&nbsp;8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or
conversion of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Common Stock (or other stock for which the Common Stock is convertible) as of the record date fixed for the determination of
the shareholders of the Company entitled to receive such dividend or distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Notice of Certain Events</U>. If: (i)&nbsp;the
Company shall declare any dividend or distribution upon its outstanding Common Stock, payable in stock, cash, property or other securities (provided that, and to the extent applicable under the Loan Agreement, the Warrantholder in its capacity as
lender under the Loan Agreement consents to such dividend); (ii) the Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or other rights; (iii)&nbsp;there shall be any Merger
Event; or (iv)&nbsp;there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice thereof at the same time and in the same manner as it
gives notice thereof to the holders of outstanding Common Stock. In addition, if at any time the number of shares of Common Stock (or other securities of any other class or classes of securities of the Company for which this Warrant is then
exercisable) outstanding is reduced such that the number of shares of Common Stock or other securities issuable upon exercise of this Warrant shall exceed five percent (5%) of the then outstanding class of such securities, then, within three
(3)&nbsp;business days of such event, the Company shall give the Warrantholder written notice thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 9. </B>REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Reservation of Common Stock</U>. The Company covenants and agrees that all shares of
Common Stock that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and will be free of any taxes,
liens, charges or encumbrances of any nature whatsoever; provided, that the Common Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made available to the
Warrantholder true, correct and complete copies of its Charter and bylaws currently in effect. The issuance of certificates or book-entry credit for shares of Common Stock upon exercise of this Warrant shall be made without charge to the
Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and related issuance of shares of Common Stock. The Company further covenants and agrees that the Company will, at all
times during the term hereof, have authorized and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Due Authority</U>. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to the Warrantholder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company. This Agreement: (i)&nbsp;does not violate the Charter
or the Company&#146;s current bylaws; (ii)&nbsp;does not contravene any law or governmental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rule, regulation or order applicable to the Company; and (iii)&nbsp;except as could not reasonably be expected to have a Material Adverse Effect (as defined in the Loan Agreement), does not and
will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which the Company is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of
the Company, enforceable in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting creditors&#146; rights generally (including, without limitation,
fraudulent conveyance laws) and by general principles of equity, regardless of whether considered in a proceeding in equity or at law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Consents and Approvals</U>. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect
of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D
under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exempt Transaction</U>. Subject to the accuracy of the Warrantholder&#146;s representations in Section&nbsp;10, the issuance of the
Common Stock upon exercise of this Agreement will constitute a transaction exempt from (i)&nbsp;the registration requirements of Section&nbsp;5 of the Act, in reliance upon Section&nbsp;4(a)(2) thereof, and (ii)&nbsp;the qualification requirements
of the applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Information Rights</U>. At all times (if any) after the Loan Agreement has been
terminated and prior to the earlier to occur of (x)&nbsp;the date on which all shares of Common Stock issued on exercise of this Warrant have been sold, or (y)&nbsp;the expiration or earlier termination of this Warrant, when the Company shall not be
required to file reports pursuant to Section&nbsp;13 or 15(d) of the Exchange Act or shall not have timely filed all such required reports, the Warrantholder shall be entitled to the information rights contained in Section&nbsp;7.1(b) &#150; (f) of
the Loan Agreement, and in any such event Section&nbsp;7.1(b) &#150; (f) of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set forth herein, provided, however, that the Company shall not be required
to deliver a Compliance Certificate once all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid. For the avoidance of doubt, Company shall not be required to deliver any information contained in
Section&nbsp;7.1(b) &#150; (f) if it has timely filed all required reports under Section&nbsp;13 or 15(d) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Rule 144 Compliance</U>. The Company shall, at all times prior to the earlier to occur of (i)&nbsp;the date of sale or other disposition by Warrantholder of this Warrant or all shares of Common Stock issued on exercise of this Warrant,
(ii)&nbsp;the expiration or earlier termination of this Warrant if the Warrant has not been exercised in full or in part on such date, use commercially reasonable efforts to timely file all reports required under the Exchange Act and otherwise
timely take all actions necessary to permit the Warrantholder to sell or otherwise dispose of this Warrant and the shares of Common Stock issued on exercise hereof pursuant to Rule 144 promulgated under the Act (&#147;Rule 144&#148;), provided that
the foregoing shall not apply in the event of a Merger Event following which the successor or surviving entity is not subject to the reporting requirements of the Exchange Act. If the Warrantholder proposes to sell Common Stock issuable upon the
exercise of this Agreement in compliance with Rule 144, then, upon the Warrantholder&#146;s written request to the Company, the Company shall furnish to the Warrantholder, within five (5)&nbsp;business days after receipt of such request, a written
statement confirming the Company&#146;s compliance with the filing and other requirements of such Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 10. </B>REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Investment Purpose</U>. This Warrant and the shares issued on exercise hereof will be acquired for investment and not with a view to
the sale or distribution of any part thereof in violation of applicable federal and state securities laws, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration
or exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Private Issue</U>. The Warrantholder understands that (i)&nbsp;the Common Stock issuable upon exercise of this
Agreement is not, as of the Effective Date, registered under the Act or qualified under applicable state securities laws, and (ii)&nbsp;the Company&#146;s reliance on exemption from such registration is predicated on the representations set forth in
this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Financial Risk</U>. The Warrantholder has such knowledge and experience in financial and business matters as
to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Accredited Investor</U>. The Warrantholder is an &#147;accredited investor&#148; within the meaning of Rule 501 of Regulation D promulgated under the Act, as presently in effect (&#147;Regulation D&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>No Short Sales</U>. The Warrantholder has not at any time on or prior to the Effective Date engaged in any short sales or equivalent
transactions in the Common Stock. Warrantholder agrees that at all times from and after the Effective Date and on or before the expiration or earlier termination of this Warrant, it shall not engage in any short sales or equivalent transactions in
the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 11. </B>TRANSFERS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or
in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when
endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company&#146;s books, shall be treated by the Company and all other persons dealing with this
Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a
notice of transfer in the form attached hereto as Exhibit III (the &#147;<U>Transfer Notice</U>&#148;), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the
Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. Notwithstanding anything herein or in any legend to the contrary, the Company shall not require an opinion of counsel in
connection with any sale, assignment or other transfer by the Warrantholder of this Warrant (or any portion hereof or any interest herein) or of any shares of Common Stock issued upon any exercise hereof to an affiliate (as defined in Regulation D)
of the Warrantholder, provided that such affiliate is an &#147;accredited investor&#148; as defined in Regulation D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECTION 12. </B>MISCELLANEOUS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Effective Date</U>. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Remedies</U>. In the event of any default hereunder, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party may proceed to
protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the Warrantholder
will not have an adequate remedy at law and where damages will not be readily ascertainable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Impairment of Rights</U>. The
Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms
and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Additional Documents</U>. In the event the Company shall not be required to file reports pursuant to Section&nbsp;13 or 15(d) of the
Exchange Act, the Company agrees to supply such other documents as the Warrantholder may from time to time reasonably request to value this Warrant for Warrantholder&#146;s accounting or reporting requirements and/or to evaluate whether to exercise
(in cash or a net issuance basis) this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Attorneys&#146; Fees</U>. In any litigation, arbitration or court proceeding
between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys&#146; fees and expenses and all reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section&nbsp;12(e), attorneys&#146; fees shall include without
limitation fees incurred in connection with the following: (i)&nbsp;contempt proceedings; (ii)&nbsp;discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv)&nbsp;garnishment, levy, and
debtor and third party examinations; and (v)&nbsp;post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Severability</U>. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or
unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the
intention of the parties underlying the invalid, illegal or unenforceable provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>. Except as otherwise provided
herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and
shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i)&nbsp;personal delivery to the party to be notified, (ii)&nbsp;when sent by confirmed telex, electronic transmission or facsimile if sent during
normal business hours of the recipient, if not, then on the next business day, (iii)&nbsp;five (5)&nbsp;days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv)&nbsp;one day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt, and shall be addressed to the party to be notified as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Warrantholder: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attention: [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Facsimile: [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Telephone:
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a
copy to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attention: [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Facsimile: [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Telephone:
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to
the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attention: Ali Bauerlein, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">4040 Campbell Ave #100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Menlo
Park, CA 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-895-7312</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Email: ABauerlein@sightsciences.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attn: Dan Van Fleet </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">505
Montgomery Street, Suite 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94111 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">415-391-0600</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Email: dan.vanfleet@lw.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or
to such other address as each party may designate for itself by like notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Entire Agreement; Amendments</U>. This Agreement
constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements,
whether written or oral, with respect to the subject matter hereof. None of the terms of this Agreement may be amended or waived except by an instrument executed by the Company and the holders of Warrants exercisable for a majority of the total
number of shares of Common Stock then issuable pursuant to all Warrants then outstanding in connection with the Loan Agreement. Any such amendment or waiver effected in accordance with this Section&nbsp;12(h) or otherwise effected pursuant to the
terms of this Warrant shall be binding upon each holder of Warrants outstanding in connection with the Loan Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
<U>Headings</U>. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Advice of Counsel</U>. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity to
discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p), 12(q) and 12(r). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>No Strict Construction</U>. The parties hereto have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>No Waiver</U>. No omission or
delay by the Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy
to which the Warrantholder is entitled, nor shall it in any way affect the right of the Warrantholder to enforce such provisions thereafter during the term of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Survival</U>. All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto
shall be for the benefit of the Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Governing Law</U>. This Agreement has been negotiated and delivered to the Warrantholder in the State of California, and shall be deemed
to have been accepted by the Warrantholder in the State of California. Delivery of Common Stock to the Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and
enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Consent to Jurisdiction and Venue</U>. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (i)&nbsp;consents to personal jurisdiction in Santa Clara County,
State of California; (ii)&nbsp;waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (iii)&nbsp;agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(iv)&nbsp;irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance
with the requirements for notice set forth in Section&nbsp;12(g), and shall be deemed effective and received as set forth in Section&nbsp;12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall
limit the right of either party to bring proceedings in the courts of any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Mutual Waiver of Jury Trial</U>.
Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration
rules), the parties desire that their disputes arising under or in connection with this Warrant be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND THE WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY
JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#147;CLAIMS&#148;) ASSERTED BY THE COMPANY AGAINST THE WARRANTHOLDER OR ITS ASSIGNEE OR BY THE WARRANTHOLDER OR ITS ASSIGNEE AGAINST
THE COMPANY RELATING TO THIS WARRANT. This waiver extends to all such Claims, including Claims that involve persons or entities other the Company and the Warrantholder; Claims that arise out of or are in any way connected to the relationship between
the Company and the Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Arbitration</U>. If the Mutual Waiver of Jury Trial set forth in Section&nbsp;12(p)
is ineffective or unenforceable, the parties agree that all Claims shall be submitted to binding arbitration in accordance with the commercial arbitration rules of JAMS (the &#147;Rules&#148;), such arbitration to occur before one arbitrator, which
arbitrator shall be a retired California state judge or a retired Federal court judge. Such proceeding shall be conducted in Santa Clara County, State of California, with California rules of evidence and discovery applicable to such arbitration. The
decision of the arbitrator shall be binding on the parties, and shall be final and nonappealable to the maximum extent permitted by law. Any judgment rendered by the arbitrator may be entered in a court of competent jurisdiction and enforced by the
prevailing party as a final judgment of such court. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U><FONT STYLE="white-space:nowrap">Pre-arbitration</FONT> Relief</U>. In the
event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction identified in Section&nbsp;12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced
to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by binding arbitration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)
<U>Counterparts</U>. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts (including by facsimile or electronic delivery (PDF), and by different parties hereto in separate
counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Specific Performance</U>. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to
the Warrantholder by reason of the Company&#146;s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by the Warrantholder. If the Warrantholder institutes any
action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that the Warrantholder has an adequate remedy at law, and such person shall
not offer in any such action or proceeding the claim or defense that such remedy at law exists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Lost, Stolen, Mutilated or
Destroyed Warrant</U>. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated
or destroyed Warrant shall be at any time enforceable by anyone. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Legends</U>. To the extent required by applicable laws, this
Warrant and the shares of Common Stock issuable hereunder (and the securities issuable, directly or indirectly, upon conversion of such shares of Common Stock, if any) may be imprinted with a restricted securities legend in substantially the
following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;), OR ANY
APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION RELATED THERETO OR, SUBJECT TO SECTION 11 OF THE WARRANT AGREEMENT DATED JANUARY&nbsp;22, 2024, BETWEEN THE
COMPANY AND [________], AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACTOR ANY STATE SECURITIES LAWS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by
its officers thereunto duly authorized as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMPANY:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">SIGHT&nbsp;SCIENCES,&nbsp;INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WARRANTHOLDER:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF EXERCISE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To:
[____________________________] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned Warrantholder hereby elects to purchase [_______] shares of the Common Stock of Sight Sciences,
Inc., a Delaware corporation, pursuant to the terms of the Warrant Agreement dated the 22nd day of January, 2024 (the &#147;Warrant Agreement&#148;) between [_________________] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of
the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section&nbsp;3(a) of the Warrant Agreement to effect a Net Issuance.] </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please issue a certificate or certificates or book-entry credit(s) representing said shares of Common Stock in
the name of the undersigned or in such other name as is specified below. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Address)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WARRANTHOLDER: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT II </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. ACKNOWLEDGMENT OF EXERCISE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned
[____________________________________], hereby acknowledges receipt of the &#147;Notice of Exercise&#148; from [________] to purchase [____] shares of the Common Stock of Sight Sciences, Inc., a Delaware corporation, pursuant to the terms of the
Warrant Agreement by and between [________] and Sight Sciences, Inc. dated as of January&nbsp;22, 2024 (the &#147;<U>Warrant Agreement</U>&#148;), and further acknowledges that [______] shares remain subject to purchase under the terms of the
Warrant Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMPANY:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">SIGHT&nbsp;SCIENCES,&nbsp;INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT III </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TRANSFER NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To transfer or assign the
foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Please Print) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whose address is__________________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:___________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Signature:___________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Address:____________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">___________________________________</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature
Guaranteed: ____________________________________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTE: The signature to this Transfer Notice must correspond with the name as it
appears on the face of the Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the
foregoing Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d715146dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED
THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LOAN AND SECURITY AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LOAN AND SECURITY AGREEMENT is made and dated as of January&nbsp;22, 2024 and is entered into by and among SIGHT SCIENCES, INC., a
Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party hereto (together with Company, individually or collectively,
as the context may require, &#147;<U>Borrower</U>&#148;), the several banks and other financial institutions or entities from time to time party hereto (each, a &#147;<U>Lender</U>&#148;, and collectively &#147;<U>Lenders</U>&#148;) and HERCULES
CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and Lenders (in such capacity, including any successors or assigns, &#147;<U>Agent</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Borrower has
requested Lenders make available to Borrower up to three tranches of term loans in an aggregate principal amount of up to Sixty-Five Million Dollars ($65,000,000) (the &#147;<U>Term Loans</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Lenders are willing to make the Term Loans on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, Borrower, Agent and Lenders agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. <U>DEFINITIONS AND RULES OF CONSTRUCTION</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 Unless otherwise defined herein, the following capitalized terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Account Control Agreement(s)</U>&#148; means any agreement entered into by and among Agent, Borrower and a third-party bank or other
institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which perfects Agent&#146;s first priority security interest in the subject account or accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ACH Authorization</U>&#148; means the ACH Debit Authorization Agreement in substantially the form of <U>Exhibit H</U>, which account
numbers shall be redacted for security purposes if and when filed publicly by Borrower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition</U>&#148; means any
transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a)&nbsp;the acquisition of all or substantially all of the assets of a Person, or of any business, line of business or division or other unit
of operation of a Person, (b)&nbsp;the acquisition of fifty percent (50%) or more of the Equity Interests of any Person, whether or not involving a merger, consolidation or similar transaction with such other Person, or otherwise causing any Person
to become a Subsidiary of Borrower, or (c)&nbsp;the acquisition of, or the right to use, develop or sell (in each case, including through licensing (other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> licenses)), any product, product line or intellectual property of or from any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Advance(s)</U>&#148; means a Term Loan Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Advance Date</U>&#148; means the funding date of any Advance. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Advance Request</U>&#148; means a request for an Advance submitted by Borrower to
Agent in substantially the form of <U>Exhibit</U><U></U><U>&nbsp;A</U>, which account numbers shall be redacted for security purposes if and when filed publicly by Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means (a)&nbsp;any Person that directly or indirectly controls, is controlled by, or is under common control with
the Person in question, (b)&nbsp;any Person directly or indirectly owning, controlling or holding with power to vote fifteen percent (15%) or more of the outstanding voting securities of another Person, or (c)&nbsp;any Person fifteen percent (15%)
or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities. As used in the definition of &#147;Affiliate,&#148; the term &#147;control&#148; means the
possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agent</U>&#148; has the meaning given to such term in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; means this Loan and Security Agreement, as amended, restated, amended and restated, supplemented or otherwise
modified from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Amortization Date</U>&#148; means August&nbsp;1, 2026; provided however, if the Interest Only
Extension Conditions are satisfied, then February&nbsp;1, 2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-Corruption Laws</U>&#148; means all laws, rules, and
regulations of any jurisdiction applicable to Borrower or any of its Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the
UK Bribery Act 2010 and other similar legislation in any other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti</U><U><FONT STYLE="white-space:nowrap">-Terrorism</FONT> Laws</U>&#148; means any laws, rules, regulations or orders relating to
terrorism or money laundering, including without limitation Executive Order No.&nbsp;13224 (effective September&nbsp;24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bankruptcy Code</U>&#148; means the federal bankruptcy law of the United States as from time to time in effect, currently as Title 11
of the United States Code. Section references to current sections of the Bankruptcy Code shall refer to comparable sections of any revised version thereof if section numbering is changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocked Person</U>&#148; means any Person: (a)&nbsp;listed in the annex to, or is otherwise subject to the provisions of, Executive
Order No.&nbsp;13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No.&nbsp;13224, (c) a Person with which any Lender is
prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d)&nbsp;a Person that commits, threatens or conspires to commit or supports &#147;terrorism&#148; as defined in Executive Order No.&nbsp;13224, or
(e)&nbsp;a Person that is named a &#147;specially designated national&#148; or &#147;blocked person&#148; on the most current list published by OFAC or other similar list. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board Approved Forecast</U>&#148; means the Original Plan; provided that the Original Plan shall be updated from time to time by
Borrower&#146;s projections delivered to Agent in accordance with Section&nbsp;7.1(i) hereof and deemed acceptable to Agent in its reasonable discretion; provided that Agent acknowledges that a forecast delivered pursuant to Section&nbsp;7.1(i)
shall be deemed acceptable to Agent if the projected revenues (determined in accordance with GAAP) for each monthly period therein demonstrate actual year-over-year revenue growth (determined in accordance with GAAP) for each measuring period
compared to the prior year&#146;s actual revenue reported in the financial statements provided pursuant to Section&nbsp;7.1(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board of Directors</U>&#148; means, with respect to any Person that is a
corporation, its board of directors, with respect to any Person that is a limited liability company, its board of managers, board of members or similar governing body, and with respect to any other Person that is another form of a legal entity, such
Person&#146;s governing body in accordance with its Organizational Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Borrower Products</U>&#148; means all current and
future products, software, service offerings, technical data or technology currently being designed, manufactured or sold or that are under clinical investigation or development by a Loan Party or which a Loan Party intends to sell, license, or
distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed or distributed by a Loan Party
since its formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Borrower&#146;s Books</U>&#148; means Borrower&#146;s or any of its Subsidiaries&#146; books and records
including ledgers, federal, state, local and foreign tax returns, records regarding Borrower&#146;s or its Subsidiaries&#146; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or
any equipment containing such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Borrower Consolidated Unrestricted Cash</U>&#148; means as of any date of
determination, unrestricted cash and cash equivalents of the Borrower and its Subsidiaries (taken as a whole) that are not subject to any Lien (other than Permitted Liens). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day other than Saturday, Sunday and any other day on which banking institutions in the State of
California or State of New York are closed for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cash</U>&#148; means all cash, cash equivalents and liquid funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>CFC</U>&#148; means a controlled foreign corporation within the meaning of Section&nbsp;957 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>CFC Holdco</U>&#148; means any Subsidiary substantially all the assets of which consist of equity interests (or equity and debt
interests) of one or more CFCs and/or of one or more other CFC Holdcos and that does not engage in any business, operations or activity other than that of a holding company. For the avoidance of doubt, it is understood and agreed that no CFC Holdcos
exist as of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Change in Control</U>&#148; means (a)&nbsp;at any time, any &#147;person&#148; or
&#147;group&#148; (as such terms are used in Sections 13(d) and 14(d) of Securities Exchange Act of 1934, as amended), shall become, or obtain rights (whether by means of warrants, options or otherwise) to become, the &#147;beneficial owner&#148;
(as defined in Rules <FONT STYLE="white-space:nowrap">13(d)-3</FONT> and <FONT STYLE="white-space:nowrap">13(d)-5</FONT> under Securities Exchange Act of 1934, as amended), directly or indirectly, of forty-nine percent (49.0%) or more of the
ordinary voting power for the election of directors, partners, managers and members, as applicable, of Company (determined on a fully diluted basis); (b) during any period of twelve (12)<I></I>&nbsp;consecutive months, a majority of the members of
the Board of Directors of Company cease to be composed of individuals (i)&nbsp;who were members of that Board of Directors on the first (1st) day of such period, (ii)&nbsp;whose election or nomination to that Board of Directors was approved by
individuals referred to in clause (i)&nbsp;above constituting at the time of such election or nomination at least a majority of that Board of Directors or (iii)&nbsp;whose election or nomination to that Board of Directors was approved by individuals
referred to in clauses (i)&nbsp;and (ii)&nbsp;above constituting at the time of such election or nomination at least a majority of that Board of Directors; or (c)&nbsp;at any time, Company shall cease to own and control, of record and beneficially,
directly or indirectly, one hundred percent (100.0%) of each class of outstanding stock, partnership, membership, or other ownership interest or other equity securities of each Subsidiary of Company free and clear of all Liens (other than Permitted
Liens). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Charter</U>&#148; means, with respect to any Person, such Person&#146;s
incorporation, formation or equivalent documents, as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the date of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Collateral Claim</U>&#148; means any and all present and future &#147;claims&#148; (used in its broadest sense, as contemplated by
and defined in Section&nbsp;101(5) of the Bankruptcy Code, but without regard to whether such claim would be disallowed under the Bankruptcy Code) of a Lender now or hereafter arising or existing under or relating to this Agreement and related Loan
Documents, whether joint, several, or joint and several, whether fixed or indeterminate, due or not yet due, contingent or <FONT STYLE="white-space:nowrap">non-contingent,</FONT> matured or unmatured, liquidated or unliquidated, or disputed or
undisputed, whether under a guaranty or a letter of credit, and whether arising under contract, in tort, by law, or otherwise, any interest or fees thereon (including interest or fees that accrue after the filing of a petition by or against Borrower
under the Bankruptcy Code, irrespective of whether allowable under the Bankruptcy Code), any costs of Enforcement Actions, including reasonable attorneys&#146; fees and costs, and any prepayment or termination premiums. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the Common Stock of Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Compliance Certificate</U>&#148; means a certificate in the form attached hereto as <U>Exhibit E</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contingent Obligation</U>&#148; means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that
Person with respect to (i)&nbsp;any Indebtedness, lease (excluding operating leases of real property), dividend, letter of credit or other obligation of another Person, including any such obligation directly or indirectly guaranteed, endorsed, <FONT
STYLE="white-space:nowrap">co-made</FONT> or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii)&nbsp;any obligations with respect to undrawn letters of credit,
corporate credit cards or merchant services issued for the account of that Person; and (iii)&nbsp;all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or
other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term &#147;Contingent Obligation&#148; shall not include endorsements for
collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed, without duplication of the primary obligation, to be an amount equal to the stated or determined amount of the primary obligation in
respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any
event exceed the maximum amount of the obligations under the guarantee or other support arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Copyright License</U>&#148;
means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Copyrights</U>&#148; means&nbsp;all copyrights, whether registered or unregistered, held pursuant to the laws of the United States of
America, any State thereof, or of any other country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Default</U>&#148; means any event, circumstance or condition that has occurred or
exists, that would, with the passage of time or the requirement that notice be given or both, become an Event of Default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Deposit Accounts</U>&#148; means any &#147;deposit accounts&#148;, as such term is defined in the UCC, and includes any checking
account, savings account, or certificate of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Division</U>&#148; means, in reference to any Person which is an entity,
the division of such Person into two (2)&nbsp;or more separate Persons, with the dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as contemplated under <FONT
STYLE="white-space:nowrap">Section&nbsp;18-217</FONT> of the Delaware Limited Liability Company Act for limited liability companies formed under Delaware law, <FONT STYLE="white-space:nowrap">Section&nbsp;17-220</FONT> of the Delaware Revised
Uniform Limited Partnership Act for limited partnerships formed under Delaware law, or any analogous action taken pursuant to any other applicable law with respect to any corporation, limited liability company, partnership or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Domestic Subsidiary</U>&#148; means any Subsidiary organized under the laws of the United States of America, any State thereof, the
District of Columbia, or any other jurisdiction within the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Due Diligence Fee</U>&#148; means
Twenty-Five Thousand Dollars ($25,000), which fee has been paid to Agent and received by Agent prior to the Closing Date, and shall be deemed fully earned on such date regardless of the early termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Enforcement Action</U>&#148; means, with respect to any Lender and with respect to any Collateral Claim of such Lender or any item of
Collateral in which such Lender has or claims a security interest lien or right of offset, any action, whether judicial or nonjudicial, to repossess, collect, accelerate, offset, recoup, give notification to third parties with respect to, sell,
dispose of, foreclose upon, give notice of sale, disposition, or foreclosure with respect to, or obtain equitable or injunctive relief with respect to, such Collateral Claim or Collateral. The filing, or the joining in the filing, by any Lender of
an involuntary bankruptcy or Insolvency Proceeding against Borrower also is an Enforcement Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Interests</U>&#148;
means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities or equity ownership interests of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Accounts</U>&#148; means any of the following accounts which are designated as such in writing to Agent as of the
Closing Date or, with respect to any account opened after the Closing Date, in the next Compliance Certificate delivered after such account is opened: (i)&nbsp;accounts exclusively used for payroll, payroll taxes, and other employee wage and benefit
payments to or for the benefit of any Loan Party&#146;s or any of its Subsidiaries&#146; employees holding an aggregate amount across all such accounts of not more than amounts needed for the then-next two (2)&nbsp;payroll cycles, (b)&nbsp;any
account which is a <FONT STYLE="white-space:nowrap">zero-balance</FONT> disbursement account, (c)&nbsp;any account which is solely used for disbursements and payments of withheld income taxes, payroll taxes and/or federal, state or local employee
taxes, (d)&nbsp;any account which is solely used as a trust account, escrow account, or other fiduciary account, (e)&nbsp;accounts of any Excluded Subsidiary, and (f)&nbsp;accounts holding only cash and cash equivalents in an amount that is
necessary to secure any letter of credit obligations in connection with clause (vii)&nbsp;of the defined term &#147;Permitted Indebtedness&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Subsidiary</U>&#148; means any Foreign Subsidiary and any CFC Holdco, subject to the limitations set forth in
Section&nbsp;7.24 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration or any successor thereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Foreign Subsidiary</U>&#148; means a Subsidiary other than any Domestic Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means generally accepted accounting principles in the United States of America, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Approval</U>&#148; means any consent, authorization, approval, order, license, franchise, permit, certificate,
accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authority</U>&#148; means any federal, state, municipal, national or other government, governmental department,
commission, board, bureau, court, agency or instrumentality or political subdivision thereof (including the FDA) or any entity or officer exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to any
government or any court, in each case whether associated with a state or locality of the United States, the United States, or a foreign government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Guarantor</U>&#148; means any Subsidiary of Borrower that enters into a Guaranty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Guaranty</U>&#148; means a guaranty with respect to the Secured Obligations, in form and substance satisfactory to Agent that may be
entered into from time to time, as the same may from time to time be amended, restated, modified or otherwise supplemented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; means (a)&nbsp;all indebtedness for borrowed money or the deferred purchase price of property or services
(excluding trade credit, purchase orders or similar indebtedness entered into in the ordinary course of business due within one hundred twenty 120) days), including reimbursement and other obligations with respect to surety bonds and letters of
credit, (b)&nbsp;all obligations evidenced by notes, bonds, debentures or similar instruments, (c)&nbsp;all capital lease obligations, (d)&nbsp;all equity securities of any Person subject to repurchase or redemption other than at the sole option of
such Person, (e) &#147;earnouts&#148; (to the extent treated as liabilities on the balance sheet in accordance with GAAP), purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or
continuing obligations of any nature arising out of purchase and sale contracts, (f)&nbsp;obligations arising under bonus, deferred compensation, incentive compensation or similar arrangements (other than those arising
<FONT STYLE="white-space:nowrap">non-contingent</FONT> obligations to reimburse any bank or Person in respect of amounts paid under a letter of credit, banker&#146;s acceptance or similar instrument, and (h)&nbsp;all Contingent Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Initial Facility Charge</U>&#148; means Three Hundred Thousand Dollars ($300,000), which is payable to Lenders in accordance with
<U>Section</U><U></U><U>&nbsp;4.1(j)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Insolvency Proceeding</U>&#148; means any proceeding by or against any Person under
the United States Bankruptcy Code, or any other bankruptcy, liquidation, moratorium, receivership, or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking
reorganization, administration, arrangement, receivership or other similar relief proceedings in the applicable jurisdiction from time to time in effect and affecting the rights of creditors generally. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means all of Borrower&#146;s Copyrights;
Trademarks; Patents; Licenses; trade secrets and inventions; mask works; Borrower&#146;s applications therefor and reissues, extensions, or renewals thereof; and Borrower&#146;s goodwill associated with any of the foregoing, together with
Borrower&#146;s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Security Agreement</U>&#148; means the Intellectual Property Security Agreement dated as of the Closing Date
between the Borrower and Agent, as the same may from time to time be amended, restated, modified or otherwise supplemented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>&#147;Interest Only Extension Conditions</U>&#148; means satisfaction of each of the following events: (a)&nbsp;no Default or Event of
Default shall have occurred and be continuing; and (b)&nbsp;Agent&#146;s receipt of evidence in form and substance satisfactory to Agent that the Company has achieved Performance Milestone II. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investment</U>&#148; means (a)&nbsp;any beneficial ownership (including stock, partnership interests, limited liability company
interests, or other equity securities) of or in any Person, (b)&nbsp;any loan, advance or capital contribution to any Person or (c)&nbsp;any Acquisition,. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>IRS</U>&#148; means the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Joinder Agreements</U>&#148; means for each Subsidiary required to join as a Borrower or as a Guarantor pursuant to
<U>Section</U><U></U><U>&nbsp;7.13</U>, a completed and executed Joinder Agreement in substantially the form attached hereto as <U>Exhibit F</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>License</U>&#148; means any Copyright License, Patent License, Trademark License or other Intellectual Property license of rights or
interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest,
encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security
interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Loan</U>&#148; means the Advances made under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Loan Documents</U>&#148; means this Agreement, the promissory notes (if any), the ACH Authorization, the Account Control Agreements,
any Joinder Agreement, all UCC Financing Statements, any Guaranty (if any), any Warrant, the Pledge Agreement, the Intellectual Property Security Agreement, and any other documents executed in connection with the Secured Obligations or the
transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Loan
Party</U>&#148; means Borrower or any Guarantor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Market Capitalization</U>&#148; means, as of any date of determination, an
amount equal to (a)&nbsp;the average of the daily volume weighted average price of Borrower&#146;s common stock as reported for each of the five (5)&nbsp;trading days preceding such date of determination (it being understood that a &#147;trading
day&#148; shall mean a day on which shares of Borrower&#146;s common stock trade on the NASDAQ (or, if the primary listing of such common stock is on another exchange, on such other exchange) in an ordinary trading session) multiplied by
(b)&nbsp;the total number of issued and outstanding shares of Borrower&#146;s common stock that are issued and outstanding on the date of the determination and listed on the NASDAQ (or, if the primary listing of such common stock is on another
exchange, on such other exchange), subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; means a material adverse effect upon:
(i)&nbsp;the business, operations, properties, assets or financial condition of the Loan Parties and their respective Subsidiaries taken as a whole; or (ii)&nbsp;the ability of Borrower to perform or pay the Secured Obligations in accordance with
the terms of the Loan Documents, or the ability of Agent or Lenders to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii)&nbsp;the Collateral or Agent&#146;s Liens on the Collateral or the priority of such Liens.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Agreement</U>&#148; means any license, agreement or other contractual arrangement, the termination of which could be
reasonably expected to result in a Material Adverse Effect, individually or in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Maximum Term Loan Amount</U>&#148;
means Fifty Million and No/100 Dollars ($50,000,000). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement</U>&#148;
means that certain <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement/Confidentiality Agreement by and between the Company and Agent dated as of November&nbsp;14, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>OFAC</U>&#148; means the U.S. Department of Treasury Office of Foreign Assets Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>OFAC Lists</U>&#148; means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to
Executive Order No.&nbsp;13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Organizational Documents</U>&#148; means with respect to any Person, such Person&#146;s Charter, and (a)&nbsp;if such Person is
a corporation, its bylaws, (b)&nbsp;if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c)&nbsp;if such Person is a partnership, its partnership agreement (or similar agreement), each
of the foregoing with all current amendments or modifications thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Original Plan</U>&#148; means the forecast approved by
the Company&#146;s Board of Directors on December&nbsp;6, 2023 and delivered by the Company to Agent and Lenders prior to the Closing Date titled &#147;High Level Scenario 11.27.23&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patent License</U>&#148; means any written agreement granting any right with respect to any invention on which a Patent is in
existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; means all letters patent of, or rights corresponding thereto, in the United States of America or in any other
country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States of America or any other country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Perfection Certificate</U>&#148; means a completed certificate entitled &#147;Perfection Certificate&#148;, dated as of the Closing
Date, delivered by Company to Agent and Lenders, signed by Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance Milestone I</U>&#148; means the occurrence of each of the following:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Borrower&#146;s public announcement of a resolution from the five Medicare Administrative Contractors (MACs) that
published future effective Local Coverage Determinations (LCDs) governing Micro-Invasive Glaucoma Surgery (MIGS) procedures in October 2023 or November 2023, which results in Medicare coverage policies that do not remove, eliminate, or materially
restrict Medicare coverage of medical procedures in which the Company&#146;s OMNI Surgical System is used; provided that Agent acknowledges and agrees that clause (i)&nbsp;has been satisfied as of the Closing Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the concurrent (as of the same measurement date) achievement on or prior to July&nbsp;31, 2025 of (a)&nbsp;consolidated
revenue, calculated in accordance with GAAP, of [***] attributable to the sale of the OMNI Surgical System and SION Surgical Instrument, and (b)&nbsp;gross profit margin of at least 80%, in each case calculated in accordance with GAAP on a trailing
three-month basis for the most-recently ended calendar month for which financial statements have been delivered to Agent in accordance with Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance Milestone II</U>&#148; means Borrower&#146;s achievement of each of the following on or prior to June&nbsp;30, 2025: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Performance Milestone I; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) as of any date of determination, consolidated revenue, calculated in accordance with GAAP on a trailing <FONT
STYLE="white-space:nowrap">six-month</FONT> basis for the most-recently ended calendar month for which financial statements have been delivered to Agent in accordance with Section&nbsp;7.1, of [***] attributable to the sale of the OMNI Surgical
System, SION Surgical Instrument, and TearCare System. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Acquisition</U>&#148; means any Acquisition, which is conducted
in accordance with the following requirements: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) of a business or Person or product engaged in a line of business
substantially related to that of any Loan Party or its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if such Acquisition is structured as a stock
acquisition, then the Person so acquired shall either (i)&nbsp;become a wholly-owned Subsidiary of a Loan Party or of a Subsidiary and Borrower shall comply, or cause such Subsidiary to comply, with <U>Section</U><U></U><U>&nbsp;7.13</U> hereof or
(ii)&nbsp;such Person shall be merged with and into a Loan Party (with such Loan Party being the surviving entity); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)
if such Acquisition is structured as the acquisition of assets or <FONT STYLE="white-space:nowrap">in-licensing,</FONT> such assets shall be acquired by a Loan Party or a newly-organized wholly-owned Subsidiary (in which event such Subsidiary shall
comply with <U>Section</U><U></U><U>&nbsp;7.13</U> hereof), and shall be free and clear of Liens other than Permitted Liens; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) (i) if the Acquisition is an equity purchase, the target and its Subsidiaries must have as its jurisdiction of formation a
state within the United States, (ii)&nbsp;and if the Acquisition is an asset purchase or a merger, all of the assets so acquired shall be located within the United States (or, in the case of any Intellectual Property so acquired, registered or
otherwise located in the United States), and (iii)&nbsp;if the Acquisition consists of an <FONT STYLE="white-space:nowrap">in-license</FONT> by a Loan Party of Intellectual Property or product, such <FONT STYLE="white-space:nowrap">in-license</FONT>
agreements shall be governed by the laws of United States, any state thereof or the District of Columbia; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Borrower shall have delivered to Lenders not less than fifteen
(15)&nbsp;nor more than forty five (45)&nbsp;days prior to the date of such Acquisition, notice of such Acquisition together with pro forma projected financial information, copies of all material documents relating to such acquisition, and
historical financial statements for such acquired entity, division or line of business (to the extent applicable), in each case in form and substance reasonably satisfactory to Lenders and demonstrating compliance with the covenants set forth in
Section&nbsp;7.21 (to the extent applicable) on a pro forma basis as if the Acquisition occurred on the first day of the most recent measurement period; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) both immediately before and after such Acquisition no Default or Event of Default shall have occurred and be continuing;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) the sum of the cash purchase price of such proposed new Acquisition, computed on the basis of total cash
acquisition consideration paid or incurred, or to be paid or incurred, by Borrower with respect thereto, including the amount of Permitted Indebtedness assumed or to which such assets, businesses or business or ownership interest or shares, or any
Person so acquired, is subject, shall not be greater than (i)&nbsp;Ten Million Dollars ($10,000,000) for any single acquisition or group of related acquisitions or (ii)&nbsp;Fifteen Million Dollars ($15,000,000) for all such acquisitions during the
term of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Indebtedness</U>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Indebtedness of Borrower and any Guarantor in favor of any Lender or Agent arising under this Agreement or any other Loan
Document; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Indebtedness existing on the Closing Date which is disclosed in <U>Schedule 1A</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Indebtedness of up to Five Hundred Thousand Dollars ($500,000) outstanding at any time secured by a Lien described in
clause (vii)&nbsp;of the defined term &#147;Permitted Liens,&#148; provided such Indebtedness does not exceed the cost of the Equipment, software or other Intellectual Property financed with such Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Indebtedness to trade creditors incurred in the ordinary course of business (due within one hundred twenty
(120)&nbsp;days), including such Indebtedness incurred in the ordinary course of business with corporate credit cards in an aggregate outstanding amount not to exceed One Million Dollars ($1,000,000) at any time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Indebtedness that also constitutes a Permitted Investment or is secured by a Permitted Lien; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Subordinated Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) reimbursement obligations in connection with letters of credit that are at any time outstanding and secured by Cash and
issued on behalf of any Loan Party or a Subsidiary in an amount not to exceed Five Hundred Thousand Dollars ($500,000); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) other unsecured Indebtedness in an amount not to exceed Five Hundred Thousand Dollars ($500,000) at any time
outstanding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) Indebtedness not to exceed One Million Dollars ($1,000,000) in the aggregate at any time outstanding
owed to any Person providing property, casualty, liability, or other insurance to the Loan Parties, including to finance insurance premiums, so long as the amount of such Indebtedness is not in excess of the amount of the unpaid cost of, and shall
be incurred only to defer the cost of, such insurance for the policy year in which such Indebtedness is incurred and such Indebtedness is outstanding only during such policy year; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Indebtedness consisting of Contingent Obligations incurred in the
ordinary course of business with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate at any time outstanding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) intercompany Indebtedness of (a)&nbsp;any Loan Party owing to another Loan Party, (b)&nbsp;any Loan Party owing to any other <FONT
STYLE="white-space:nowrap">non-Loan</FONT> Party in an amount not to exceed $2,000,000 and (c)&nbsp;any <FONT STYLE="white-space:nowrap">non-Loan</FONT> Party Subsidiary owing to another <FONT STYLE="white-space:nowrap">non-Loan</FONT> Party
Subsidiary; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the
principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be, and subject to any limitations on the aggregate amount of such Indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Investment</U>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Investments existing on the Closing Date which are disclosed in <U>Schedule 1B</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) (a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or
any State thereof maturing within one year from the date of acquisition thereof currently having a rating of at least <FONT STYLE="white-space:nowrap">A-2</FONT> or <FONT STYLE="white-space:nowrap">P-2</FONT> from either Standard&nbsp;&amp;
Poor&#146;s Corporation or Moody&#146;s Investors Service, (b)&nbsp;commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least <FONT STYLE="white-space:nowrap">A-2</FONT> or <FONT
STYLE="white-space:nowrap">P-2</FONT> from either Standard&nbsp;&amp; Poor&#146;s Corporation or Moody&#146;s Investors Service, (c)&nbsp;certificates of deposit issued by any bank with assets of at least Five Hundred Million Dollars ($500,000,000)
maturing no more than one year from the date of investment therein, (d)&nbsp;money market accounts and (e)&nbsp;Investments made in accordance with Borrower&#146;s investment policy, dated as of July&nbsp;6, 2021, in the form delivered to Agent
prior to the Closing Date (as amended or otherwise modified from time to time so long as Agent consents in writing to such investment policy); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) repurchases of stock of Borrower from employees, former employees, directors, or consultants of Borrower under the terms
of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed Seven Hundred Fifty Thousand Dollars ($750,000) in any fiscal year, provided that no Event of Default has occurred, is
continuing or could exist after giving effect to the repurchases; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Investments accepted in connection with Permitted
Transfers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of
customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower&#146;s business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and
suppliers who are not Affiliates, in the ordinary course of business, provided that this <U>subsection (vi)</U>&nbsp;shall not apply to Investments of any Loan Party in any Subsidiary of a Loan Party; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Investments consisting of loans not involving the net transfer on a
substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Company pursuant to employee stock purchase plans or other similar agreements approved by Company&#146;s Board of
Directors; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Investments consisting of: (A)&nbsp;travel advances and employee relocation loans in the ordinary course
of business, and (B)&nbsp;loans to employees, officers, managers or directors relating to the purchase of equity securities of Borrower pursuant to employee stock purchase plans or agreements approved by Borrower&#146;s Board of Directors or similar
governing body; not to exceed Five Hundred Thousand Dollars ($500,000) in the aggregate for (A)&nbsp;and (B), collectively, at any time outstanding; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) Investments in newly-formed Subsidiaries, provided that each such Subsidiary enters into a Joinder Agreement promptly
after its formation and executes such other documents as shall be reasonably requested by Agent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) joint ventures or
strategic alliances in the ordinary course of Borrower&#146;s business consisting of the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licensing of technology, the development of technology or the providing of technical support, provided
that any cash Investments (if any) by Borrower or the applicable Subsidiary do not exceed One Million Dollars ($1,000,000) in the aggregate in any fiscal year; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) Investments constituting Permitted Acquisitions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) so long as no Event of Default exists at the time of such Investment or after giving effect to such Investment,
Investments by any Loan Party or any Subsidiary thereof of Cash in an Excluded Subsidiary in an aggregate amount not exceed Five Million Dollars ($5,000,000) in any twelve (12)&nbsp;month period; provided that (a)&nbsp;such Investment shall be used
for payroll costs and other expenses in the ordinary course of business and (b)&nbsp;in no event shall any such Investment be made unless the Borrower is in compliance with Section&nbsp;7.24 before and after giving effect to such Investment; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) Investments accepted in connection with Permitted Transfers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) Investments consisting of extensions of credit in the nature of accounts or notes receivable arising from the grant of
trade credit in the ordinary course of business in an amount not exceeding $500,000 in the aggregate outstanding at any time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) Investments consisting of intercompany Indebtedness in accordance with and to the extent permitted by clause (xi)&nbsp;of
the definition of &#147;Permitted Indebtedness&#148;; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) additional Investments that do not exceed Five Hundred
Thousand Dollars ($500,000) in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Liens in favor of Agent or Lenders; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Liens existing on the Closing Date which are disclosed in <U>Schedule
1C</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not yet delinquent or
being contested in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor on Borrower&#146;s Books in accordance with GAAP; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like
Persons arising in the ordinary course of Borrower&#146;s business and imposed without action of such parties; provided, that the payment thereof is not yet delinquent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Liens arising from judgments, decrees, orders or attachments in circumstances which do not constitute an Event of Default
hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the following deposits, to the extent made in the ordinary course of business: deposits under
worker&#146;s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other
similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure
indemnity, performance or other similar bonds; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Liens on Equipment or software or other intellectual property
constituting purchase money Liens and other Liens in connection with capital leases securing Indebtedness permitted in <U>clause (iii)</U>&nbsp;of &#147;Permitted Indebtedness&#148;; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Liens incurred in connection with Subordinated Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) leasehold interests in leases or subleases and licenses (other than with respect to Intellectual Property) granted in the
ordinary course of business and not interfering in any material respect with the business of the licensor; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Liens in
favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the
date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) statutory and common law rights of <FONT STYLE="white-space:nowrap">set-off</FONT> and other similar rights as to
deposits of cash and securities in favor of banks, other depository institutions and brokerage firms or securities intermediaries to cover fees, similar expenses and charges; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) easements, servitudes, zoning restrictions,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way</FONT></FONT> and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value
or marketability of the related property; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) (a) Liens on Cash securing obligations permitted under <U>clause
(vii)</U>&nbsp;of the definition of Permitted Indebtedness and (b)&nbsp;security deposits in connection with real property leases, the combination of (a)&nbsp;and (b) in an aggregate amount not to exceed Three Million Dollars ($3,000,000) at any
time; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) licenses and other arrangements for the use of Intellectual Property permitted hereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) additional Liens so long as (A)&nbsp;such Liens do not secure debt for borrowed money, (B)&nbsp;such Liens attach to
specific, and not substantially all of the, assets of the Company or any of its Subsidiaries, and (C)&nbsp;the aggregate principal amount of the obligations secured thereby does not exceed Five Hundred Thousand Dollars ($500,000) at any time
outstanding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) attachments, appeal bonds, judgments and other similar Liens on Collateral for sums not exceeding Five
Hundred Thousand Dollars ($500,000) in the aggregate arising in connection with court proceedings; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) Liens arising
out of consignment for the sale of goods entered into by any Loan Party or any of its Subsidiaries in the ordinary course of business; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type
described in <U>clauses</U><U></U><U>&nbsp;(i)</U> through <U>(xviii)</U>&nbsp;above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the
Indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Transfers</U>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) sales of Inventory in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) licenses and similar arrangements for the use of Intellectual Property in the ordinary course of business on an arms&#146;
length basis, including in connection with business development transactions, <FONT STYLE="white-space:nowrap">co-development</FONT> or <FONT STYLE="white-space:nowrap">co-promotion</FONT> transactions, collaborations, licensing, partnering or
similar transactions with third parties and that are entered into with commercially reasonable terms, that could not result in a legal transfer of title of the licensed property that are <FONT STYLE="white-space:nowrap">non-exclusive</FONT> or may
be exclusive in respects other than territory or may be exclusive as to territory but only as to discrete geographical areas outside of the United States of America in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) transfers by and among any Loan Party and any Subsidiary that (i)&nbsp;has executed a Joinder Agreement or
(ii)&nbsp;constitutes a Permitted Investment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) transfers constituting the making of Permitted Investments, or the
granting of Permitted Liens; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) dispositions of <FONT STYLE="white-space:nowrap">worn-out,</FONT> obsolete or surplus
Equipment in the ordinary course of business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) dispositions of tangible personal property so long as (i)&nbsp;the
assets subject to such dispositions are sold for fair value, as determined by the Borrower in good faith, (ii)&nbsp;at least 75% of the consideration therefor is Cash and (iii)&nbsp;the aggregate amount of such dispositions pursuant to this clause
(vi)&nbsp;in any <FONT STYLE="white-space:nowrap">12-month</FONT> period does not exceed Seven Hundred Fifty Thousand Dollars ($750,000); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) use of Cash in the ordinary course of business or as otherwise permitted herein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) sale of Equity Interests in the ordinary course of business and distributions on Equity Interests not prohibited by
Section&nbsp;7.7 of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) the abandonment or dispositions to third parties in each case in the ordinary
course of business, of Intellectual Property that is no longer used or useful to Borrower or their Subsidiaries and that is not necessary or required for the commercialization of any commercial Product; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) other Transfers of assets having a fair market value of not more than Five Hundred Thousand Dollars ($500,000) in the
aggregate in any fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any individual, sole proprietorship, partnership, joint venture, trust,
unincorporated organization, association, corporation, limited liability company, institution, other entity or government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Pledge Agreement</U>&#148; means the Pledge Agreement dated as of the Closing Date between Borrower and any other pledgor party
thereto and Agent, as the same may from time to time be amended, restated, modified or otherwise supplemented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prime
Rate</U>&#148; means the &#147;prime rate&#148; as reported in <I>The</I> <I>Wall Street Journal</I><I><U> </U></I>or any successor publication thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Cash</U>&#148; means an amount equal to (a)&nbsp;the amount of the Loan Party&#146;s Cash held in accounts subject to an
Account Control Agreement in favor of Agent, <I><U>minus</U></I> (b)&nbsp;the Qualified Cash A/P Amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Cash A/P
Amount</U>&#148; means the amount of any of Borrower&#146;s accounts payable under GAAP not paid after the 120th day following the invoice for such account payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Receivables</U>&#148; means (i)&nbsp;all of Borrower&#146;s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations,
letters of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii)&nbsp;all customer lists, software, and business records related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration</U>&#148; means any registration, authorization, approval, license, permit, clearance, certificate, and exemption issued
or allowed by the FDA or state pharmacy licensing authorities (including, without limitation, pricing and reimbursement approvals, labelling approvals or their foreign equivalent, and wholesale distributor permits). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Lenders</U>&#148; means at any time, the holders of more than fifty percent (50%) of the sum of the aggregate unpaid
principal amount of the Term Loans then outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted License</U>&#148; means any material License or other agreement with
respect to which Borrower is the licensee (a)&nbsp;that prohibits or otherwise restricts Borrower from granting a security interest in Borrower&#146;s interest in such License or agreement or any other property, or (b)&nbsp;for which a default under
or termination of could interfere with Agent&#146;s right to sell any Collateral, in each case, other than as a result of customary anti-assignment provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctioned Country</U>&#148; means, at any time, a country or territory which is the subject or target of any Sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctioned Person</U>&#148; means, at any time, (a)&nbsp;any Person listed in any Sanctions-related list of designated Persons
maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member state, (b)&nbsp;any Person operating, organized
or resident in a Sanctioned Country or (c)&nbsp;any Person controlled by any such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctions</U>&#148; means economic or
financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a)&nbsp;the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S.
Department of State, or (b)&nbsp;the United Nations Security Council, the European Union or Her Majesty&#146;s Treasury of the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SBA Funding Date</U>&#148; means each date on which a Lender which is an SBIC funds any portion of the Term Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Secured Obligations</U>&#148; means Borrower&#146;s obligations under this Agreement and any Loan Document (other than the Warrant),
including any obligation to pay any amount now owing or later arising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsequent Financing</U>&#148; means an offering of
equity securities of the Company to bona fide investors for the primary purpose of generating cash proceeds to the Company that is exempt from the registration requirements of the United States Securities Act of 1933, as amended (excluding, for the
avoidance of doubt and without limitation any offering pursuant to the company&#146;s benefit plans, pursuant to existing derivative or convertible securities, pursuant to a strategic transaction or in any transaction registered pursuant to the
United States Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means an entity, whether a corporation, partnership,
limited liability company, joint venture or otherwise, in which Borrower owns or controls, either directly or indirectly, fifty percent (50%) or more of the outstanding voting securities, including each entity listed on <U>Schedule 1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>T6M Revenue</U>&#148; means consolidated revenues of Borrower and its Subsidiaries (as determined in accordance with GAAP, but which
shall not include any upfront or <FONT STYLE="white-space:nowrap">non-sales-based</FONT> milestone payments under business development of licensing transactions), measured on a trailing <FONT STYLE="white-space:nowrap">six-month</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding),
assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Term Commitment</U>&#148; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrower in a
principal amount not to exceed the amount set forth under the heading &#147;Tranche 1 Commitment&#148;, &#147;Tranche 2 Commitment&#148; or &#147;Tranche 3 Commitment&#148;, as the case may be, opposite such Lender&#146;s name on <U>Schedule
1.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Term Loan</U>&#148; means any Term Loan Advance made under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Term Loan Advance</U>&#148; means each Tranche 1(a) Advance, Tranche 1(b) Advance,
Tranche 2 Advance, Tranche 3 Advance, and any other funds advanced under <U>Section</U><U></U><U>&nbsp;2.2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Term Loan
Interest Rate</U>&#148; means for any day a per annum rate of interest equal to the greater of either (i)&nbsp;(x) the Prime Rate <I><U>plus</U></I> (y) 2.35%, and (ii) 10.35%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Term Loan Maturity Date</U>&#148; means July&nbsp;1, 2028 provided that if such day is not a Business Day, the Term Loan Maturity
Date shall be the immediately preceding Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trademark License</U>&#148; means any written agreement granting any right
to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trademarks</U>&#148; means all trademarks (registered, common law or otherwise) and any applications in connection therewith,
including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States of America, any State thereof or any other country or any political subdivision thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tranche</U>&#148; means the Tranche 1(a) Advance, Tranche 1(b) Advance, Tranche 2 Advance and/or the Tranche 3 Advance, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tranche 1(b) Availability Period</U>&#148; means the period commencing on the Closing Date and ending on
December&nbsp;15, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tranche 1 Commitment</U>&#148; means as to any Lender, the obligation of such Lender, if any, to make a
Term Loan Advance to Borrower in a principal amount not to exceed the amount set forth under the heading Tranche 1 Commitment opposite such Lender&#146;s name on <U>Schedule 1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tranche 2 Availability Period</U>&#148; means the period commencing on the date that Agent receives evidence in form and substance
reasonably satisfactory to Agent that the Company has achieved Performance Milestone II and ending on September&nbsp;15, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tranche 2 Commitment</U>&#148; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrower
in a principal amount not to exceed the amount set forth under the heading Tranche 2 Commitment opposite such Lender&#146;s name on <U>Schedule 1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tranche 3 Commitment</U>&#148; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrower
in a principal amount not to exceed the amount set forth under the heading Tranche 3 Commitment opposite such Lender&#146;s name on <U>Schedule 1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tranche Facility Charge</U>&#148; means three-quarters one percent (0.75%) of any Advance (other than a Tranche 1 Advance), which is
payable to Lenders in accordance with <U>Section</U><U></U><U>&nbsp;4.2(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>U.S. Person</U>&#148; means any Person that is a
&#147;United States person&#148; as defined in Section&nbsp;7701(a)(30) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>UCC</U>&#148; means the Uniform Commercial
Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to,
Agent&#146;s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term &#147;UCC&#148; shall mean the Uniform Commercial Code as
in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant</U>&#148; means any warrant entered into in connection with the Loan, as
may be amended, restated or modified from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 The following terms are defined in the Sections or subsections referenced
opposite such terms: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Defined Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>1940 Act</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.6(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Affected Lender</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Addendum 3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Agent</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Assignee</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11.14</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Borrower</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Claims</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11.11(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Collateral</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Confidential Information</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11.13</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>End of Term Charge</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.6</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Event of Default</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Financial Statements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Indemnified Person</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Lenders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Maximum Rate</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Participant Register</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11.8</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Payment Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.2(e)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Prepayment Charge</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.5</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Process Letter</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Addendum 4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Publicity Materials</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11.19</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Register</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11.7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Rights to Payment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>SBA</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.16</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>SBIC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.16</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>SBIC Act</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.16</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Tranche 1 Advance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Tranche 1(a) Advance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Tranche 1(b) Advance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Tranche 2 Advance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Tranche 3 Advance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Transfer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.8</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 Unless otherwise specified, all references in this Agreement or any Annex or Schedule
hereto to a &#147;Section,&#148; &#147;subsection,&#148; &#147;Exhibit,&#148; &#147;Annex,&#148; or &#147;Schedule&#148; shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise
specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP as in effect on the date hereof, and all financial computations hereunder
shall be computed in accordance with GAAP as in effect on the date hereof, consistently applied. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall
have the meanings given to them in the UCC. For all purposes under the Loan Documents, in connection with any Division or plan of Division under Delaware law (or any comparable event under a different jurisdiction&#146;s laws): (a) if any asset,
right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person and (b)&nbsp;if any new Person
comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 If at any time any change in GAAP would affect the computation of any financial requirement set forth in any Loan Document, and either
Borrower or the Required Lenders shall so request, Agent, Lenders and Borrower shall negotiate in good faith to amend such requirement to preserve the original intent thereof in light of such change in GAAP; provided that, until so amended, such
requirement shall continue to be computed in accordance with GAAP prior to such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 Notwithstanding anything in the definition of
GAAP to the contrary, any obligations under a lease (whether existing now or entered into in the future) that is not (or would not be) a capital lease under GAAP as in effect prior to giving effect to FASB Accounting Standards Update <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> Leases, shall not be treated as a capital lease solely as a result of the adoption of changes in GAAP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Any reference in any Loan Document to a merger, transfer, consolidation, amalgamation, consolidation, assignment, sale,
disposition or transfer, or similar term, shall be deemed to apply to a Division of or by a limited liability company, or an allocation of assets to a series of a limited liability company (or the unwinding of such a Division or allocation), as if
it were a merger, transfer, consolidation, amalgamation, consolidation, assignment, sale or transfer, or similar term, as applicable, to, of or with a separate Person. Any Division of a limited liability company shall constitute a separate Person
under the Loan Documents (and each Division of any limited liability company that is a Subsidiary, joint venture or any other like term shall also constitute such a Person or entity) on the first date of its existence. In connection with any
Division, if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then such asset shall be deemed to have been transferred from the original Person to the subsequent Person.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. <U>THE LOAN</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 [Reserved] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Term Loan Advances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Advances</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Tranche 1(a)</U><I>. </I>Subject to the terms and conditions of this
Agreement, on the Closing Date, Lenders will severally (and not jointly) make, and Borrower agrees to draw, a Term Loan Advance in an aggregate principal amount equal to Thirty-Five Million Dollars ($35,000,000) (such Term Loan Advance, the
&#147;<U>Tranche 1(a) Advance</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Tranche 1(b)</U><I>. </I>Subject to the terms and conditions of this
Agreement,<I> </I>Borrower may request, and the Lenders shall severally (and not jointly) make, in each case, during the Tranche 1(b) Availability Period, one Term Loan Advance in an aggregate principal amount equal to Five Million Dollars
($5,000,000) (such Term Loan Advance, the &#147;<U>Tranche 1(b) Advance</U>&#148; and, together with the Tranche 1(a) Advance, collectively, the &#147;<U>Tranche 1 Advances</U>&#148; and each a &#147;<U>Tranche 1 Advance</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Tranche 2</U><I>. </I>Subject to the terms and conditions of this Agreement,<I> </I>Borrower may request, and the
Lenders shall severally (and not jointly) make, in each case, during the Tranche 2 Availability Period, one or more additional Term Loan Advances in minimum increments of Five Million Dollars ($5,000,000) (or if less, the remaining amount of Term
Loan Advances available to be drawn pursuant to this <U>Section</U><U></U><U>&nbsp;2.2(a)(iii)</U>) in an aggregate principal amount up to Ten Million Dollars ($10,000,000) (such Term Loan Advances, the &#147;<U>Tranche 2 Advances</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Tranche 3</U><I>. </I>Subject to the terms and conditions of this Agreement,<I> </I>Borrower may request, and the
Lenders shall severally (and not jointly) make, in each case, beginning on the Closing Date and continuing through the last Business Day prior to the Amortization Date, and conditioned on approval by Lenders&#146; investment committee in is sole and
unfettered discretion, one or more additional Term Loan Advances in minimum increments of Five Million Dollars ($5,000,000) (or if less, the remaining amount of Term Loan Advances available to be drawn pursuant to this
<U>Section</U><U></U><U>&nbsp;2.2(a)(iv)</U>) in an aggregate principal amount up to Fifteen Million Dollars ($15,000,000) (such Term Loan Advances, the &#147;<U>Tranche 3 Advances</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Maximum Term Loan Amount</U>. The aggregate outstanding Term Loan Advances shall not exceed the Maximum Term Loan
Amount. Each Term Loan Advance of each Lender shall not exceed its respective Term Commitment. After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Advance Request</U>. To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at
least one (1)&nbsp;Business Day before the Closing Date and at least five (5)&nbsp;Business Days before each Advance Date other than the Closing Date) to Agent. <I></I>Lenders shall fund the Term Loan Advance in the manner requested by the Advance
Request provided that each of the conditions precedent set forth in <U>Section</U><U></U><U>&nbsp;4</U> and applicable to such Term Loan Advance is satisfied as of the requested Advance Date. The proceeds of any Term Loan Advance shall be deposited
into an account that is subject to an Account Control Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Term Loan Interest Rate</U>. The principal balance
shall bear interest thereon from such Advance Date at the Term Loan Interest Rate based on a year consisting of three hundred sixty (360)&nbsp;days, with interest computed daily based on the actual number of days elapsed. The Term Loan Interest Rate
will float and change on the day the Prime Rate changes from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Payment</U>. Borrower will pay accrued but unpaid interest on each
Term Loan Advance on the first Business Day of each month (each such date, a &#147;<U>Payment Date</U>&#148;), beginning the month after the Advance Date. Borrower shall repay the aggregate principal balance of the Term Loan Advances that is
outstanding on the day immediately preceding the Amortization Date, in equal monthly installments of principal and interest (mortgage style) beginning on the Amortization Date and continuing on the first Business Day of each month thereafter until
the Secured Obligations (other than inchoate indemnity obligations) are repaid, provided that if the Term Loan Interest Rate is adjusted or the Amortization Date is extended, the amount of each subsequent monthly installment shall be recalculated.
The entire principal balance of the Term Loan Advances and all accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or
deduction and regardless of any counterclaim or defense. If a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day. Agent for the benefit of the
Lenders<B><I> </I></B>shall initiate debit entries to Borrower&#146;s account as authorized on the ACH Authorization (i)&nbsp;on each Payment Date of all periodic obligations payable to Lenders under each Term Loan Advance and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(ii)&nbsp;out-of-pocket</FONT></FONT> legal fees and costs incurred by Agent or Lenders in connection with <U>Section</U><U></U><U>&nbsp;11.12</U>; provided that, with respect to <U>clause
(i)</U>&nbsp;above, in the event that Agent informs Borrower that Agent shall not initiate a debit entry to Borrower&#146;s account for a certain amount of the periodic obligations due on a specific Payment Date, Borrower shall pay to Agent, for the
benefit of Lenders, such amount of periodic obligations in full in immediately available funds on such Payment Date; provided, further, that, with respect to clause (i)&nbsp;above, if Agent informs Borrower that Agent shall not initiate a debit
entry as described above later than the date that is three (3)&nbsp;Business Days prior to such Payment Date, Borrower shall pay to Agent for the ratable benefit of the Lenders such amount of periodic obligations in full in immediately available
funds on the date that is three (3)&nbsp;Business Days after the date on which Agent notifies Borrower of such; provided, further, that, with respect to <U>clause (ii)</U>&nbsp;above, in the event that Agent informs Borrower that Agent shall not
initiate a debit entry to Borrower&#146;s account for specified <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal fees and costs incurred by Agent, Borrower shall pay to Agent such amount in full in
immediately available funds within three (3)&nbsp;Business Days. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Maximum Interest</U>. Notwithstanding any
provision in this Agreement or any other Loan Document, it is the parties&#146; intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall
deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the &#147;<U>Maximum Rate</U>&#148;). If a court of competent jurisdiction shall
finally determine that Borrower has actually paid to Lenders an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest
actually paid by Borrower shall be applied as follows: first, to the payment of the Secured Obligations consisting of the outstanding principal; second, after all principal is repaid, to the payment of Lenders&#146; accrued interest, costs,
expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Default Interest</U>. In the event any payment is not paid on the scheduled payment date, other than due to a failure of
any ACH debit due solely to an administrative or operational error of Agent or Lender or Borrower&#146;s bank if Borrower had the funds to make the payment when due and makes the payment within three (3)&nbsp;Business Days following Borrower&#146;s
knowledge of such failure to pay, an amount equal to three percent (3%) of such past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all outstanding Secured
Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in <U>Section</U><U></U><U>&nbsp;2.2(d)</U> plus three percent (3%) per annum. In the event
any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in <U>Section</U><U>&nbsp;2.2(d)</U> or <U>2.4</U>, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Prepayment</U>. At its option Borrower may prepay all, or a portion
of the outstanding Advances, by paying the entire principal balance (or any portion thereof), all accrued and unpaid interest thereon to the date of repayment, all unpaid Lenders&#146; fees and expenses due hereunder accrued to the date of the
repayment (including, without limitation, the portion of the End of Term Charge applicable to the aggregate original principal amount of the Term Loan Advances being prepaid in accordance with Section<U>&nbsp;2.6(a))</U>, together with a prepayment
charge equal to the following percentage of the outstanding principal amount of such Advance amount being so prepaid: with respect to each Advance<I> </I>(a)&nbsp;if the principal amount of such Advance amounts are prepaid on or prior to the date
which is twelve (12)&nbsp;months following the Closing Date, three percent (3.00)%; (b) if the principal amount of such Advance amounts are prepaid after the date which is twelve (12)&nbsp;months following the Closing Date but on or prior to the
date which is twenty-four (24)&nbsp;months following the Closing Date, two percent (2.00)%; and (c)&nbsp;thereafter through the day before the Term Loan Maturity Date, one percent (1.00)% (each, a &#147;<U>Prepayment Charge</U>&#148;). If at any
time Borrower elects to make a prepayment, and at such time, there are outstanding Advances under multiple Tranches, the Prepayment Charge shall be determined by applying the amount of such prepayment in the following order: first, to the
outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the latest initial funding date; second, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances
outstanding under the Tranche with the next latest initial funding date and so on until the entire principal balance of all Advances made hereunder (and all accrued but unpaid interest thereon) is paid in full.<I> </I>Borrower agrees that the
Prepayment Charge is a reasonable calculation of Lenders&#146; lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount
of all principal and accrued interest through the prepayment date and the Prepayment Charge upon the occurrence of a Change in Control or any other prepayment hereunder. Notwithstanding the foregoing, Agent and Lenders agree to waive the Prepayment
Charge if Agent and Lenders or their respective Affiliates (in their sole and absolute discretion) agree in writing to refinance the Advances prior to the Term Loan Maturity Date. Any amounts paid under this Section shall be applied by Agent to the
then unpaid amount of any outstanding Secured Obligations (including principal and interest) in such order and priority as Agent may choose in its sole discretion. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day
that is not a Business Day, the due date thereof shall be the immediately preceding Business Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>End of Term
Charge</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On the earliest to occur of (i)&nbsp;the Term Loan Maturity Date, (ii)&nbsp;the date that Borrower prepays
the outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) in full, (iii)&nbsp;the date that the outstanding Secured
Obligations become due and payable, or (iv)&nbsp;as required pursuant to <U>Section</U><U></U><U>&nbsp;2.5</U>, Borrower shall pay Lenders a charge equal to five and ninety-five hundredths of one percent (5.95%) <I><U>multiplied</U></I> by the
aggregate original principal amount of any Term Loan Advances funded hereunder (the &#147;<U>End of Term Charge</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the required payment date of such End of Term Charge,
the applicable pro rata portion of the End of Term Charge shall be deemed earned by Lenders as of each date that an applicable Term Loan Advance is made. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not
a Business Day, the due date thereof shall be the immediately preceding Business Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Pro Rata Treatment</U>. Each
payment (including prepayment) on account of any fee and any reduction of the Term Loan Advances shall be made pro rata according to the Term Commitments of the relevant Lender. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <U>Taxes; Increased Costs</U>. Borrower, Agent and Lenders each hereby agree to the terms and conditions set forth on
<U>Addendum 1</U> attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <U>Treatment of Prepayment Charge and End of Term Charge</U>. Borrower agrees that
any Prepayment Charge and any End of Term Charge payable shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and Borrower agrees that it is reasonable under the circumstances currently
existing and existing as of the Closing Date. The Prepayment Charge and the End of Term Charge shall also be payable in the event the Secured Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial
proceeding), deed in lieu of foreclosure, or by any other means. Each Loan Party expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits or may prohibit the collection of
the foregoing Prepayment Charge and End of Term Charge in connection with any such acceleration. Borrower agrees (to the fullest extent that each may lawfully do so): (a) each of the Prepayment Charge and the End of Term Charge is reasonable and is
the product of an arm&#146;s length transaction between sophisticated business people, ably represented by counsel; (b)&nbsp;each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market rates
at the time payment is made; (c)&nbsp;there has been a course of conduct between Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge as a charge (and not
interest) in the event of prepayment or acceleration; and (d)&nbsp;Borrower shall be estopped from claiming differently than as agreed to in this Section. Borrower expressly acknowledges that its agreement to pay each of the Prepayment Charge and
the End of Term Charge to Lenders as herein described was on the Closing Date and continues to be a material inducement to Lenders to provide the Term Loan Advances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. <U>SECURITY INTEREST</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Grant of Security Interest</U>. As security for the prompt and complete payment when due (whether on the payment dates
or otherwise) of all the Secured Obligations, each Borrower grants to Agent a security interest in all of such Borrower&#146;s right, title, and interest in, to and under all of such Borrower&#146;s personal property and other assets including
without limitation the following (except as set forth herein) whether now owned or hereafter acquired (collectively, the &#147;<U>Collateral</U>&#148;): (a) Receivables; (b)&nbsp;Equipment; (c) Fixtures; (d)&nbsp;General Intangibles;
(e)&nbsp;Inventory; (f) Investment Property; (g)&nbsp;Deposit Accounts; (h)&nbsp;Cash; (i) Goods; and all other tangible and intangible personal property of such Borrower whether now or hereafter owned or existing, leased, consigned by or to, or
acquired by, Borrower and wherever located, and any of such Borrower&#146;s property in the possession or under the control of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to,
substitutions and replacements for, and rents, profits and products of each of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 Notwithstanding the broad grant of the security interest set forth in
<U>Section&nbsp;3.1</U>, above, the Collateral shall not include (a)&nbsp;more than 65% of the presently existing and hereafter arising issued and outstanding Equity Interests owned by Borrower of any Excluded Subsidiary which Equity Interests
entitle the holder thereof to vote for directors or any other matter to the extent that Borrower has provided Agent reasonably satisfactory evidence that the grant of a security interest in excess of such percentage to secure the Secured Obligations
could reasonably be expected cause material adverse tax consequences for any Loan Party, (b)&nbsp;any &#147;intent to use&#148; trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a
statement of use with the United States Patent and Trademark Office or otherwise, <U>provided</U>, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-use</FONT></FONT> trademark application pursuant to 15 U.S.C. Section&nbsp;1060(a) (or any successor provision) such <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">intent-to-use</FONT></FONT> application shall constitute Collateral, and (c)&nbsp;nonassignable licenses or contracts, which by their terms require the consent of the licensor thereof or another party (but only to the
extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406, 9407 and 9408 of the UCC)&nbsp;(d) any Excluded Account, (e)&nbsp;any asset that is subject to a purchase money security interest
or lease permitted pursuant to the terms of this Agreement and which derives from an agreement which prohibits any junior security interest, other than to the extent that any such prohibition would be terminated or rendered unenforceable or
otherwise deemed ineffective by the UCC or any other Law, (f)&nbsp;any governmental licenses or state or local franchises, charters or authorizations, to the extent security interests in such licenses, franchises, charters or authorizations are
prohibited or restricted thereby, after giving effect to the applicable anti-assignment provisions of the UCC of any applicable jurisdiction or any other applicable Law notwithstanding such prohibition or restriction, (g)&nbsp;any leasehold
interests in real estate and (h)&nbsp;any assets as to which the Agent in its reasonable discretion shall determine that the costs and burdens of obtaining or perfecting a security interest therein substantially outweigh the benefit to the Lenders
of the security afforded thereby (including, without limitation, vehicles or other assets subject to a certificate of title). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION
4. <U>CONDITIONS PRECEDENT TO LOAN</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Lenders to make the Loan hereunder are subject to the satisfaction by
Borrower of the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Initial Advance</U>. On or prior to the Closing Date, Borrower shall have
delivered to Agent the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) duly executed copies of the Loan Documents (other than the Warrant, which shall be
an original), and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance
reasonably acceptable to Agent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) duly executed Account Control Agreement(s) with respect to each Deposit Account and
account holding Investment Property (other than an Excluded Account) maintained by Borrower or any Subsidiary; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) a legal
opinion of Borrower&#146;s counsel in form and substance reasonably acceptable to Agent; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) copy of resolutions of each Borrower&#146;s Board of Directors,
certified by an officer of such Borrower, evidencing (i)&nbsp;approval of the Loan and other transactions evidenced by the Loan Documents, (ii)&nbsp;authorizing a specified person or persons to execute the Loan Documents to which it is a party on
its behalf, (iii)&nbsp;authorizing a specified person or persons, on its behalf, to sign and/or dispatch all documents and notices (including, if relevant, any Advance Request or other relevant notice) to be signed and/or dispatched by it under or
in connection with the Loan Documents to which it is a party, and (iv)&nbsp;acknowledging that the Board of Directors are acting for a proper purpose and that the Loan Documents are in the best interests of that Borrower and for its commercial
benefit; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) copies of the Charter of Borrower, certified by the Secretary of State of the applicable jurisdiction of
organization and the other Organizational Documents, as amended through the Closing Date, of Borrower, certified by an officer of Borrower; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) a certificate of good standing for Borrower from its jurisdiction of organization and similar certificates from all other
jurisdictions in which it does business and where the failure to be qualified could have a Material Adverse Effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
certified copies, dated as of a recent date, of searches for financing statements; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) a duly executed payoff letter from
MidCap Financial Trust; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) evidence that (i)&nbsp;the Liens securing Indebtedness owed by Borrower to MidCap Financial
Trust will be terminated, and (ii)&nbsp;the documents and/or filings evidencing the perfection of such Liens, including without limitation any financing statements and/or control agreements, have been or will be, concurrently with or promptly after
the initial Advance, terminated; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) payment of the Due Diligence Fee, Initial Facility Charge and reimbursement of
Agent&#146;s and Lenders&#146; current <FONT STYLE="white-space:nowrap">non-legal</FONT> expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) a duly executed copy of the Perfection Certificate and each exhibit and addendum thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) all certificates of insurance and copies of each insurance policy and endorsements required hereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) duly executed bailee agreements for any bailee location holding a portion of Borrower&#146;s assets or property valued,
individually or in the aggregate, in excess of Five Hundred Thousand Dollars $(500,000), except for the bailee location located at No.&nbsp;99 Jishi East Road, Wu Jiang District, Suzhou City, Jiangsu Province, P.R. China 215200; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) (i)&nbsp;the certificates representing the Equity Interests required to be pledged pursuant to the Pledge Agreement,
together with an undated stock power or similar instrument of transfer for each such certificate endorsed in blank by a duly authorized officer of the pledgor thereof, and (ii)&nbsp;each material debt instrument (if any) endorsed (without recourse)
in blank (or accompanied by an transfer form endorsed in blank) by the pledgor thereof required to be pledged to Agent under the Pledge Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) all reports, declarations and forms required by the SBA, including but
not limited to SBA 652, SBA 1031 and SBA 480; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) such other documents as Agent may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>All Advances</U>. On each Advance Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Agent shall have received (i)&nbsp;an Advance Request for the relevant Advance as required by
<U>Section</U><U></U><U>&nbsp;2.2(c)</U>, duly executed by Borrower&#146;s Chief Executive Officer, Chief Financial Officer or Chief Accounting Officer, (ii)&nbsp;a duly executed Warrant with respect to the relevant Advance, together with the
original signature page of Borrower thereto, and (iii)&nbsp;any other documents Agent may reasonably request in good faith; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The representations and warranties set forth in this Agreement shall be true and correct in all material respects on and as
of the applicable Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its
part to be observed or performed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) With respect to any Advance (other than the Tranche 1 Advance) made available on
such Advance Date, the Loan Parties shall have paid the Tranche Facility Charge applicable to such Advance; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each
Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in <U>Section</U><U></U><U>&nbsp;4.2(b)</U>, <U>Section</U><U></U><U>&nbsp;4.2(c)</U> and
<U>Section</U><U></U><U>&nbsp;4.4</U> and as to the matters set forth in the Advance Request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>[Reserved]</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>No Default</U>. As of the Closing Date and at the time of and immediately after each Advance Date, (i)&nbsp;no fact or
condition exists that could (or could, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii)&nbsp;no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is
continuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. <U>REPRESENTATIONS AND WARRANTIES OF BORROWER</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower represents and warrants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Corporate Status; Execution and Delivery; Binding Effect</U>. Each Borrower is a corporation or limited liability
company, as the case may be, duly organized, legally existing and in good standing under the laws of its jurisdiction of incorporation or formation, and is duly qualified as a foreign corporation, limited liability company or partnership, as the
case may be, in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect. Borrower&#146;s
present name, former names (if any), locations, place of formation, tax identification number, organizational identification number and other information are correctly set forth in <U>Exhibit B</U>, as may be updated by Borrower in a written notice
(including any Compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Certificate) provided to Agent after the Closing Date in accordance with this Agreement. This Agreement has been, and each other Loan Document, when delivered hereunder, will have been, duly
executed and delivered by the Borrower. This Agreement constitutes, and each other Loan Document when so delivered will constitute, a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms,
except as such enforceability may be limited by bankruptcy, insolvency, reorganization, receivership, moratorium or other laws affecting creditors&#146; rights generally and by general principles of equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Collateral</U>. Borrower owns or otherwise has the rights in the Collateral, free of all Liens, except for Permitted
Liens. Borrower has the power and authority to grant to Agent a Lien in the Collateral as security for the Secured Obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Consents</U>. Borrower&#146;s execution, delivery and performance of this Agreement and all other Loan Documents to
which it is a party, (i)&nbsp;have been duly authorized by all necessary action of Borrower in accordance with its Organizational Documents and applicable law, (ii)&nbsp;will not result in the creation or imposition of any Lien upon the Collateral,
other than Permitted Liens, (iii)&nbsp;do not violate (A)&nbsp;any provisions of Borrower&#146;s Organizational Documents or (B)&nbsp;any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject in any material
respect and (iv)&nbsp;except as described on <U>Schedule 5.3</U>, do not violate any material contract or agreement or require the consent or approval of any other Person or Governmental Authority which has not already been obtained. The individual
or individuals executing the Loan Documents on behalf of Borrower are duly authorized to do so. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Material Adverse
Effect</U>. No event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. Borrower is not aware of any event or circumstance that is likely to occur that is reasonably expected to result in a
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Actions Before Governmental Authorities</U>. There are no actions, suits, claims, disputes
or proceedings at law or in equity or by or before any Governmental Authority now pending or, to the knowledge of Borrower, threatened against or affecting Borrower or its property, that is reasonably expected to result in a Material Adverse Effect.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Laws</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither Borrower nor any of its Subsidiaries is in violation of any law, rule or regulation, or in default with respect to
any judgment, writ, injunction or decree of any Governmental Authority to which Borrower or such Subsidiaries are subject, where such violation or default could reasonably be expected to result in a Material Adverse Effect. Borrower is not in
default in any manner under any provision of any agreement or instrument evidencing material Indebtedness, or any other agreement to which it is a party or by which it is bound. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither Borrower nor any of its Subsidiaries is an &#147;investment company,&#148; a company that would be an
&#147;investment company&#148; except for the exclusion from the definition of &#147;investment company&#148; in Section&nbsp;3(c) of the Investment Company Act of 1940, as amended (the &#147;<U>1940 Act</U>&#148;), or a company
&#147;controlled&#148; by an &#147;investment company&#148; under the 1940 Act. Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the
Federal Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a &#147;holding company&#148; or an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;affiliate&#148; of a &#147;holding company&#148; or a &#147;subsidiary company&#148; of a &#147;holding company&#148; as each term is defined and used in the Public Utility Holding Company
Act of 2005. Neither Borrower&#146;s nor any of its Subsidiaries&#146; properties or assets have been used by Borrower or such Subsidiary or, to Borrower&#146;s knowledge, by previous Persons, in disposing, producing, storing, treating, or
transporting any hazardous substance other than in material compliance with applicable laws. Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all
notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) None of Borrower, any of its Subsidiaries, or any of Borrower&#146;s or its Subsidiaries&#146; Affiliates or any of their
respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i)&nbsp;in violation of any Anti-Terrorism Law, (ii)&nbsp;engaging in or conspiring to engage in any transaction that
evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii)&nbsp;is a Blocked Person. None of Borrower, any of its Subsidiaries, or (to the knowledge of
Borrower) any of their Affiliates or agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x)&nbsp;conducts any business or engages in making or receiving any contribution of funds, goods or
services to or for the benefit of any Blocked Person, or (y)&nbsp;deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No.&nbsp;13224, any similar executive order or
other Anti-Terrorism Law. None of the funds to be provided under this Agreement will be used, directly or indirectly, (a)&nbsp;for any activities in violation of any applicable anti-money laundering, economic sanctions and anti-bribery laws and
regulations or (b)&nbsp;for any payment to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct
business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Information Correct and Current</U>. No information, report, Advance Request, financial statement, exhibit or schedule
furnished, by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained, or, when taken as a whole, contains or will contain any material misstatement of fact or, when taken
together with all other such information or documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not materially
misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Agent, whether prior to or after the Closing Date, shall be (i)&nbsp;provided in good faith and based
on the most current data and information available to Borrower, and (ii)&nbsp;the most current of such projections provided to Borrower&#146;s Board of Directors (it being understood that the projections and forecasts provided by Borrower in good
faith and based upon reasonable assumptions are not viewed as facts, that such projections are subject to significant uncertainties and contingencies, many of which are beyond the control of Borrower, that no assurance is given that any particular
projections will be realized, and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Tax Matters</U>. Except as set forth on <U>Schedule 5.8</U>, (a) Borrower and its Subsidiaries have filed all federal
and state income Tax returns and other material Tax returns that they are required to file, (b)&nbsp;Borrower and its Subsidiaries have duly paid all federal and state income Taxes and other material Taxes or installments thereof that they are
required to pay, except Taxes being contested in good faith by appropriate proceedings and for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP, and (c)&nbsp;to the best of Borrower&#146;s knowledge, no proposed
or pending Tax assessments, deficiencies, audits or other proceedings with respect to Borrower or any Subsidiary have had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Intellectual Property Claims</U>. Borrower is the sole owner of, or
otherwise has the right to use, the Intellectual Property material to Borrower&#146;s business. Except as described on Schedule 5.9 and as may be updated by Borrower in a written notice provided from time to time after the Closing Date, (i)&nbsp;to
the best knowledge of Borrower each of the material Copyrights, Trademarks and Patents (other than patent applications) is valid and enforceable, (ii)&nbsp;no material part of the Intellectual Property has been judged invalid or unenforceable, in
whole or in part, and (iii)&nbsp;except as set forth in any previously delivered Compliance Certificate in accordance with Section&nbsp;7.1(d), no claim has been made to Borrower in writing that any material part of the Intellectual Property
violates the rights of any third party. Exhibit&nbsp;C is a true, correct and complete list of each of Borrower&#146;s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property
from third parties (other than shrink-wrap software licenses or other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> licenses or open-source software), together with application or
registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform (when and as required) any material obligations under, any of
the foregoing material contracts, licenses or agreements and, to Borrower&#146;s knowledge, no third party to any such material contract, license or agreement is in material breach thereof or has failed to perform (when and as required) any material
obligations thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as described on <U>Schedule 5.10</U>, to its best knowledge, Borrower has all material rights with respect to
intellectual property necessary in the operation or conduct of Borrower&#146;s business as currently conducted by Borrower. Without limiting the generality of the foregoing, except for restrictions that are unenforceable under Division 9 of the UCC
or otherwise permitted under this Agreement with respect to Licenses which have any material value, Borrower has the right, to the extent required to operate Borrower&#146;s business, to freely transfer, license or assign Intellectual Property
necessary or material in the operation or conduct of Borrower&#146;s business as currently conducted and proposed to be conducted by Borrower, without condition, restriction or payment of any kind (other than license or royalty payments in the
ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are material
in the operation or conduct of Borrower&#146;s business and used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products except customary covenants in inbound license agreements and
equipment leases where Borrower is the licensee or lessee. Except as disclosed on <U>Schedule 5.10</U> as may be deemed updated from time to time by delivery of each delivered Compliance Certificate, Borrower is not a party to, nor is it bound by,
any Restricted License. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No material software or other materials used by Borrower or any of its Subsidiaries (or used
in any Borrower Products or any Subsidiaries&#146; products) are subject to an open-source or similar license (including but not limited to the General Public License, Lesser General Public License, Mozilla Public License, or Affero License) in a
manner that would cause such software or other materials to have to be (i)&nbsp;distributed to third parties at no charge or a minimal charge (royalty-free basis); (ii) licensed to third parties to modify, make derivative works based on, decompile,
disassemble, or reverse engineer; or (iii)&nbsp;used in a manner that requires disclosure or distribution in source code form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There are no material unpaid fees or royalties under any Material
Agreements that have become overdue. Each Material Agreement is in full force and effect and is legal, valid, binding, and enforceable in accordance with its respective terms, except as may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws relating to or limiting creditors&#146; rights generally or by equitable principles relating to enforceability. Except as set forth on Schedule 5.10(c), to the knowledge of Borrower, neither Borrower nor any of its
Subsidiaries, as applicable, is in breach of or default in any manner that could reasonably be expected to materially affect the Borrower Products under any Material Agreement to which it is a party, and no circumstances or grounds exist that would
give rise to a claim of breach or right of rescission, termination or nonrenewal of any of the Material Agreements, including the execution, delivery and performance of this Agreement and the other Loan Documents.. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Borrower Products</U>. Except as set forth on <U>Schedule 5.11</U>, no Intellectual Property owned by Borrower or
Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened (in writing) litigation, proceeding (including any <FONT STYLE="white-space:nowrap">non-prosecution</FONT> proceeding in the United States Patent and
Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any manner Borrower&#146;s use, transfer or licensing thereof or that may affect the
validity, use or enforceability thereof. There is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or
ownership interest in any future Intellectual Property material to the operation or conduct of the business of Borrower or Borrower Products. Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or
claim, challenging or questioning Borrower&#146;s ownership in any material Intellectual Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that
any third party has any claim of legal or beneficial ownership with respect thereto nor, to the knowledge of Borrower, is there a reasonable basis for any such claim. Neither Borrower&#146;s use of its Intellectual Property nor the production and
sale of Borrower Products infringes the valid Intellectual Property rights or other rights of others. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Financial
Accounts</U>. Exhibit D, as may be updated by Borrower in a written notice provided to Agent after the Closing Date, is a true, correct and complete list of (a)&nbsp;all banks and other financial institutions at which Borrower or any Subsidiary
maintains Deposit Accounts and (b)&nbsp;all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other
institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Employee Loans</U>. Except for loans constituting Permitted Investments or as described on <U>Schedule 5.13</U>,
Borrower has no outstanding loans to any employee, officer or director of Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of Borrower by a third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 <U>Subsidiaries</U>. Borrower does not own any stock, partnership interest or other securities of any Person, except for
Permitted Investments. Attached as <U>Schedule 5.14</U>, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.15 <U>Solvency</U>. The fair salable value of Borrower&#146;s consolidated
assets (including goodwill minus disposition costs) exceeds the fair value of Borrower&#146;s liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement; and Borrower and each of its Subsidiaries are
able to pay their debts (including trade debts) as they mature. The amount of any contingent liability at any time shall be computed as the amount that would reasonably be expected to become an actual and matured liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. <U>INSURANCE; INDEMNIFICATION</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Coverage</U>. Borrower shall cause to be carried and maintained commercial general liability insurance covering Borrower
and its Subsidiaries, on an occurrence form, against risks and in such amounts customarily insured against in Borrower&#146;s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury,
advertising injury, and contractual liability per the terms of the indemnification agreement found in <U>Section</U><U></U><U>&nbsp;6.3</U>. Borrower must maintain a minimum of One Million Dollars ($1,000,000) of commercial general liability
insurance for each occurrence. Borrower maintains and shall continue to maintain a minimum of Two Million Dollars ($2,000,000) of directors&#146; and officers&#146; insurance for each occurrence and Five Million Dollars ($5,000,000) in the
aggregate. So long as there are any Secured Obligations outstanding (other than inchoate indemnity obligations which, by their terms, survive termination of this Agreement), Borrower shall also cause to be carried and maintained insurance upon the
business and assets of Borrower and its Subsidiaries, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to
standard exceptions and deductibles. If Borrower fails to obtain the insurance called for by this <U>Section</U><U></U><U>&nbsp;6.1</U> or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under
this Agreement or any other Loan Document or which may be required to preserve the Collateral, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are immediately due and payable, bearing interest at the then
highest rate applicable to the Secured Obligations, and secured by the Collateral.&nbsp;Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time
thereafter.&nbsp;No payments by Agent are deemed an agreement to make similar payments in the future or Agent&#146;s waiver of any Event of Default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Certificates</U>. Borrower shall deliver to Agent certificates of insurance that evidence Borrower&#146;s compliance
with its insurance obligations in <U>Section</U><U></U><U>&nbsp;6.1</U> and the obligations contained in this <U>Section</U><U></U><U>&nbsp;6.2</U>. Borrower&#146;s insurance certificate shall reflect Agent (shown as &#147;Hercules Capital, Inc., as
Agent, and its successors and/or assigns&#148;) is an additional insured for commercial general liability, a lenders loss payable for all risk property damage insurance, subject to the insurer&#146;s approval, and a lenders loss payable for property
insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender&#146;s loss
payable endorsements for all risk property damage insurance. All certificates of insurance will provide for a minimum of thirty (30)&nbsp;days advance written notice to Agent of cancellation (other than cancellation for <FONT
STYLE="white-space:nowrap">non-payment</FONT> of premiums, for which ten (10)&nbsp;days&#146; advance written notice shall be sufficient). Any failure of Agent to scrutinize such insurance certificates for compliance is not a waiver of any of
Agent&#146;s rights, all of which are reserved. Borrower shall provide Agent with copies of each insurance policy, and upon entering or amending any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies and
shall promptly deliver to Agent updated insurance certificates with respect to such policies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Indemnity</U>. Borrower agrees to indemnify and hold Agent, Lenders
and their officers, directors, employees, agents, <FONT STYLE="white-space:nowrap">in-house</FONT> attorneys, representatives and shareholders (each, an &#147;<U>Indemnified Person</U>&#148;) harmless from and against any and all third-party claims,
costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable and documented attorneys&#146; fees and disbursements and
other costs of investigation or defense (including those incurred upon any appeal) (collectively, &#147;<U>Liabilities</U>&#148;), that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been
extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to
act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent such Liabilities arise solely out of gross negligence or willful misconduct of any Indemnified Person
or changes in income tax rates. This <U>Section</U><U></U><U>&nbsp;6.3</U> shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any <FONT STYLE="white-space:nowrap">non-Tax</FONT>
claim. In no event shall any Indemnified Person be liable on any theory of liability for any special, indirect, consequential or punitive damages (including any loss of profits, business or anticipated savings). This
<U>Section</U><U></U><U>&nbsp;6.3</U> shall survive the repayment of indebtedness under, and otherwise shall survive the expiration or other termination of, this Agreement, in each case, subject to the applicable statute of limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. <U>COVENANTS OF BORROWER</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Financial Reports</U>. Borrower shall furnish to Agent the financial statements and reports listed hereinafter (the
&#147;<U>Financial Statements</U><B><I>&#148;):</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) as soon as practicable (and in any event within thirty
(30)&nbsp;days) after the end of each month, unaudited interim and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> financial statements as of the end of such month (prepared on a consolidated basis, if
applicable), including balance sheet and related statements of income accompanied by a report detailing the commencement of any material litigation by or against Borrower or any other occurrence that could reasonably be expected to have a Material
Adverse Effect, all certified by Borrower&#146;s Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or other authorized executive of Borrower to the effect that they have been prepared in accordance with GAAP, except
(i)&nbsp;for the absence of footnotes, (ii)&nbsp;that they are subject to normal quarter and <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments, and (iii)&nbsp;they do not contain certain <FONT STYLE="white-space:nowrap">non-cash</FONT>
items that are customarily included in quarterly and annual financial statements; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) as soon as practicable (and in any
event within forty-five (45)&nbsp;days) after the end of each calendar quarter), unaudited interim and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> financial statements as of the end of such calendar
quarter (prepared on a consolidated basis, if prepared), including balance sheet and related statements of income and cash flows, certified by Borrower&#146;s Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or other
authorized executive of Borrower to the effect that they have been prepared in accordance with GAAP, except (i)&nbsp;for the absence of footnotes, and (ii)&nbsp;that they are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT>
adjustments; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) as soon as practicable (and in any event within ninety (90)) after the
end of each fiscal year, unqualified (other than as to going concern qualification based solely on the upcoming maturity date of the Secured Obligations under this Agreement occurring within 12 months of the date of such audit, any Loan Party having
negative profits or a determination that any Loan Party has less than 12 months liquidity) audited financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if prepared), including balance sheet and,
related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified without qualification (other than as to going concern qualification based solely on the upcoming
maturity date of the Secured Obligations under this Agreement occurring within 12 months of the date of such audit, any Loan Party having negative profits or a determination that any Loan Party has less than 12 months liquidity) by a firm of
independent certified public accountants selected by Borrower and reasonably acceptable to Agent, accompanied by any management report from such accountants; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) as soon as practicable (and in any event within thirty (30)&nbsp;days) after the end of each month, a Compliance
Certificate in the form of Exhibit E; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) as soon as practicable (and in any event within thirty (30)&nbsp;days) after the
end of each month, a report showing agings of accounts receivable and accounts payable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) promptly after the sending or
filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that Company has made available to holders of its common stock and copies of any regular, periodic and special reports or registration statements
that Company files with the Securities and Exchange Commission or any Governmental Authority that may be substituted therefor, or any national securities exchange; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) upon Agent&#146;s request, copies of any material Governmental Approvals obtained by Borrower or any of its Subsidiaries;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) at the same time and in the same manner as provided to the investors of Borrower that are not members of
Borrower&#146;s Board of Directors, such materials prepared and provided or made available by Borrower on a quarterly basis to all such investors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) financial and business projections promptly following their approval by Company&#146;s Board of Directors, and in any
event, within sixty (60)&nbsp;days prior to the end of Borrower&#146;s fiscal year, as well as budgets, operating plans and other financial information reasonably requested by Agent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) [Reserved]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) insurance renewal statements, annually or otherwise promptly upon renewal of insurance policies required to be maintained
in accordance with <U>Section</U><U></U><U>&nbsp;6.1</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) prompt notice of any legal process that is reasonably likely
to result in damages, judgements or penalties against any Loan Party in excess of One Million Dollars ($1,000,000); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) prompt (but in any event no more than three (3)&nbsp;Business Days&#146;) notice if Borrower or any Subsidiary has
knowledge that Borrower, or any Subsidiary or controlled Affiliate of Borrower, is listed on the OFAC Lists or (a)&nbsp;is convicted on, (b)&nbsp;pleads <I>nolo contendere</I> to, (c)&nbsp;is indicted on, or (d)&nbsp;is arraigned and held over on
charges involving money laundering or predicate crimes to money laundering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Borrower shall not make any change in its (a)&nbsp;accounting policies or reporting
practices(other than as permitted under GAAP or pursuant to applicable securities laws or regulations of the SEC), or (b)&nbsp;fiscal years or fiscal quarters. The fiscal year of Borrower shall end on December 31. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The executed Compliance Certificate, and all Financial Statements required to be delivered hereunder shall be sent via <FONT
STYLE="white-space:nowrap">e-mail</FONT> to financialstatements@htgc.com with a copy to lmcguire@htgc.com and cbarnes@htgc.com provided, that if <FONT STYLE="white-space:nowrap">e-mail</FONT> is not available or sending such Financial Statements via
<FONT STYLE="white-space:nowrap">e-mail</FONT> is not possible, they shall be faxed to Agent at: (650) <FONT STYLE="white-space:nowrap">473-9194,</FONT> attention Account Manager: Sight Sciences, Inc.. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, documents required to be delivered under <U>Sections 7.1(a)</U>, <U>(b)</U>, <U>(c)</U> or <U>(f)</U> (to the
extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower emails a link thereto to Agent; provided that
Borrower shall directly provide Agent all Financial Statements required to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;7.1(b)</U> and <U>(c)</U>&nbsp;hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Management Rights</U>. Borrower shall permit any representative that Agent or Lenders authorizes, including its
attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours; <U>provided</U>, however,
that so long as no Event of Default has occurred and is continuing, such examinations shall be limited to no more often than once per fiscal year. In addition, in connection with such inspections, any such representative shall have the right to meet
with management and officers of Borrower to discuss such books of account and records at reasonable times and upon reasonable notice. In addition, Agent or Lenders shall be entitled at reasonable times and intervals to consult with and advise the
management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower&#146;s business operations. The parties intend that the rights granted Agent and Lenders
shall constitute &#147;management rights&#148; within the meaning of 29 C.F.R. <FONT STYLE="white-space:nowrap">Section&nbsp;2510.3-101(d)(3)(ii),</FONT> but that any advice, recommendations or participation by Agent or Lenders with respect to any
business issues shall not be deemed to give Agent or Lenders, nor be deemed an exercise by Agent or Lenders of, control over Borrower&#146;s management or policies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Further Assurances</U>. Borrower shall, and shall cause each other Loan Party to, from time to time execute, deliver and
file, alone or with Agent, any financing statements, security agreements, collateral assignments, notices, control agreements, promissory notes or other documents to perfect, give the highest priority to Agent&#146;s Lien on the Collateral, subject
to Permitted Liens, or otherwise evidence Agent&#146;s rights herein, in each case as reasonably requested by Agent. Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Agent, and take all further
action that may be necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby or pursuant to applicable Loan Documents. In addition, and for such purposes only, Borrower hereby authorizes Agent to execute and
deliver on behalf of Borrower and to file such financing statements (including an indication that the financing statement covers &#147;all assets or all personal property&#148; of Borrower in accordance with Section&nbsp;9504 of the UCC) without the
signature of Borrower either in Agent&#146;s name or in the name of Agent as agent and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for Borrower. Borrower shall in good faith and in its reasonable
commercial discretion, in each case subject to the terms of this Agreement, protect and defend Borrower&#146;s title to the Collateral and Agent&#146;s Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than
Permitted Liens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <U>Indebtedness</U>. Borrower shall not create, incur, assume, guarantee
or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except
for (a)&nbsp;the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion, (b)&nbsp;purchase money Indebtedness pursuant to its then applicable payment schedule or with
other purchase money Indebtedness permitted hereunder, (c)&nbsp;prepayment by any Loan Party or its Subsidiary of (i)&nbsp;inter-company Indebtedness owed by such Subsidiary or Loan Party to any Loan Party, or (ii)&nbsp;if such Subsidiary is not a
Loan Party, intercompany Indebtedness owed by such Subsidiary that is not a Loan Party to another Subsidiary that is not a Loan Party, (d)&nbsp;as may be permitted under any Subordination Agreement, (e)&nbsp;Permitted Indebtedness with the proceeds
of other Permitted Indebtedness and (f)&nbsp;as otherwise permitted hereunder or approved in writing by Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5
<U>Collateral</U>. Borrower shall at all times keep the Collateral and all other property and assets used in Borrower&#146;s business or in which Borrower now or hereafter holds any interest free and clear from any Liens whatsoever (except for
Permitted Liens) Borrower shall not agree with any Person other than Agent or Lenders not to encumber its property other than in connection with Permitted Liens. Borrower shall not enter into or suffer to exist or become effective any agreement that
prohibits or limits the ability of any Borrower to create, incur, assume or suffer to exist any Lien upon any of its property (including Intellectual Property), whether now owned or hereafter acquired, to secure its obligations under the Loan
Documents to which it is a party other than (i)&nbsp;this Agreement and the other Loan Documents, (ii)&nbsp;any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or
limitation shall only be effective against the assets financed thereby) and (iii)&nbsp;customary restrictions on the assignment of leases, licenses and other agreements. Borrower shall cause its Subsidiaries to protect and defend such
Subsidiary&#146;s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary&#146;s property and assets free and clear from Liens
whatsoever (except for Permitted Liens). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 <U>Investments</U>. Borrower shall not directly or indirectly acquire or own,
or make any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 <U>Distributions</U>. Borrower shall not, and shall not allow any Subsidiary to, (a)&nbsp;repurchase or redeem any class of
stock or other Equity Interest other than pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in each case the repurchase or redemption price does not exceed Five Hundred Thousand Dollars
($500,000) per fiscal year, or (b)&nbsp;declare or pay any cash dividend or make any other cash distribution on any class of stock or other Equity Interest, except that (i)&nbsp;a Subsidiary may pay dividends or make other distributions to Borrower
or any Subsidiary of Borrower, and (ii)&nbsp;any Loan Party may make payments in cash for fractional shares/units upon conversion or in connection with the exercise or conversion of warrants or other securities, or (c)&nbsp;except for Permitted
Investments, lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate, or (d)&nbsp;the conversion of any of its
convertible securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange thereof, (e)&nbsp;the repurchases described in clause (iii)&nbsp;of &#147;Permitted Investments&#148; or (f)&nbsp;waive,
release or forgive any Indebtedness owed by any employees, officers or directors in excess of Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 <U>Transfers</U>. Except for Permitted Transfers, Borrower shall not,
and shall not permit any Subsidiary to, voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey (&#147;<U>Transfer</U>&#148;) any equitable, beneficial or legal interest in any material portion of its assets
(including, without limitation, pursuant to a Division). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9 <U>Mergers and Consolidations</U>. Borrower shall not, nor
will it permit any Subsidiary to, merge, dissolve, liquidate, consolidate with or into another Person, or dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter
acquired) to or in favor of any Person (other than (i)&nbsp;mergers or consolidations of (a)&nbsp;a Subsidiary which is not a Borrower into another Subsidiary or into Loan Party, or (b)&nbsp;a Loan Party into another Loan Party (provided that
Company shall be the surviving entity in any transaction involving Company) and (ii)&nbsp;Permitted Acquisitions). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10
<U>Taxes</U>. Borrower shall, and shall cause each of its Subsidiaries to, pay when due all material Taxes of any nature whatsoever now or hereafter imposed or assessed against Borrower or such Subsidiary or the Collateral or upon Borrower&#146;s
(or such Subsidiary&#146;s) ownership, possession, use, operation or disposition thereof or upon Borrower&#146;s (or such Subsidiary&#146;s) rents, receipts or earnings arising therefrom. Borrower shall, and shall cause each of its Subsidiaries to,
file on or before the due date therefor (taking into account proper extensions) all federal and state income Tax returns and other material Tax returns required to be filed. Notwithstanding the foregoing, Borrower and its Subsidiaries may contest,
in good faith and by appropriate proceedings diligently conducted, Taxes for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11 <U>Corporate Changes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No Loan Party shall change its corporate name, legal form or jurisdiction of formation without twenty (20)&nbsp;days&#146;
prior written notice to Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No Loan Party shall suffer a Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No Loan Party shall relocate its chief executive office or its principal place of business unless: (i)&nbsp;it has provided
prior written notice to Agent; and (ii)&nbsp;(x) to the extent such Loan Party is a Domestic Subsidiary, such relocation shall be within the continental United States of America and (y)&nbsp;to the extent such Loan Party is not Domestic Subsidiary,
such relocation shall be within the country and legal regime of the one in which its chief executive office or its principal place of business was when it became a Loan Party, unless otherwise approved by Agent in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If Borrower intends to add any new offices or business locations, including warehouses, containing any portion of
Borrower&#146;s assets or property valued, individually or in the aggregate, in excess of Five Hundred Thousand Dollars $(500,000), then Borrower will cause the landlord of any such new offices or business locations, including warehouses, to execute
and deliver a landlord consent in form and substance reasonably satisfactory to Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If Borrower intends to deliver
any portion of Borrower&#146;s assets or property valued, individually or in the aggregate, in excess of Five Hundred Thousand Dollars $(500,000) to a bailee, and Agent and such bailee are not already parties to a bailee agreement governing both the
Collateral and the location to which Borrower intends to deliver the Collateral, then Borrower will cause such bailee to execute and deliver a bailee agreement in form and substance satisfactory to Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Borrower will not, and will not permit any Loan Party to, engage to
any material extent in any business other than those businesses conducted by the Borrower and its Subsidiaries on the date hereof or any business reasonably related or incidental thereto or representing a reasonable expansion thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.12 <U>Deposit Accounts</U>. Other than Excluded Accounts, no Loan Party shall maintain any Deposit Accounts, or accounts
holding Investment Property, except with respect to which Agent has an Account Control Agreement. Furthermore, Borrower shall not maintain any Deposit Accounts, or accounts holding Investment Property, outside of the United States except for
(i)&nbsp;Borrower&#146;s accounts in the UK which shall not hold amounts in excess of GBP (&pound;)10,000 and (ii)&nbsp;Borrower&#146;s accounts in the Germany which shall not hold amounts in excess of EUR &#128;&nbsp;125,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.13 <U>Joinder of Subsidiaries</U>. Borrower shall notify Agent of each Subsidiary formed or acquired subsequent to the
Closing Date (including any new Subsidiary formed by Division) and, within twenty (20)&nbsp;days of such formation or acquisition (or such longer period of time as agreed to by Agent in writing in its sole discretion), shall cause any such
Subsidiary that is not an Excluded Subsidiary to execute and deliver to Agent a Joinder Agreement and such other documents and instruments as shall be requested by Agent to effectuate the transactions contemplated by such Joinder Agreement (in each
case in form and substance reasonably acceptable to Agent), or, if requested by Agent, a Guaranty and appropriate collateral security documents to secure the obligations pursuant to such Guaranty (in each case in form and substance reasonably
acceptable to Agent); it being agreed that if such new Subsidiary that is not an Excluded Subsidiary is formed by a Division, the foregoing requirements shall be satisfied substantially concurrently with the formation of such Subsidiary that is not
an Excluded Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.14 [<U>Reserved]</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.15 <U>Notification of Event of Default</U>. Borrower shall notify Agent promptly, in any event within three (3)&nbsp;Business
Days, upon knowledge thereof of the occurrence of any Event of Default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.16 <U>SBA</U>. One or more affiliates of Agent
have received a license from the U.S. Small Business Administration (&#147;<U>SBA</U>&#148;) to extend loans as a small business investment company (&#147;<U>SBIC</U>&#148;) pursuant to the Small Business Investment Act of 1958, as amended, and the
associated regulations (collectively, the &#147;<U>SBIC Act</U>&#148;). Portions of the Loan to Borrower may be made by a Lender that is a SBIC. <U>Addendum 2</U> to this Agreement outlines various responsibilities of Agent, each Lender and Borrower
associated with a loan made by a SBIC, and such <U>Addendum 2</U> is hereby incorporated in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.17 <U>Use of
Proceeds</U>. Borrower agrees that the proceeds of the Loans shall be used solely to refinance existing indebtedness, to pay related fees and expenses in connection with the Loan Documents and for working capital and general corporate purposes. The
proceeds of the Loans will not be used in violation of Anti-Corruption Laws or applicable Sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.18
<U>[Reserved]</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.19 <U>Material Agreement</U>. Borrower shall give prompt written notice to
Agent of entering into a Material Agreement or materially amending or terminating a Material Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.20 <U>Compliance
with Laws</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Borrower (i)&nbsp;shall maintain, and shall cause its Subsidiaries to maintain, compliance in all
material respects with all material applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and (ii)&nbsp;shall, or cause its Subsidiaries to, obtain
and maintain all required material governmental authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary in connection with the conduct of Borrower&#146;s business. Borrower shall not become an &#147;investment
company,&#148; a company that would be an &#147;investment company&#148; except for the exclusion from the definition of &#147;investment company&#148; in Section&nbsp;3(c) of the 1940 Act, as amended, or a company controlled by an &#147;investment
company&#148; under the 1940 Act, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation X, T and U of the Federal Reserve Board of Governors). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any controlled
Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its
Subsidiaries, permit any controlled Affiliate to, directly or indirectly, (i)&nbsp;conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of
funds, goods or services to or for the benefit of any Blocked Person, (ii)&nbsp;deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No.&nbsp;13224 or any similar
executive order or other <FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> Law, or (iii)&nbsp;engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of
the prohibitions set forth in Executive Order No.&nbsp;13224 or other <FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Borrower has implemented and shall maintain in effect policies and procedures designed to reasonably ensure compliance by
Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective officers and employees and to the knowledge of Borrower
its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) None of Borrower, any of its Subsidiaries or any of their respective directors, officers or employees, or to the knowledge
of Borrower, any agent for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. No Loan, use of proceeds or other transaction contemplated by
this Agreement will violate Anti-Corruption Laws or applicable Sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.21 <U>Financial Covenants</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Minimum Cash</U>. Beginning on the Closing Date and at all times thereafter, Borrower shall maintain Qualified Cash in
an amount greater than or equal to (i)&nbsp;prior to the date that Agent receives evidence, in form and substance reasonably satisfactory to Agent, that the Company has achieved Performance Milestone I, eighty-five percent (85%) of the Secured
Obligations, and (ii)&nbsp;from and after the date that Agent receives evidence, in form and substance reasonably satisfactory to Agent, that the Company has achieved Performance Milestone I, thirty-five percent (35%) of the Secured Obligations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Minimum Net Revenue</U>. From the date that Agent receives evidence,
in form and substance reasonably satisfactory to Agent, that the Company has achieved Performance Milestone I and tested as of the last day of each calendar month thereafter, Borrower shall achieve T6M Revenue of at least 80% of the T6M Revenue
included in the Board Approved Forecast for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ending on the last day of such calendar month. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Minimum Net Revenue covenant set forth in 7.21(b) above shall not apply at any time in which
Borrower (x)&nbsp;(i) maintains a Market Capitalization in excess of Four Hundred Million Dollars ($400,000,000) and (ii)&nbsp;maintains Qualified Cash in an amount greater than or equal to seventy percent (70%) of the Secured Obligations or
(y)&nbsp;maintains Qualified Cash in an amount equal greater than or equal to one hundred percent (100%) of the Secured Obligations (the &#147;Waiver Condition&#148;). For the avoidance of doubt, the Waiver Condition is subject to satisfaction on a
daily basis, and if Borrower fails to satisfy either the preceding clause (x)&nbsp;or (y) of the Waiver Condition as of any day, Borrower shall be required to demonstrate compliance with the Minimum Net Revenue covenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.22 <U>Intellectual Property</U>. Each Borrower shall (i)&nbsp;use commercially reasonable efforts to protect, defend and
maintain the validity and enforceability of its Intellectual Property; (ii)&nbsp;promptly advise Agent in writing of material infringements of its Intellectual Property; and (iii)&nbsp;not allow any Intellectual Property material to Borrowers&#146;
business to be abandoned, forfeited or dedicated to the public without Agent&#146;s written consent not to be unreasonably withheld, delayed or conditioned. If a Borrower (a)&nbsp;obtains any Patent, registered Trademark, registered Copyright,
registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (b)&nbsp;applies for any Patent or the registration of any Trademark, then such Borrower shall promptly provide written notice
thereof to Agent (and no later than with the next due monthly Compliance Certificate) and shall execute such intellectual property security agreements and other documents and take such other actions as Agent may request in its good faith business
judgment to perfect and maintain a first priority perfected security interest in favor of Agent in such property. If a Borrower decides to register any Copyrights or mask works in the United States Copyright Office, such Borrower shall:
(x)&nbsp;provide Agent with contemporaneous written notice of such Borrower&#146;s intent to register such Copyrights or mask works together with a copy of the application it intends to file with the United States Copyright Office (excluding
exhibits thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Agent may request in its good faith business judgment to perfect and maintain a first priority perfected security
interest in favor of Agent in the Copyrights or mask works intended to be registered with the United States Copyright Office; and (z)&nbsp;record such intellectual property security agreement with the United States Copyright Office contemporaneously
with filing the Copyright or mask work application(s) with the United States Copyright Office. Borrowers shall promptly provide to Agent copies of all applications that it files for Patents or for the registration of Trademarks, Copyrights or mask
works, together with evidence of the recording of the intellectual property security agreement required for Agent to perfect and maintain a first priority perfected security interest in such property, such notice to be provided in the form of
monthly updates with the next due monthly Compliance Certificate. Borrower shall provide written notice to Agent within fifteen (15)&nbsp;Business Days of entering or becoming bound by any Restricted License (other than <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software that is commercially available to the public). Borrower shall use commercially reasonable efforts if reasonably requested of Agent to obtain the consent
of, or waiver by, any person whose consent or waiver is necessary for (1)&nbsp;any Restricted License to be deemed &#147;Collateral&#148; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
for Agent to have a security interest in it that might otherwise be restricted or prohibited by law or by the terms of any such Restricted License, whether now existing or entered into in the
future, and (2)&nbsp;Agent to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Agent&#146;s rights and remedies under this Agreement and the other Loan Documents </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.23 <U>Transactions with Affiliates</U>. Except as otherwise described on <U>Schedule 7.23</U>, Borrower shall not, and shall
not permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary on terms that are less favorable to Borrower or such Subsidiary, as the case may be,
than those that might be obtained in an arm&#146;s length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary, other than (a)&nbsp;any equity investments in Borrower by existing investors of Borrower not constituting a
Change of Control, or Subordinated Indebtedness, (b)&nbsp;any compensation, director indemnification or similar arrangements in the ordinary course of business of Borrower and as approved by Company&#146;s Board, or (c)&nbsp;transactions between or
among the Loan Parties not involving any other Affiliate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.24 <U>Excluded Subsidiaries; Joint Ventures</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Borrower shall not, at any time, permit the aggregate amount of Cash held by Excluded Subsidiaries (collectively) to exceed
ten percent (10%) of the Borrower Consolidated Unrestricted Cash at such time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Borrower shall not, at any time, permit
the aggregate amount of aggregate amount of revenue of the Excluded Subsidiaries (as determined in accordance with GAAP, but which shall not include any upfront or <FONT STYLE="white-space:nowrap">non-sales-based</FONT> milestone payments under
business development of licensing transactions), measured monthly on a trailing <FONT STYLE="white-space:nowrap">six-month</FONT> basis to exceed ten percent (10%) of the T6M Revenue at such time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Borrower shall not make any Transfer to or Investment in any Excluded Subsidiary or any joint venture entity other than
Investments of Cash permitted to be made pursuant to the definition of &#147;Permitted Investment&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Borrowers
will not permit any Excluded Subsidiary or any other entity which is not a Borrower to commingle any of its assets (including any bank accounts, cash or cash equivalents) with the assets of Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.25 Post-Closing Obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any provision herein or in any other Loan Document to the contrary, to the extent not actually delivered on
or prior to the Closing Date, Borrower shall use commercially reasonable efforts to deliver to Agent fully executed copies of landlord waivers for its(i) chief executive office or its principal place of business and (ii)&nbsp;offices or business
locations, including warehouses, containing in excess of Five Hundred Thousand Dollars $(500,000) of Borrower&#146;s assets or property, in each case, within thirty (30)&nbsp;days after the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding any provision herein or in any other Loan Document to
the contrary, to the extent not actually delivered on or prior to the Closing Date, Borrower shall deliver to Agent a fully executed copy of the Account Control Agreement with respect to Borrower&#146;s accounts holding Investment Property
maintained with Merrill Lynch within five (5)&nbsp;Business Days after the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any provision
herein or in any other Loan Document to the contrary, to the extent not actually delivered on or prior to the Closing Date, Borrower shall deliver to Agent a fully executed copy of the Account Control Agreement with respect to Borrower&#146;s
Deposit Accounts maintained with Bank of America within two (2)&nbsp;Business Days after the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
Notwithstanding any provision herein or in any other Loan Document to the contrary, to the extent not actually delivered on or prior to the Closing Date, Borrower shall deliver to Agent all certificates of insurance and copies of each insurance
policy and endorsements required hereunder within fifteen (15) days after the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 8. <U>RIGHT TO INVEST</U>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 Borrower agrees to endeavor to use commercially reasonable efforts to permit, to the extent permitted by
applicable law, Lenders or their assignee or nominee to, for so long as such applicable Lender shall constitute a &#147;Lender&#148; under this Agreement, have the right, in its discretion, to participate in any Subsequent Financing in an aggregate
amount of up to Three Million Dollars ($3,000,000) on the same terms, conditions and pricing afforded to others participating in any such Subsequent Financing. This <U>Section</U><U></U><U>&nbsp;8.1</U>, and all rights and obligations provided for
hereunder, shall terminate upon the termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 9. <U>EVENTS OF DEFAULT</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any one or more of the following events shall be an &#147;<U>Event of Default</U>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <U>Payments</U>. A Loan Party fails to pay any amount when due under this Agreement or any of the other Loan Documents on
the due date; provided, however, that, in each case, an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational error of Agent or Lenders or Borrower&#146;s bank if Borrower had the funds to
make the payment when due and makes the payment within three (3)&nbsp;Business Days following Borrower&#146;s knowledge of such failure to pay; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <U>Covenants</U>. A Loan Party breaches or defaults in the performance of any covenant or Secured Obligation under this
Agreement, or any of the other Loan Documents, Agent and Lenders, and (a)&nbsp;with respect to a Default under any covenant under this Agreement (other than under <U>clause (b)</U><U></U><U>&nbsp;hereof</U>), any other Loan Document, Agent and
Lenders, such default continues for more than fifteen (15)&nbsp;Business Days after the earlier of the date on which (i)&nbsp;Agent or Lenders has given notice of such Default to Borrower and (ii)&nbsp;Borrower has actual knowledge of such default
or (b)&nbsp;with respect to a Default under any of <U>Sections 6</U>, <U>7.4</U>, <U>7.5</U>, <U>7.6</U>, <U>7.7</U>, <U>7.8</U>, <U>7.9</U>, <U>7.15</U>, <U>7.16,</U> <U>7.17</U>, <U>7.19</U>, <U>7.21</U>, and <U>7.22</U>, the occurrence of such
Default; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>Material Adverse Effect</U>. A Material Adverse Effect has occurred; provided that, solely for purposes
of this Section&nbsp;9.3, the failure to achieve the Performance Milestone I Date and the Performance Milestone II Date, shall not in and of itself constitute a Material Adverse Effect under this Section&nbsp;9.3; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>Representations</U>. Any representation or warranty made by any Loan Party in any Loan Document shall have been false or
misleading in any material respect when made or when deemed made; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>Insolvency</U>. (a)&nbsp;Loan Party or any of its Subsidiaries fails
to be solvent as described under <U>Section</U><U></U><U>&nbsp;5.15</U> hereof; (b)&nbsp;a Loan Party or any of its Subsidiaries begins an Insolvency Proceeding; or (c)&nbsp;an Insolvency Proceeding is begun against a Loan Party or any of its
Subsidiaries and is not dismissed or stayed within forty-five (45)&nbsp;days (but no Advances shall be made while any of the conditions described in clause (a)&nbsp;exist or until any Insolvency Proceeding is dismissed); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 <U>Judgments; Penalties</U>. One or more fines, penalties or final judgments, orders or decrees for the payment of money in
an amount, individually or in the aggregate, of at least Five Hundred Thousand Dollars ($500,000) (not covered by independent third-party insurance as to which liability has not been rejected by such insurance carrier) shall be rendered against any
Loan Party or any of its Subsidiaries by any Governmental Authority, and the same are not, within forty-five (45)&nbsp;days after the entry, assessment or issuance thereof, discharged, or after execution thereof, or stayed pending appeal, or such
judgments are not discharged prior to the expiration of any such stay (provided that no Advances shall be made prior to the discharge, or stay of such fine, penalty, judgment, order or decree); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 <U>Attachment; Levy; Restraint on Business</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of any Loan Party or any of its
Subsidiaries, or (ii)&nbsp;a notice of lien or levy is filed against any of any Loan Party&#146;s or any of its Subsidiaries&#146; assets by any Governmental Authority, and the same under subclauses (i)&nbsp;and (ii) hereof are not, within twenty
(20)&nbsp;days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Advances shall be made during any twenty (20)&nbsp;day cure period; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) any material portion of any the Collateral is attached, seized, levied on, or comes into possession of a trustee or
receiver, or (ii)&nbsp;any court order enjoins, restrains, or prevents any Loan Party from conducting all or any material part of its business; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 <U>Other Obligations</U>. The occurrence of any default under (i)&nbsp;any agreement or obligation of a Loan Party
involving any Indebtedness in excess of Seven Hundred Fifty Thousand Dollars ($750,000), or (ii)&nbsp;any other material agreement or obligation, if a Material Adverse Effect could reasonably be expected to result from such default </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.9 <U>Governmental Approvals; FDA Action</U>. (a)&nbsp;Any Governmental Approval shall have been revoked, rescinded,
suspended, modified in an adverse manner, or not renewed in the ordinary course for a full term and such revocation, rescission, suspension, modification or non renewal has resulted in or could reasonably be expected to result in a Material Adverse
Effect; or (b)&nbsp;(i) the FDA, DOJ or other Governmental Authority initiates a regulatory action or any other enforcement action against Borrower or any of its Subsidiaries or any supplier of Borrower or any of its Subsidiaries that causes
Borrower or any of its Subsidiaries to recall, withdraw, remove or discontinue manufacturing, distributing, and/or marketing any of its products, even if such action is based on previously disclosed conduct, in each case, that would result in a
Material Adverse Effect; (ii)&nbsp;the FDA or any other comparable Governmental Authority issues a warning letter to Borrower or any of its Subsidiaries with respect to any of its activities or products which could reasonably be expected to result
in a Material Adverse Effect; (iii)&nbsp;Borrower or any of its Subsidiaries conducts a mandatory or voluntary recall which could reasonably be expected to result in liability and expense to Borrower or any of its Subsidiaries of Five Hundred
Thousand Dollars ($500,000) or more; (iv)&nbsp;Borrower or any of its Subsidiaries enters into a settlement agreement with the FDA, DOJ or other Governmental Authority that results in aggregate liability as to any single or related series of
transactions, incidents or conditions, of Five Hundred Thousand Dollars ($500,000) or more, or that could reasonably be expected to result in a Material Adverse Effect, even if such settlement agreement is based on previously disclosed conduct; or
(v)&nbsp;the FDA or any other comparable Governmental Authority revokes any authorization or permission granted under any Registration, or Borrower or any of its Subsidiaries withdraws any Registration, that could reasonably be expected to result in
a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 10. <U>REMEDIES</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>General</U>. Upon the occurrence and continuance of any one or more Events of Default, Agent may, and at the direction
of the Required Lenders shall, accelerate and demand payment of all or any part of the outstanding Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an
Event of Default of the type described in <U>Section</U><U></U><U>&nbsp;9.5</U>, all of the Secured Obligations (including, without limitation, the Prepayment Charge and the End of Term Charge) shall automatically be accelerated and made due and
payable, in each case without any further notice or act). Borrower hereby irrevocably appoints Agent as its lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to:&nbsp;exercisable following the
occurrence of an Event of Default, (i)&nbsp;sign Borrower&#146;s name on any invoice or bill of lading for any account or drafts against account debtors; (ii)&nbsp;demand, collect, sue, and give releases to any account debtor for monies due, settle
and adjust disputes and claims about the accounts directly with account debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in
Agent&#146;s or Borrower&#146;s name, as Agent may elect); (iii) make, settle, and adjust all claims under Borrower&#146;s insurance policies; (iv)&nbsp;pay, contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to
the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; (v)&nbsp;transfer the Collateral into the name of Agent or a third party as the UCC permits; (vi)&nbsp;receive, open and dispose of mail
addressed to Borrower; (vii)&nbsp;endorse Borrower&#146;s name on any checks, payment instruments, or other forms of payment or security; and (viii)&nbsp;notify all account debtors to pay Agent directly.&nbsp;Borrower hereby appoints Agent as its
lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to sign Borrower&#146;s name on any documents necessary to perfect or continue the perfection of Agent&#146;s security interest in the Collateral
regardless of whether an Event of Default has occurred until all Secured Obligations have been satisfied in full and the Loan Documents (other than the Warrant) have been terminated.&nbsp;Agent&#146;s foregoing appointment as Borrower&#146;s
attorney in fact, and all of Agent&#146;s rights and powers, coupled with an interest, are irrevocable until all Secured Obligations (other than inchoate indemnity obligations which, by their terms, survive termination of this Agreement) have been
fully repaid and performed and the Loan Documents have been terminated. Agent may, and at the direction of the Required Lenders shall, exercise all rights and remedies with respect to the Collateral under the Loan Documents (other than the Warrant)
or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize,
process and commingle the Collateral. All Agent&#146;s rights and remedies shall be cumulative and not exclusive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2
<U>Collection; Foreclosure</U>. Upon the occurrence and during the continuance of any Event of Default, Agent may, and at the direction of the Required Lenders shall, at any time or from time to time, apply, collect, liquidate, sell in one or more
sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Agent may elect. Any such sale may be made either at public or private
sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10)&nbsp;calendar days&#146; prior written notice to Borrower. Agent may require Borrower to assemble the Collateral and make it
available to Agent at a place designated by Agent that is reasonably convenient to Agent and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in the following order
of priorities: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>First</I>, to Agent, in an amount equal to the sum of all fees owing to Agent hereunder
and under any other Loan Document; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Second</I>, to Agent and Lenders in an amount sufficient to pay in full Agent&#146;s and
Lenders&#146; reasonable costs and professionals&#146; and advisors&#146; fees and expenses as described in <U>Section</U><U></U><U>&nbsp;11.12</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Third</I>, to Lenders, ratably, in an amount equal to the sum of all accrued interest owing to Lenders on the Term Loan Advances hereunder;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Fourth</I>, to Lenders, ratably, in an amount equal to the sum of the outstanding principal and premium, if any owing to Lenders from
Borrower on the Term Loan Advances hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Fifth</I>, to Lenders and Agent, ratably (in proportion to all remaining Secured
Obligations owing to each), in an amount equal to the sum of all other outstanding and unpaid Secured Obligations (including principal, interest, and the default rate interest set forth in <U>Section</U><U></U><U>&nbsp;2.4</U>, if required under
this Agreement), in such order and priority as Agent may choose in its sole discretion; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Finally</I>, after the full and final
payment in Cash of all of the Secured Obligations (other than inchoate obligations which, by their terms, survive termination of this Agreement), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a
court of competent jurisdiction may direct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agent shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the
Collateral if it complies with the obligations of a secured party under the UCC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>No Waiver</U>. Agent shall be
under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 <U>Waivers</U>. Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any
default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Agent on which Borrower is liable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5 <U>Cumulative Remedies</U>. The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers
and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights,
powers and remedies of Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>SECTION 11. <U>MISCELLANEOUS</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 <U>Severability</U>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <U>Notice</U>. Except as
otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents
or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i)&nbsp;the day of transmission by electronic mail or hand delivery or delivery
by an overnight express service or overnight mail delivery service; or (ii)&nbsp;the third calendar day after deposit in the United States of America mails, with proper first class postage prepaid, in each case addressed to the party to be notified
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Agent: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">HERCULES CAPITAL, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Legal
Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer and Lake McGuire </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">email:
legal@htgc.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-289-3060</FONT></FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Lenders: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">HERCULES CAPITAL, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If SBA:
HERCULES CAPITAL IV L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Legal Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer and Cristy Barnes </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">email:
legal@htgc.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-289-3060</FONT></FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Borrower: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Ali Bauerlein, Chief Financial Officer, Jeremy Hayden, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">4040 Campbell Ave #100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Menlo
Park, CA 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">email: ABauerlein@sightsciences.com, JHayden@sightsciences.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-895-7312</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other address as each party may designate for itself by like notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 <U>Entire Agreement; Amendments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in
respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or confidentiality agreements, letters, negotiations or other
documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Agent&#146;s revised proposal letter dated December&nbsp;11, 2023 and the <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT>
Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither this Agreement, any other Loan Document, nor any terms hereof or
thereof may be amended, supplemented or modified except in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;11.3(b)</U>. The Required Lenders and Loan Parties party to the relevant Loan Document may, or, with the written consent
of the Required Lenders, Agent and Loan Parties party to the relevant Loan Document may, from time to time, (i)&nbsp;enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of adding any
provisions to this Agreement or the other Loan Documents or changing in any manner the rights of Lenders or of Loan Parties hereunder or thereunder or (ii)&nbsp;waive, on such terms and conditions as the Required Lenders or Agent, as the case may
be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any Default or Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or
modification shall (A)&nbsp;forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of any amortization payment in respect of any Term Loan Advance, reduce the stated rate of any interest
(or fee payable hereunder) or extend the scheduled date of any payment thereof, in each case without the written consent of each Lender directly affected thereby; (B)&nbsp;eliminate or reduce the voting rights of any Lender under this
<U>Section</U><U></U><U>&nbsp;11.3(b)</U> without the written consent of such Lender; (C)&nbsp;reduce any percentage specified in the definition of Required Lenders, consent to the assignment or transfer by Loan Parties of any of its rights and
obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral or release a Loan Party from its obligations under the Loan Documents, in each case without the written consent of all Lenders; or
(D)&nbsp;amend, modify or waive any provision of <U>Section</U><U></U><U>&nbsp;11.18</U> or <U>Addendum 3</U> without the written consent of Agent. Any such waiver and any such amendment, supplement or modification shall apply equally to each Lender
and shall be binding upon the applicable Loan Parties, Lenders, Agent and all future holders of the Loans. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 <U>No
Strict Construction</U>. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted
jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5 <U>No Waiver</U>. The powers conferred upon Agent and Lenders by this Agreement are solely to protect their rights
hereunder and under the other Loan Documents and their interest in the Collateral and shall not impose any duty upon Agent or Lenders to exercise any such powers. No omission or delay by Agent or Lenders at any time to enforce any right or remedy
reserved to them, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Agent or Lenders is entitled, nor shall it in any way affect
the right of Agent or Lenders to enforce such provisions thereafter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6 <U>Survival</U>. All agreements, representations
and warranties contained in this Agreement and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Agent, Lenders and Borrower (as applicable) and shall survive the execution and delivery of
this Agreement. <U>Sections 6.3</U>, <U>8.1</U>, <U>11.9</U>, <U>11.11</U>, <U>11.14</U>, <U>11.15</U>, <U>11.17</U> and <U>11.18</U> shall survive the termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7 <U>Successors and Assigns</U>. The provisions of this Agreement and the
other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). No Loan Party shall assign its obligations under this Agreement or any of the other Loan Documents without Agent&#146;s express prior
written consent, and any such attempted assignment shall be void and of no effect. Agent and Lenders may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights
shall inure to the benefit of Agent&#146;s and Lenders&#146; successors and assigns; provided that as long as no Event of Default has occurred and is continuing, neither Agent nor any Lender may assign, transfer or endorse its rights hereunder or
under the Loan Documents to any party that is a direct competitor of Borrower or a distressed debt or vulture fund (as reasonably determined by Agent), it being acknowledged that in all cases, any transfer to an Affiliate of any Lender or Agent
shall be allowed. Notwithstanding the foregoing, (x)&nbsp;in connection with any assignment by a Lender as a result of a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Agent and
Lenders may assign, transfer or endorse its rights hereunder and under the other Loan Documents to any Person or party and (y)&nbsp;in connection with a Lender&#146;s own financing or securitization transactions, the restrictions set forth herein
shall not apply and Agent and Lenders may assign, transfer or endorse its rights hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such securitization transaction and any transferee
of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment under this <U>clause
(y)</U>&nbsp;shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective assignment agreement from such Person or
party in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such assignee as Agent reasonably shall require. Agent, acting solely for this
purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of Borrower, shall maintain at one of its offices in the United States a register for the recordation of the names and addresses of Lender(s), and the Term Commitments of, and
principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#147;<U>Register</U>&#148;). The entries in the Register shall be conclusive absent manifest error, and Borrower, Agent
and Lender(s) shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by Borrower and any Lender, at any
reasonable time and from time to time upon reasonable prior notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.8 <U>Participations</U>. Each Lender that sells a
participation shall, acting solely for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated
interest) of each participant&#146;s interest in the Loans or other obligations under the Loan Documents (the &#147;<U>Participant Register</U>&#148;); provided that no Lender shall have any obligation to disclose all or any portion of the
Participant Register (including the identity of any participant or any information relating to a participant&#146;s interest in any commitments, loans, its other obligations under any Loan Document) to any Person except to the extent that such
disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under <FONT STYLE="white-space:nowrap">Section&nbsp;5f.103-1(c)</FONT> of the United States Treasury Regulations. The entries
in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding
any notice to the contrary. For the avoidance of doubt, Agent (in its capacity as Agent) shall have no responsibility for maintaining a Participant Register. Borrower agrees that each participant shall be entitled to the benefits of the provisions
in <U>Addendum 1</U> attached hereto (subject to the requirements and limitations therein, including the requirements under <U>Section</U><U></U><U>&nbsp;7</U> of <U>Addendum 1</U> attached hereto (it being understood that the documentation required
under <U>Section</U><U></U><U>&nbsp;7</U> of <U>Addendum 1</U> attached hereto shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to <U>Section</U><U></U><U>&nbsp;11.7</U>; provided that
such participant shall not be entitled to receive any greater payment under Addendum 1 attached hereto, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to
receive a greater payment results from a change in law that occurs after the participant acquired the applicable participation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.9 <U>Governing Law</U>. This Agreement and the other Loan Documents have been negotiated and delivered to Agent and Lenders
in the State of California, and shall have been accepted by Agent and Lenders in the State of California. Payment to Agent and Lenders by Borrower of the Secured Obligations is due in the State of California. Except as otherwise expressly provided
in any of the Loan Documents, this Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the
application of laws of any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.10 <U>Consent to Jurisdiction and Venue</U>. All judicial proceedings
(to the extent that the reference requirement of <U>Section</U><U></U><U>&nbsp;11.11</U> is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents (except as expressly provided otherwise in any other Loan
Document) may be brought in any state or federal court located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a)&nbsp;consents to nonexclusive personal jurisdiction in Santa
Clara County, State of California; (b)&nbsp;waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c)&nbsp;agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(d)&nbsp;irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be
effective if given in accordance with the requirements for notice set forth in <U>Section</U><U></U><U>&nbsp;11.2</U>, and shall be deemed effective and received as set forth in <U>Section</U><U></U><U>&nbsp;11.2</U>. Nothing herein shall affect the
right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.11 <U>Mutual Waiver of Jury Trial / Judicial Reference</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an
experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER, AGENT AND
LENDERS SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#147;<U>CLAIMS</U>&#148;) ASSERTED BY BORROWER AGAINST AGENT, LENDERS
OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, LENDERS OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower or any Lenders; Claims that arise out of or are
in any way connected to the relationship among Borrower, Agent and Lenders; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan
Document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the waiver of jury trial set forth in
<U>Section</U><U></U><U>&nbsp;11.11(a)</U> is ineffective or unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section&nbsp;638, before a
mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and
discovery applicable to such proceeding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In the event Claims are to be resolved by judicial reference, either party
may seek from a court identified in <U>Section</U><U></U><U>&nbsp;11.10</U>, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all
Claims are otherwise subject to resolution by judicial reference. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.12 <U>Professional Fees</U>. Borrower promises to pay
Agent&#146;s and Lenders&#146; reasonable and documented out of pocket fees and expenses necessary to finalize the Loan Documents, including but not limited to reasonable attorneys&#146; fees, UCC searches, filing costs, and other miscellaneous
expenses, provided that the Due Diligence Fee shall be applied in its entirety to the Lenders&#146; <FONT STYLE="white-space:nowrap">non-legal</FONT> transaction costs and due diligence expenses. In addition, Borrower promises to pay any and all
reasonable and documented out of pocket attorneys&#146; and other professionals&#146; fees (including allocated costs of <FONT STYLE="white-space:nowrap">in-house</FONT> counsel) and expenses incurred by Agent and Lenders after the Closing Date in
connection with or related to: (a)&nbsp;the Loan; (b)&nbsp;the administration, collection, or enforcement of the Loan; (c)&nbsp;the amendment or modification of the Loan Documents; (d)&nbsp;any waiver, consent, release, or termination under the Loan
Documents; (e)&nbsp;the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f)&nbsp;any legal, litigation, administrative, arbitration, or
out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g)&nbsp;any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or
other action related to Borrower, the Collateral, the Loan Documents, including representing Agent or Lenders in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower&#146;s estate, and any appeal or review
thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.13 <U>Confidentiality</U>. Agent and Lenders acknowledge that certain items of Collateral and information
provided to Agent and Lenders by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either (x)&nbsp;is marked as confidential by Borrower at the time of disclosure, or (y)&nbsp;should reasonably
be understood to be confidential (the &#147;<U>Confidential Information</U>&#148;). Accordingly, Agent and Lenders agree that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Agent&#146;s security
interest in the Collateral shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Agent and Lenders may disclose any such information:
(a)&nbsp;to its Affiliates and its partners, investors, lenders, directors, officers, employees, agents, advisors, counsel, accountants, representative and other professional advisors if Agent or Lenders in their sole discretion determines that any
such party should have access to such information in connection with such party&#146;s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i)&nbsp;agrees to be
bound by the confidentiality provisions of this Section or (ii)&nbsp;is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information pursuant to similar terms; (b)&nbsp;if such
information is generally available to the public or to the extent such information becomes publicly available other than as a result of a breach of this Section or becomes available to Agent or any Lender, or any of their respective Affiliates on a <FONT
STYLE="white-space:nowrap">non-confidential</FONT> basis from a source other than Borrower and not in violation of any confidentiality obligations known to the Agent or such Lender; (c)&nbsp;if required or appropriate in any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
report, statement or testimony submitted to any Governmental Authority having or claiming to have jurisdiction over Agent or Lenders and any rating agency; (d)&nbsp;if required or appropriate in
response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Agent&#146;s or Lenders&#146; counsel; (e)&nbsp;to comply with any legal requirement or law applicable to Agent or Lenders or
demanded by any Governmental Authority; (f)&nbsp;to the extent reasonably necessary in connection with the exercise of, or preparing to exercise, or the enforcement of, or preparing to enforce, any right or remedy under any Loan Document (including
Agent&#146;s sale, lease, or other disposition of Collateral after the occurrence of a Default), or any action or proceeding relating to any Loan Document; (g)&nbsp;to any participant or assignee of Agent or Lenders or any prospective participant or
assignee, provided, that such participant or assignee or prospective participant or assignee is subject to confidentiality restrictions no less protective than the provisions of this Section&nbsp;11.13; (h) to any investor or potential investor (and
each of their respective Affiliates or clients) in Agent or Lenders (or each of their respective Affiliates); provided that such investor, potential investor, Affiliate or client is subject to confidentiality obligations with respect to the
Confidential Information; (i)&nbsp;otherwise to the extent consisting of general portfolio information that does not identify Borrower; or (j)&nbsp;otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this
Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or the other Loan Documents. Agent&#146;s and Lenders&#146; obligations under this <U>Section</U><U></U><U>&nbsp;11.13</U> shall
supersede all of their respective obligations under the <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.14 <U>Assignment of Rights</U>. Borrower acknowledges and understands that Agent or Lenders may, subject to
<U>Section</U><U></U><U>&nbsp;11.7</U>, sell and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity (an &#147;<U>Assignee</U>&#148;). After such assignment the term &#147;Agent&#148; or
&#147;Lender&#148; as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and Lenders hereunder with respect to the interest so assigned; but with respect
to any such interest not so transferred, Agent and Lenders shall retain all rights, powers and remedies hereby given. No such assignment by Agent or Lenders shall relieve Borrower of any of its obligations hereunder. Lenders agree that in the event
of any transfer by it of the promissory note(s) (if any), it will endorse thereon a notation as to the portion of the principal of the promissory note(s), which shall have been paid at the time of such transfer and as to the date to which interest
shall have been last paid thereon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.15 <U>Revival of Secured Obligations</U>. Other than as set forth in
Section&nbsp;11.6, shall terminate on the final and indefeasible payment in full in cash of the Secured Obligations (other than for inchoate indemnification obligations for which no claim has been made and which, by their terms, survive termination
of this Agreement). Notwithstanding the preceding sentence, this Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization,
if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower&#146;s assets, or if any payment or transfer of Collateral is recovered from Agent
or Lenders. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any
transfer of Collateral to Agent, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, Lenders or by any obligee of the Secured Obligations (other than
for inchoate indemnification obligations for which no claim has been made and which, by their terms, survive termination of this Agreement), whether as a &#147;voidable preference,&#148; &#147;fraudulent conveyance,&#148; or otherwise, all as though
such payment, performance, or transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations
shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Agent or Lenders in Cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.16 <U>Counterparts</U>. This Agreement and any amendments, waivers,
consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but
one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.17 <U>No Third-Party Beneficiaries</U>. No provisions of the Loan Documents are intended,
nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, Lenders and Borrower unless specifically provided otherwise herein, and, except as otherwise so
provided, all provisions of the Loan Documents will be personal and solely among Agent, Lenders and the Loan Parties party thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.18 <U>Agency</U>. Agent and each Lender hereby agree to the terms and conditions set forth on <U>Addendum 3</U> attached
hereto. Borrower acknowledges and agrees to the terms and conditions set forth on <U>Addendum 3</U> attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.19
<U>Publicity</U>. None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties&#146; prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a)&nbsp;the
other party&#146;s name (including a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties&#146; web site, separately or together, in written and oral presentations, advertising, promotional and
marketing materials, client lists, public relations materials or on its web site (together, the &#147;<U>Publicity Materials</U>&#148;); (b) the names of officers of such other parties in the Publicity Materials; and (c)&nbsp;such other
parties&#146; name, trademarks, servicemarks in any news or press release concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i)&nbsp;to the extent necessary to comply with the
requests of any regulators, legal requirements or laws applicable to such party, pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other party hereto to the extent reasonably
practicable) and (ii)&nbsp;to comply with <U>Section</U><U></U><U>&nbsp;11.13</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.20 <U>Multiple Borrowers</U>. If
another party is joined as a Borrower hereunder after the Closing Date, each Borrower hereby agrees to the terms and conditions set forth on <U>Addendum 4</U> attached hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.21 [<U>Reserved]</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.22 <U>Managerial Assistance</U>. Borrower acknowledges that Hercules Capital, Inc. has elected to be regulated as a business
development company under the 1940 Act, and as such is required to make available significant managerial assistance to its portfolio companies. Significant managerial assistance may include, but is not limited to, guidance and counsel concerning the
portfolio company&#146;s management, operations, business objectives and policies, arrangement of financing, management of relationships with financing sources, recruitment of management personnel and evaluation of acquisition and divestiture
opportunities. Borrower hereby acknowledges and agrees that it may request such assistance at any time from Hercules Capital, Inc. by contacting legal@htgc.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.23 <U>Electronic Execution of Certain Other Documents</U>. The words
&#147;execution,&#148; &#147;execute&#148;, &#147;signed,&#148; &#147;signature,&#148; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without
limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent, or the keeping of
records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any
applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(SIGNATURES TO FOLLOW) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Borrower, Agent and Lenders have duly executed and delivered this Loan
and Security Agreement as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BORROWER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SIGHT SCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted in Palo Alto, California: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AGENT:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES CAPITAL, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LENDERS:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES CAPITAL, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES PRIVATE CREDIT FUND 1 L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table of Addenda, Exhibits and Schedules </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Addendum 1:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Taxes; Increased Costs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Addendum 2:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SBA Provisions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Addendum 3:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agent and Lender Terms</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Addendum 4:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Multiple Borrower Terms</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit A:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Advance Request</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attachment to Advance Request</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name, Locations, and Other Information for Borrower</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Borrower&#146;s Patents, Trademarks, Copyrights and Licenses</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Borrower&#146;s Deposit Accounts and Investment Accounts</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Compliance Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit F:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joinder Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit G:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Warrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit H:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ACH Debit Authorization Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit I:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Reserved]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">J-1:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">J-2:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">J-3:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">J-4:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Commitments</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Subsidiaries</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Existing Permitted Indebtedness</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1B</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Existing Permitted Investments</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1C</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Existing Permitted Liens</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 5.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consents, Etc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 5.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tax Matters</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 5.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Intellectual Property Claims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 5.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Intellectual Property</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 5.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Borrower Products</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule&nbsp;5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employee Loans</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 5.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Capitalization</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 7.23</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Affiliate Transactions</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDENDUM 1 to LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAXES; INCREASED COSTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defined Terms</B>. For purposes of this Addendum 1: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Connection Income Taxes</B>&#148; means Other Connection Taxes that are imposed on or measured by net
income (however denominated) or that are franchise Taxes or branch profits Taxes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Excluded Taxes</B>&#148; means any of the following Taxes imposed on or with respect to a Recipient or
required to be withheld or deducted from a payment to a Recipient, (i)&nbsp;Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (A)&nbsp;imposed as a result of such Recipient
being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B)&nbsp;that are Other
Connection Taxes, (ii)&nbsp;in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Term Commitment pursuant to a law in effect on
the date on which (A)&nbsp;such Lender acquires such interest in the Loan or Term Commitment or (B)&nbsp;such Lender changes its lending office, except in each case to the extent that, pursuant to Section&nbsp;2 or Section&nbsp;4 of this Addendum 1,
amounts with respect to such Taxes were payable either to such Lender&#146;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii)&nbsp;Taxes attributable to such
Recipient&#146;s failure to comply with Section&nbsp;7 of this Addendum 1 and (iv)&nbsp;any withholding Taxes imposed under FATCA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>FATCA</B>&#148; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any
amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section&nbsp;1471(b)(1) of
the Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Foreign Lender</B>&#148; means a Lender that is not a U.S. Person. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Indemnified Taxes</B>&#148; means (i)&nbsp;Taxes, other than Excluded Taxes, imposed on or with
respect to any payment made by or on account of any obligation of Borrower under any Loan Document and (ii)&nbsp;to the extent not otherwise described in clause (i), Other Taxes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Other Connection Taxes</B>&#148; means, with respect to any Recipient, Taxes imposed as a result of a
present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under,
received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Other Taxes</B>&#148; means all present or future stamp, court or documentary, intangible, recording,
filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document,
except any such Taxes that are Other Connection Taxes imposed with respect to an assignment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Recipient</B>&#148; means Agent or any Lender, as applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Withholding Agent</B>&#148; means Borrower and Agent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payments Free of Taxes</B>. Any and all payments by or on account of any obligation of Borrower under any
Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or
withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental
Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and
withholdings applicable to additional sums payable under this <U>Section&nbsp;2</U> or <U>Section&nbsp;4</U> of this Addendum 1) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding
been made. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment of Other Taxes by Borrower</B>. Borrower shall timely pay to the relevant Governmental Authority in
accordance with applicable law, or at the option of Agent timely reimburse it for the payment of, any Other Taxes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification by Borrower</B>. Borrower shall indemnify each Recipient, within ten (10)&nbsp;days after
demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under <U>Section&nbsp;2</U> of this Addendum 1 or this <U>Section&nbsp;4</U>) payable or paid by
such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the
relevant Governmental Authority. A certificate describing the amount of such payment or liability delivered to Borrower by a Lender (with a copy to Agent), or by Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest
error. In addition, Borrower agrees to pay, and to hold Agent and any Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar Taxes (excluding Taxes imposed on
or measured by the net income of Agent or such Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification by Lenders</B>. Each Lender shall severally indemnify Agent, within ten (10)&nbsp;days after
demand therefor, for (a)&nbsp;any Indemnified Taxes attributable to such Lender (but only to the extent that Borrower has not already indemnified Agent for such Indemnified Taxes and without limiting the obligation of Borrower to do so), (b) any
Taxes attributable to such Lender&#146;s failure to comply with the provisions of <U>Section&nbsp;11.8</U> of the Agreement relating to the maintenance of a Participant Register and (c)&nbsp;any Excluded Taxes attributable to such Lender, in each
case, that are payable or paid by Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental
Authority. A certificate as to the amount of such payment or liability delivered to any Lender by Agent shall be conclusive absent manifest error. Each Lender hereby authorizes Agent to set off and apply any and all amounts at any time owing to such
Lender under any Loan Document or otherwise payable by Agent to Lenders from any other source against any amount due to Agent under this <U>Section&nbsp;5</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Evidence of Payments</B>. As soon as practicable after any payment of Taxes by Borrower to a Governmental
Authority pursuant to the provisions of this Addendum 1, Borrower shall deliver to Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or
other evidence of such payment reasonably satisfactory to Agent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Status of Lenders</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made
under any Loan Document shall deliver to Borrower and Agent, at the time or times reasonably requested by Borrower or Agent, such properly completed and executed documentation reasonably requested by Borrower or Agent as will permit such payments to
be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by Borrower or Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by Borrower or Agent
as will enable Borrower or Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and
submission of such documentation (other than such documentation set forth in <U>Sections 7(b)(i)</U>, <U>7(b)(ii)</U> and <U>7(b)(iv)</U> of this Addendum 1) shall not be required if in such Lender&#146;s reasonable judgment such completion,
execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting the generality of the foregoing, in the event that Borrower is a U.S. Person,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Lender that is a U.S. Person shall deliver to Borrower and Agent on or prior to the date on which such
Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower or Agent), executed copies of IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> certifying that such Lender is exempt from U.S.
federal backup withholding tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower and Agent (in such
number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower or Agent), whichever of the
following is applicable: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a
party (x)&nbsp;with respect to payments of interest under any Loan Document, executed copies of IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#147;interest&#148; article of such tax treaty and (y)&nbsp;with
respect to any other applicable payments under any Loan Document, IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> establishing an exemption
from, or reduction of, U.S. federal withholding Tax pursuant to the &#147;business profits&#148; or &#147;other income&#148; article of such tax treaty; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">executed copies of IRS Form <FONT STYLE="white-space:nowrap">W-8ECI;</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under
Section&nbsp;881(c) of the Code, (x)&nbsp;a certificate substantially in the form of <U>Exhibit <FONT STYLE="white-space:nowrap">J-1</FONT></U> to the effect that such Foreign Lender is not a &#147;bank&#148; within the meaning of
Section&nbsp;881(c)(3)(A) of the Code, a &#147;10&nbsp;percent shareholder&#148; of Borrower within the meaning of Section&nbsp;871(h)(3)(B) of the Code, or a &#147;controlled foreign corporation&#148; related to Borrower as described in
Section&nbsp;881(c)(3)(C) of the Code (a &#147;<U>U.S. Tax Compliance Certificate</U>&#148;) and (y)&nbsp;executed copies of IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E;</FONT></FONT> or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form <FONT
STYLE="white-space:nowrap">W-8IMY,</FONT> accompanied by IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> a U.S. Tax Compliance Certificate substantially in the form of <U>Exhibit <FONT STYLE="white-space:nowrap">J-2</FONT></U> or <U>Exhibit <FONT
STYLE="white-space:nowrap">J-3</FONT></U>, IRS Form <FONT STYLE="white-space:nowrap">W-9,</FONT> and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more
direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of <U>Exhibit
<FONT STYLE="white-space:nowrap">J-4</FONT></U> on behalf of each such direct and indirect partner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower and Agent (in such
number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower or Agent), executed copies
of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit
Borrower or Agent to determine the withholding or deduction required to be made; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed
by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section&nbsp;1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to Borrower and Agent at the time
or times prescribed by law and at such time or times reasonably requested by Borrower or Agent such documentation prescribed by applicable law (including as prescribed by Section&nbsp;1471(b)(3)(C)(i) of the Code) and such additional documentation
reasonably requested by Borrower or Agent as may be necessary for Borrower and Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#146;s obligations under FATCA or to determine the
amount, if any, to deduct and withhold from such payment. Solely for purposes of this <U>clause (iv)</U>, &#147;FATCA&#148; shall include any amendments made to FATCA after the date of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or
inaccurate in any respect, it shall update such form or certification or promptly notify Borrower and Agent in writing of its legal inability to do so. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Treatment of Certain Refunds</B>. If any party determines, in its sole discretion exercised in good faith,
that it has received a refund of any Taxes as to which it has been indemnified pursuant to the provisions of this Addendum 1 (including by the payment of additional amounts pursuant to the provisions of this Addendum 1), it shall pay to the
indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under the provisions of this Addendum 1 with respect to the Taxes giving rise to such refund), net of all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying
party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this <U>Section&nbsp;8</U> (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in
the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this <U>Section&nbsp;8</U>, in no event will the indemnified party be required to pay any amount to an
indemnifying party pursuant to this <U>Section&nbsp;8</U> the payment of which would place the indemnified party in a less favorable net <FONT STYLE="white-space:nowrap">after-Tax</FONT> position than the indemnified party would have been in if the
Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This <U>Section&nbsp;8</U> shall
not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Increased Costs</B>. If any change in applicable law shall subject any Recipient to any Taxes (other than
(A)&nbsp;Indemnified Taxes, (B)&nbsp;Taxes described in <U>clauses (ii)</U>&nbsp;through <U>(iv)</U> of the definition of Excluded Taxes and (C)&nbsp;Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its
deposits, reserves, other liabilities or capital attributable thereto, and the result shall be to increase the cost to such Recipient of making, converting to, continuing or maintaining any Term Loan Advance or of maintaining its obligation to make
any such Loan, or to reduce the amount of any sum received or receivable by such Recipient (whether of principal, interest or any other amount), then, upon the request of such Recipient, Borrower will pay to such Recipient such additional amount or
amounts as will compensate such Recipient for such additional costs incurred or reduction suffered. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax Treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party hereto hereby acknowledges and agrees that, for U.S. federal and other applicable income tax
purposes, to the extent any Warrant is issued in connection with any Tranche, such Warrant and Tranche shall constitute an investment unit within the meaning of Section&nbsp;1273(c)(2) of the Code. Notwithstanding anything to the contrary contained
herein, each party further acknowledges and agrees that for U.S. federal and other applicable income tax purposes the fair market value of the Warrant issued with the Tranche 1 Advance is $700,000, which value shall be taken into account in the
determination of the &#147;issue price&#148; (as defined in Section&nbsp;1273(b) of the Code) of the Tranche 1 Advance in accordance with Section&nbsp;1273(c)(2) of the Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party hereto hereby further acknowledges and agrees that the fair market value of any Warrant issued with
any Tranche 2 Advance or Tranche 3 Advance shall be determined by the parties in good faith, which value shall be taken into account in the determination of the &#147;issue price&#148; (as defined in Section&nbsp;1273(b) of the Code) of the
applicable Tranche in accordance with Section&nbsp;1273(c)(2) of the Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival</B>. Each party&#146;s obligations under the provisions of this Addendum 1 shall survive the
resignation or replacement of Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Term Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDENDUM 2 to LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SBIC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Borrower&#146;s Business</I>.&nbsp;For purposes of this Addendum 2, Borrower shall be deemed to include its &#147;affiliates&#148; as defined in Title 13 Code of Federal Regulations Section&nbsp;121.103. Borrower represents and warrants to Agent
and Lenders as of each SBA Funding Date and covenants to Agent and Lenders for a period of one year after each SBA Funding Date or for such longer period as set forth below with respect to <U>subsections 2</U>, <U>3</U>, <U>4</U>, <U>5</U>, <U>6</U>
and <U>7</U> below, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Size Status. Borrower&#146;s primary NAICS code is 339112 and has less than 250 employees in the aggregate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Relender. Borrower&#146;s primary business activity does not involve, directly or indirectly, providing
funds to others, purchasing debt obligations, factoring, or long-term leasing of equipment with no provision for maintenance or repair; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Passive Business. Borrower is engaged in a regular and continuous business operation (excluding the mere
receipt of payments such as dividends, rents, lease payments, or royalties). Borrower&#146;s employees are carrying on the majority of day to day operations. Borrower will not pass through substantially all of the proceeds of the Loan to another
entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Real Estate Business. Borrower is not classified under North American Industry Classification System (NAICS)
codes 531110 (lessors of residential buildings and dwellings), 531120 (lessors of nonresidential buildings except miniwarehouses), 531190 (lessors of other real estate property), 237210 (land subdivision), or 236117 (new housing <FONT
STYLE="white-space:nowrap">for-sale</FONT> builders). Borrower is not classified under NAICS codes 236118 (residential remodelers), 236210 (industrial building construction), or 236220 (commercial and institutional building construction), if
Borrower is primarily engaged in construction or renovation of properties on its own account rather than as a hired contractor. Borrower is not classified under NAICS codes 531210 (offices of real estate agents and brokers), 531311 (residential
property managers), 531312 (nonresidential property managers), 531320 (offices of real estate appraisers), or 531390 (other activities related to real estate), unless it derives at least 80&nbsp;percent of its revenue from <FONT
STYLE="white-space:nowrap">non-Affiliate</FONT> sources. The proceeds of the Loan will not be used to acquire or refinance real property unless Borrower (x)&nbsp;is acquiring an existing property and will use at least 51&nbsp;percent of the usable
square footage for its business purposes; (y)&nbsp;is building or renovating a building and will use at least 67&nbsp;percent of the usable square footage for its business purposes; or (z)&nbsp;occupies the subject property and uses at least
67&nbsp;percent of the usable square footage for its business purposes. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Project Finance. Borrower&#146;s assets are not intended to be reduced or consumed, generally without
replacement, as the life of its business progresses, and the nature of Borrower&#146;s business does not require that a stream of cash payments be made to the business&#146;s financing sources, on a basis associated with the continuing sale of
assets (e.g., real estate development projects and oil and gas wells).&nbsp;The primary purpose of the Loan is not to fund production of a single item or defined limited number of items, generally over a defined production period, where such
production will constitute the majority of the activities of Borrower (e.g., motion pictures and electric generating plants). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Farm Land Purchases. Borrower will not use the proceeds of the Loan to acquire farm land which is or is
intended to be used for agricultural or forestry purposes, such as the production of food, fiber, or wood, or is so taxed or zoned. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Foreign Investment. The proceeds of the Loan will not be used substantially for a foreign operation.
Borrower will not have, on or within one year after each SBA Funding Date and each other Loan provided by a Lender that is an SBIC more than 49&nbsp;percent of its employees or tangible assets located outside the United States of America.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Small Business Administration Documentation</I>.&nbsp;Agent and Lenders acknowledge that Borrower
completed, executed and delivered to Agent prior to each SBA Funding Date SBA Forms 480, 652 and 1031 (Parts&nbsp;A and B) together with a business plan showing Borrower&#146;s financial projections (including balance sheets and income and cash
flows statements) for the period described therein and a written statement (whether included in the purchase agreement or pursuant to a separate statement) from Agent regarding its intended use of proceeds from the sale of securities to Lenders (the
&#147;<U>Use of Proceeds Statement</U>&#148;).&nbsp;Borrower represents and warrants to Agent and Lenders that the information regarding Borrower and its affiliates set forth in the SBA Form&nbsp;480, Form&nbsp;652 and Form&nbsp;1031 and the Use of
Proceeds Statement delivered as of each SBA Funding Date is accurate and complete. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Inspection</I>.&nbsp;The
following covenants contained in this <U>Section (c)</U>&nbsp;are intended to supplement and not to restrict the related provisions of the Loan Documents.&nbsp;Subject to the preceding sentence, Borrower will permit, for so long as Lenders hold any
debt or equity securities of Borrower, Agent, Lenders or their representative, at Agent&#146;s or Lenders&#146; expense, and examiners of the SBA to visit and inspect the properties and assets of Borrower, to examine its books of account and
records, and to discuss Borrower&#146;s affairs, finances and accounts with Borrower&#146;s officers, senior management and accountants, all at such reasonable times as may be requested by Agent or Lenders or the SBA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Annual Assessment</I>.&nbsp;Upon request of Agent or Lender, promptly after the end of each calendar year (but in any
event prior to February&nbsp;28 of each year) and at such other times as may be reasonably requested by Agent or Lenders, Borrower will deliver to Agent a written assessment of the economic impact of Lenders&#146; investment in Borrower, specifying
the full-time equivalent jobs created or retained in connection with the investment, the impact of the investment on the businesses of Borrower in terms of expanded revenue and taxes, other economic benefits resulting from the investment (such as
technology development or commercialization, minority business development, or expansion of exports) and such other information as may be required regarding Borrower in connection with the filing of Lenders&#146; SBA Form 468.&nbsp;Lenders will
assist Borrower with preparing such assessment.&nbsp;In addition to any other rights granted hereunder, Borrower will grant Agent and Lenders and the SBA access to Borrower&#146;s books and records for the purpose of verifying the use of such
proceeds.&nbsp;Borrower also will furnish or cause to be furnished to Agent and Lenders such other information regarding the business, affairs and condition of Borrower as Agent or Lenders may from time to time reasonably request, and such
information shall be certified by the President, Chief Executive Officer or Chief Financial Officer of Borrower to the extent requested by Agent or Lender for compliance with the SBIC Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Use of Proceeds.</I>&nbsp;Borrower will use the proceeds from the
Loan only for purposes set forth in <U>Section</U><U></U><U>&nbsp;7.17</U>. Borrower will deliver to Agent from time to time promptly following Agent&#146;s request, a written report, certified as correct by Borrower&#146;s Chief Financial Officer,
verifying the purposes and amounts for which proceeds from the Loan have been disbursed.&nbsp;Borrower will supply to Agent such additional information and documents as Agent reasonably requests with respect to its use of proceeds and will, to the
extent required by <U>Section</U><U></U><U>&nbsp;7.2</U>, permit Agent and Lenders and the SBA to have access to any and all Borrower records and information and personnel as Agent deems necessary to verify how such proceeds have been or are being
used, and to assure that the proceeds have been used for the purposes specified in <U>Section</U><U></U><U>&nbsp;7.17</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Activities and Proceeds</I>. Neither Borrower nor any of its affiliates (if any) will engage in any activities or use
directly or indirectly the proceeds from the Loan for any purpose for which a small business investment company is prohibited from providing funds by the SBIC Act, including 13&nbsp;C.F.R. &#167;107.720.&nbsp;Borrower shall not, nor shall it cause
or permit any of its subsidiaries to, without obtaining the prior written approval of Agent, change Borrower&#146;s or any such subsidiary&#146;s business activities from that conducted on the date hereof to a business activity from which a licensee
under the SBIC Act is prohibited from providing funds by the SBIC Act. Borrower agrees that any such change in its or any such subsidiary&#146;s business activities without such prior written consent of Agent shall constitute a material breach of
the obligations of Borrower under this Addendum 2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Redemption Provisions. </I>Notwithstanding any provision to the
contrary contained in the Charter, if, pursuant to the redemption provisions contained in the Charter, Lenders is entitled to a redemption of its Warrant, such redemption (in the case of Lenders) will be at a price equal to the redemption price set
forth in the Charter (the &#147;<U>Existing Redemption Price</U>&#148;). If, however, Lenders delivers written notice to Borrower that the then current regulations promulgated under the SBIC Act prohibit payment of the Existing Redemption Price in
the case of an SBIC (or, if applied, the Existing Redemption Price would cause the any series of preferred stock to lose its classification as an &#147;equity security&#148; and Lenders has determined that such classification is unadvisable), the
amount Lenders will be entitled to receive shall be the greater of (i)&nbsp;fair market value of the securities being redeemed taking into account the rights and preferences of such securities plus any costs and expenses of Lenders incurred in
making or maintaining the Warrant, and (ii)&nbsp;the Existing Redemption Price where the amount of accrued but unpaid dividends payable to Lenders is limited to Borrower&#146;s earnings plus any costs and expenses of Lenders incurred in making or
maintaining the Warrant; provided, however, the amount calculated in <U>subsections (i)</U>&nbsp;or <U>(ii)</U> above shall not exceed the Existing Redemption Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Compliance and Resolution.</I>&nbsp;Borrower agrees that a failure to
comply with Borrower&#146;s obligations under this Addendum, or any other set of facts or circumstances where it has been asserted by any governmental regulatory agency (or Agent or Lenders believes that there is a substantial risk of such
assertion) that Agent, Lenders and their affiliates are not entitled to hold, or exercise any significant right with respect to, any securities issued to Lenders by Borrower, will constitute a breach of the obligations of Borrower under the
financing agreements among Borrower, Agent and Lenders.&nbsp;In the event of (i)&nbsp;a failure to comply with Borrower&#146;s obligations under this Addendum; or (ii)&nbsp;an assertion by any governmental regulatory agency (or Agent or Lenders
believe that there is a substantial risk of such assertion) of a failure to comply with Borrower&#146;s obligations under this Addendum, then (i)&nbsp;Agent, Lenders and Borrower will meet and resolve any such issue in good faith to the satisfaction
of Borrower, Agent, Lenders, and any governmental regulatory agency, and (ii)&nbsp;upon request of Lenders or Agent, Borrower will cooperate and assist with any assignment of the financing agreements among Hercules Technology III, L.P. and Hercules
Capital, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDENDUM 3 to LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Agent and Lender Terms </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Lender hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as Agent hereunder and under the other
Loan Documents and irrevocably authorizes Agent to take such actions on its behalf and to exercise such powers as are delegated to Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.
Agent shall have only those duties which are specified in this Agreement and it may perform such duties by or through its agents, representatives or employees. In performing its duties on behalf of Lenders, Agent shall exercise the same care which
it would exercise in dealing with loans made for its own account, but it shall not be responsible to any Lender for the execution, effectiveness, genuineness, validity, enforceability, collectability or sufficiency of all or any of the Loan
Documents, or for any representations, warranties, recitals or statements made therein or made in any written or oral statement or in any financial or other statements, instruments, reports, certificates or any other documents furnished or delivered
in connection herewith or therewith by Agent to any Lender or by or on behalf of Borrower to Agent or any Lender, or be required to ascertain or inquire as to the performance or observance of any of the terms, conditions, provisions, covenants or
agreements contained herein or therein, as to the use of the proceeds of the Term Loan Advances, the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, the validity,
enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or the satisfaction of any condition set forth in <U>Section</U><U></U><U>&nbsp;4</U> or elsewhere herein, other
than to confirm receipt of items expressly required to be delivered to Agent. Agent shall not be responsible for insuring the Collateral or for the payment of any Taxes, assessments, charges or any other charges or liens of any nature whatsoever
upon the Collateral or otherwise for the maintenance of the Collateral, except in the event Agent enters into possession of a part or all of the Collateral, in which event Agent shall preserve the part in its possession. Unless the officers of Agent
acting in their capacity as officer of Agent on Borrower&#146;s account have actual knowledge thereof or have been notified in writing thereof by Lenders, Agent shall not be required to ascertain or inquire as to the existence or possible existence
of any Event of Default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither Agent nor any of its officers, directors, employees, attorneys, representatives or
agents shall be liable to Lenders for any action taken or omitted hereunder or under any of the other Loan Documents or in connection herewith or therewith unless caused by its or their gross negligence or willful misconduct. No provision of this
Agreement or of any other Loan Document shall be deemed to impose any duty or obligation on Agent to perform any act or to exercise any power in any jurisdiction in which it shall be illegal, or shall be deemed to impose any duty or obligation on
Agent to perform any act or exercise any right or power if such performance or exercise (a)&nbsp;would subject Agent to a Tax in a jurisdiction where it is not then subject to a Tax or (b)&nbsp;would require Agent to qualify to do business in any
jurisdiction where it is not so qualified. Without prejudice to the generality of the foregoing, no Lender shall have any right of action whatsoever against Agent as a result of Agent acting or (where so instructed) refraining from acting under this
Agreement or under any of the other Loan Documents in accordance with the instructions of Lenders. Agent shall be entitled to refrain from exercising any power, discretion or authority vested in it under this Agreement unless and until it has
obtained the written instructions of Lenders. The agency hereby created shall in no way impair or affect any of the rights and powers of, or impose any duties or obligations upon Agent in its individual capacity. With respect to its participation in
the Loan Agreement hereunder, Agent shall have the same rights and powers hereunder as any other Lender and may exercise the same rights and powers as though it were not performing the duties and functions delegated to it hereunder and the term
&#147;Lender&#148; or &#147;Lenders&#148; or any similar term shall unless the context clearly indicates otherwise include Agent in its individual capacity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Agent may rely, and shall be fully protected in acting, or refraining to
act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or presented by the
proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties. In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of the statements
and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and conforming to the requirements of this Agreement or any of the other Loan Documents. Agent may consult with counsel, and any opinion or
legal advice of such counsel shall be full and complete authorization and protection in respect of any action taken, not taken or suffered by Agent hereunder or under any Loan Documents in accordance therewith. Agent shall have the right at any time
to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction. Agent shall not be under any obligation to exercise any of the rights or powers granted to Agent by this Agreement and the other Loan
Documents at the request or direction of Lenders unless Agent shall have been provided by Lenders with adequate security and indemnity against the costs, expenses and liabilities that may be incurred by it in compliance with such request or
direction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each Lender agrees to indemnify Agent in its capacity as such (to the extent not reimbursed by Borrower and
without limiting the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding Term Commitments) in effect on the date on which indemnification is sought under this <U>Addendum 3</U>,
from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time be imposed on, incurred by or asserted against Agent in any
way relating to or arising out of, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by Agent under or
in connection with any of the foregoing; The agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) To the extent not reimbursed either by Borrower or from the application of Collateral proceeds pursuant to
<U>Section</U><U></U><U>&nbsp;10.2</U>, a Lender (the &#147;<U>Indemnified Lender</U>&#148;) shall be indemnified by the other Lender (an &#147;<U>Indemnifying Lender</U>&#148;), on a several basis in proportion to each Lender&#146;s pro rata
portion of the Term Commitment, and each Indemnifying Lender agrees to reimburse the Indemnified Lender for the Indemnifying Lender&#146;s pro rata share of the following items (an &#147;<U>Indemnified Payment</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and
expenses of the Indemnified Lender incurred by the Indemnified Lender in connection with the discharge of its activities under this Agreement or the Loan Agreement, including reasonable legal expenses and attorneys&#146; fees; provided, that the
Indemnified Lender shall consult with the other Lender regarding the incurrence of such costs and expenses at reasonable intervals (but not more often than monthly) and any such reasonable costs and expenses shall be &#147;Claims&#148; hereunder
notwithstanding any disagreement by the other Lender as to their incurrence; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) from and against any and all liabilities, obligations, losses, damages,
penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever, which may be imposed on, incurred by or asserted against the Indemnified Lender in any way relating to or arising out of this Agreement, or any
action taken or omitted by the Indemnified Lender hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided, however, that the Indemnified Lender shall not be reimbursed or
indemnified for an Indemnified Payment, except to the extent that the Indemnified Lender paid more than its ratable share of such payment. All Indemnified Payments as set forth in this <U>clause (e)</U>&nbsp;to an Indemnified Lender are intended to
be paid ratably by the other Lender. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>[Reserved</U>.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>[Reserved</U>.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Agent in Its Individual Capacity</U>. The Person serving as Agent hereunder shall have the same rights and powers in its
capacity as a Lender as any other Lender and may exercise the same as though it were not Agent and the term &#147;Lender&#148; shall, unless otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as
Agent hereunder in its individual capacity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Exculpatory Provisions</U>. Agent shall have no duties or obligations
except those expressly set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, Agent shall not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be subject to any fiduciary, advisory or other implied duties, regardless of whether any Default or any Event
of Default has occurred and is continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have any duty to take any discretionary action or exercise any discretionary powers, except discretionary
rights and powers expressly contemplated hereby or by the other Loan Documents that Agent is required to exercise as directed in writing by Lenders, provided that Agent shall not be required to take any action that, in its opinion or the opinion of
its counsel, may expose Agent to liability or that is contrary to any Loan Document or applicable law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and Agent
shall not be liable for the failure to disclose, any information relating to Borrower or any of its Affiliates that is communicated to or obtained by any Person serving as Agent or any of its Affiliates in any capacity. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) In connection with any exercise of Enforcement Actions hereunder, neither any Agent nor any Lender or any of its partners,
or any of their respective directors, officers, employees, attorneys, accountants, or agents shall be liable as such for any action taken or omitted by it or them, except for its or their own gross negligence or willful misconduct with respect to
its duties under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Each Lender and Agent may execute any of its powers and perform any duties hereunder
either directly or by or through agents or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact.</FONT></FONT> Each Lender and Agent shall be entitled to advice of counsel concerning all matters pertaining to such
powers and duties. No Lender or Agent shall be responsible for the negligence or misconduct of any agents or <FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT> selected by it, if the selection of such agents or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> was done without gross negligence or willful misconduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Each Lender agrees that it will make its own independent investigation
of the financial condition and affairs of Borrower in connection with the making of Term Loan Advances pursuant to the Loan Agreement and has made and shall continue to make its own appraisal of the creditworthiness of Borrower. Neither Agent nor
any Lender shall have any duty or responsibility either initially or on a continuing basis to make any such investigation or any such appraisal on behalf of all Lenders or to provide the other Lenders with any credit or other information with
respect thereto whether coming into its possession before the date hereof or any time or times thereafter and shall further have no responsibility with respect to the accuracy of or the completeness of the information provided to Lenders by
Borrower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDENDUM 4 to LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Multiple Borrower Terms </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Borrower&#146;s Agent. Each Borrower hereby irrevocably appoints Company as its agent, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and legal representative for all purposes, including requesting disbursement of the Term Loan and receiving account statements and other notices and communications to Borrowers (or any of
them) from Agent or any Lender. Agent may rely, and shall be fully protected in relying, on any request for the Term Loan Advances, disbursement instruction, report, information or any other notice or communication made or given by Company, whether
in its own name or on behalf of one or more of the other Borrowers, and Agent shall not have any obligation to make any inquiry or request any confirmation from or on behalf of any other Borrower as to the binding effect on it of any such request,
instruction, report, information, other notice or communication, nor shall the joint and several character of Borrowers&#146; obligations hereunder be affected thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Waivers. Each Borrower hereby waives: (i)&nbsp;any right to require Agent to institute suit against, or to exhaust its
rights and remedies against, any other Borrower or any other person, or to proceed against any property of any kind which secures all or any part of the Secured Obligations, or to exercise any right of offset or other right with respect to any
reserves, credits or deposit accounts held by or maintained with Agent or any Indebtedness of Agent or any Lender to any other Borrower, or to exercise any other right or power, or pursue any other remedy Agent or any Lender may have; (ii)&nbsp;any
defense arising by reason of any disability or other defense of any other Borrower or any guarantor or any endorser, <FONT STYLE="white-space:nowrap">co-maker</FONT> or other person, or by reason of the cessation from any cause whatsoever of any
liability of any other Borrower or any guarantor or any endorser, <FONT STYLE="white-space:nowrap">co-maker</FONT> or other person, with respect to all or any part of the Secured Obligations, or by reason of any act or omission of Agent or others
which directly or indirectly results in the discharge or release of any other Borrower or any guarantor or any other person or any Secured Obligations or any security therefor, whether by operation of law or otherwise; (iii)&nbsp;any defense arising
by reason of any failure of Agent to obtain, perfect, maintain or keep in force any Lien on, any property of any Borrower or any other person; (iv)&nbsp;any defense based upon or arising out of any bankruptcy, insolvency, reorganization,
arrangement, readjustment of debt, liquidation or dissolution proceeding commenced by or against any other Borrower or any guarantor or any endorser, <FONT STYLE="white-space:nowrap">co-maker</FONT> or other person, including without limitation any
discharge of, or bar against collecting, any of the Secured Obligations (including without limitation any interest thereon), in or as a result of any such proceeding. Until all of the Secured Obligations have been paid, performed, and discharged in
full, nothing shall discharge or satisfy the liability of any Borrower hereunder except the full performance and payment of all of the Secured Obligations. If any claim is ever made upon Agent for repayment or recovery of any amount or amounts
received by Agent in payment of or on account of any of the Secured Obligations, because of any claim that any such payment constituted a preferential transfer or fraudulent conveyance, or for any other reason whatsoever, and Agent repays all or
part of said amount by reason of any judgment, decree or order of any court or administrative body having jurisdiction over Agent or any of its property, or by reason of any settlement or compromise of any such claim effected by Agent with any such
claimant (including without limitation the any other Borrower), then and in any such event, each Borrower agrees that any such judgment, decree, order, settlement and compromise shall be binding upon such Borrower, notwithstanding any revocation or
release of this Agreement or the cancellation of any note or other instrument evidencing any of the Secured Obligations, or any release of any of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Secured Obligations, and each Borrower shall be and remain liable to Agent and Lenders under this Agreement for the amount so repaid or recovered, to the same extent as if such amount had
never originally been received by Agent or any Lender, and the provisions of this sentence shall survive, and continue in effect, notwithstanding any revocation or release of this Agreement. Each Borrower hereby expressly and unconditionally waives
all rights of subrogation, reimbursement and indemnity of every kind against any other Borrower, and all rights of recourse to any assets or property of any other Borrower, and all rights to any collateral or security held for the payment and
performance of any Secured Obligations, including (but not limited to) any of the foregoing rights which Borrower may have under any present or future document or agreement with any other Borrower or other person, and including (but not limited to)
any of the foregoing rights which any Borrower may have under any equitable doctrine of subrogation, implied contract, or unjust enrichment, or any other equitable or legal doctrine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Consents. Each Borrower hereby consents and agrees that, without notice to or by Borrower and without affecting or
impairing in any way the obligations or liability of Borrower hereunder, Agent may, from time to time before or after revocation of this Agreement, do any one or more of the following in its sole and absolute discretion: (i)&nbsp;accept partial
payments of, compromise or settle, renew, extend the time for the payment, discharge, or performance of, refuse to enforce, and release all or any parties to, any or all of the Secured Obligations; (ii)&nbsp;grant any other indulgence to any
Borrower or any other Person in respect of any or all of the Secured Obligations or any other matter; (iii)&nbsp;accept, release, waive, surrender, enforce, exchange, modify, impair, or extend the time for the performance, discharge, or payment of,
any and all property of any kind securing any or all of the Secured Obligations or any guaranty of any or all of the Secured Obligations, or on which Agent at any time may have a Lien, or refuse to enforce its rights or make any compromise or
settlement or agreement therefor in respect of any or all of such property; (iv)&nbsp;substitute or add, or take any action or omit to take any action which results in the release of, any one or more other Borrowers or any endorsers or guarantors of
all or any part of the Secured Obligations, including, without limitation one or more parties to this Agreement, regardless of any destruction or impairment of any right of contribution or other right of Borrower; (v)&nbsp;apply any sums received
from any other Borrower, any guarantor, endorser, or <FONT STYLE="white-space:nowrap">co-signer,</FONT> or from the disposition of any Collateral or security, to any Indebtedness whatsoever owing from such person or secured by such Collateral or
security, in such manner and order as Agent determines in its sole discretion, and regardless of whether such Indebtedness is part of the Secured Obligations, is secured, or is due and payable. Each Borrower consents and agrees that Agent shall be
under no obligation to marshal any assets in favor of Borrower, or against or in payment of any or all of the Secured Obligations. Each Borrower further consents and agrees that Agent shall have no duties or responsibilities whatsoever with respect
to any property securing any or all of the Secured Obligations. Without limiting the generality of the foregoing, Agent shall have no obligation to monitor, verify, audit, examine, or obtain or maintain any insurance with respect to, any property
securing any or all of the Secured Obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Independent Liability. Each Borrower hereby agrees that one or more
successive or concurrent actions may be brought hereon against such Borrower, in the same action in which any other Borrower may be sued or in separate actions, as often as deemed advisable by Agent. Each Borrower is fully aware of the financial
condition of each other Borrower and is executing and delivering this Agreement based solely upon its own independent investigation of all matters pertinent hereto, and such Borrower is not relying in any manner upon any representation or statement
of Agent or any Lender with respect thereto. Each Borrower represents and warrants that it is in a position to obtain, and each Borrower hereby assumes full responsibility for obtaining, any additional information concerning any other
Borrower&#146;s financial condition and any other matter pertinent hereto as such Borrower may desire, and such Borrower is not relying upon or expecting Agent to furnish to it any information now or hereafter in Agent&#146;s possession concerning
the same or any other matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Subordination. All Indebtedness of a Borrower now or hereafter arising
held by another Borrower is subordinated to the Secured Obligations and Borrower holding the Indebtedness shall take all actions reasonably requested by Agent to effect, to enforce and to give notice of such subordination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVANCE REQUEST </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Agent:
</P></TD></TR></TABLE></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Date:__________, 202[ ]
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hercules Capital, Inc.
(&#147;<U>Agent</U>&#148;) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">email:
legal@htgc.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES, INC.,
a Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Agreement (together with Company, individually or
collectively, as the context may require, &#147;<U>Borrower</U>&#148;) hereby requests Agent to cause Lenders to make a [Tranche 1(a)] [Tranche 1(b)] [Tranche 2] [Tranche 3] Advance in the amount of _____________________ Dollars ($________________)
(the &#147;<U>Advance Amount</U>&#148;) on ______________, _____ (the &#147;<U>Advance Date</U>&#148;) pursuant to the Loan and Security Agreement among Borrower, Agent and Lenders (the &#147;<U>Agreement</U>&#148;). Capitalized words and other
terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Issue a check payable to Borrower ________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Wire Funds to
Borrower&#146;s account ________ [IF FILED PUBLICLY, ACCOUNT INFO REDACTED FOR SECURITY PURPOSES] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bank:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ABA Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Account Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Account Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Contact Person:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To Verify Wire Info:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower represents that the conditions precedent to the Advance set forth in the Agreement are
satisfied and shall be satisfied upon the making of such Advance, including but not limited to: (i)&nbsp;that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; (ii)&nbsp;that the
representations and warranties set forth in the Loan Documents are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such
representations and warranties expressly relate to an earlier date; (iii)&nbsp;that Borrower is in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iv)&nbsp;that as of the
Advance Date, no fact or condition exists that constitutes (or could, with the passage of time, the giving of notice, or both constitute) an Event of Default under the Loan Documents. Borrower understands and acknowledges that Agent has the right to
review the financial information supporting this representation and, based upon such review in its sole discretion, Lenders may decline to fund the requested Advance. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower hereby represents that as of the date hereof Borrower&#146;s corporate status and
locations have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower hereby authorizes Agent to deduct an amount from the proceeds of this Advance to be applied towards the payment of the Tranche
Facility Charge applicable to this Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower agrees to notify Agent promptly before the funding of the Loan if any of the matters
which have been represented above shall not be true and correct on the Advance Date and if Agent has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true
and correct as of the Advance Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY BLANK] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Advance Request is duly executed as of the date set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMPANY: SIGHT SCIENCES, INC., on behalf of all Borrowers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SIGNATURE:________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TITLE:_____________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PRINT NAME:______________________</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT TO ADVANCE REQUEST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: _______________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrower hereby
represents and warrants to Agent that Borrower&#146;s current legal name and organizational status is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of organization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State of organization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organization file number:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrower hereby represents and warrants to Agent that the street addresses, cities, states and postal codes of its current
chief executive office locations are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&nbsp;<FONT STYLE="FONT-SIZE:70%">&#9899;</FONT>&nbsp;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrower hereby represents and warrants to Agent that the Advance Amount does not exceed the Maximum Term Loan Amount as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Advance Amount: $________________ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum Term Loan Amount: $50,000,000.00 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Is clause a. less than or equal to clause b.? Yes/Compliant _______
<FONT STYLE="white-space:nowrap">No/Non-Compliant</FONT> _______ </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Borrower</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prior Names</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity /</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>State of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Formation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>States</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Qualified</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>State Org.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ID</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Federal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tax ID</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Location of<BR>Borrower<BR>(address)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sight Sciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4040 Campbell Avenue, Suite 100,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Menlo Park, CA
94025 U.S.A.</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BORROWER&#146;S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Copyrights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trademarks </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Mark/Serial Number/Registration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number/Listed Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class/Goods and Services</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE <BR>Serial No: 85/928,463 <BR>Reg. No: 5,133,983 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States of America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices for the treatment of ophthalmological conditions<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered<BR>App Date: 05/10/2013<BR>Reg Date: 01/31/2017<BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section 8 &amp; 15 Due: 01/31/2023<BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OMNI <BR>Serial No: 87/549,559 <BR>Reg. No: 5,740,490 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States of America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices, namely, manual surgical instruments for performing anterior segment surgery in the eye<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered<BR>App Date: 07/31/2017<BR>Reg Date: 04/30/2019<BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section 8 &amp; 15 Due: 04/30/2025<BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OMNI <BR>Serial No: 3020201100317 <BR>Reg. No: 302020110031 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Germany</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices, namely, manual surgical instruments for performing anterior segment surgery in the eye<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered<BR>App Date: 07/23/2020<BR>Reg Date: 07/29/2020<BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 07/23/2025<BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 07/23/2030<BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OMNI <BR>Serial No: 018373625 <BR>Reg. No: 018373625 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">European Union</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices, namely manual surgical instruments for performing anterior segment surgery in the eye<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered <BR>App Date: 01/12/2021 <BR>Reg Date: 05/21/2021 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 05/21/2026 <BR>Renewal Due: 01/12/2031</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OMNI</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: UK00003578025</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: UK00003578025</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices, namely manual surgical instruments for performing anterior segment surgery in the eye<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">01/12/2021</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">05/14/2021 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 05/14/2026</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 01/12/2031<BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OMNI <BR>Serial No: 081042021 <BR>Reg. No: 770623</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices, namely manual surgical instruments for performing anterior segment surgery in the eye<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">05/21/2021</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10/12/2021</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 1/12/2027</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Date: 05/21/2031<BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE CLEARANCE ASSISTANT <BR>Serial No: 88/253,594 <BR>Reg. No: 6,142,656</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States of America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices, namely, manual forceps for compression of eyelid glands<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">01/08/2019</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">09/01/2020</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section 8 &amp; 15 Due: 09/01/2026<BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE SMARTLIDS <BR>Serial No: 88/253,808 <BR>Reg. No: 5,998,186</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States of America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10:<BR>Medical devices in the nature of therapeutic eyelid devices for the treatment of eye conditions<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">01/08/2019</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">02/25/2020</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section 8 &amp; 15 Due: 02/25/2026<BR></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN) <BR>Serial No: 90/730,806 <BR>Reg. No:</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g0123144526750.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United&nbsp;States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of&nbsp;America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05: <BR>Pharmaceuticals and diagnostic preparations for the treatment of ophthalmic conditions</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:<BR>Medical devices for treatment of ophthalmic conditions; drug delivery
systems<BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered <BR>App Date: 05/24/2021 <BR>Reg Date: 12/06/2022 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8 &amp; 15: 12/06/2028<BR></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial
No: 925007285 (Class 05)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serioal No: 925007358 (Class 10)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g0123144526750.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05: Pharmaceuticals and diagnostic preparations for the treatment of ophthalmic conditions</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10: Medical devices for treatment of ophthalmic conditions; drug delivery systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Published</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/24/2021</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;5:&nbsp;<I><FONT STYLE="white-space:nowrap">Third-party</FONT><BR>application for<BR><FONT STYLE="white-space:nowrap">PRO-SIGHT</FONT>
(App.<BR>No.</I><I></I><I>&nbsp;501565550) in<BR>the name of New<BR>Zealand Milk<BR>Brands&nbsp;Limited&nbsp;was<BR>cited against the<BR>application;<BR>application<BR>currently in<BR>abeyance pending<BR>the&nbsp;final&nbsp;decision&nbsp;on<BR>the
third-party<BR>application by the<BR>Brazilian&nbsp;trademark<BR>office.</I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10: Appeal<BR>filed; examination<BR>pending</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial
No: IR 1649045</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR 1649045</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146part2b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Union</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Republic of Korea</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mexico</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Singapore</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: Medical devices for treatment of ophthalmic conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/24/2021</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 11/24/2021</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 11/24/2031</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S SIGHT SCIENCES DESIGN</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No:
IR1649045</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1649045</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146part2b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class 10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of
ophthalmic conditions; drug delivery systems for treatment of ophthalmic conditions <BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/24/2021</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 05/23/2022</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 05/23/2025</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial
No: IR1649045</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1649045</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146part2b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">European Union</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of
ophthalmic conditions; drug delivery systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/24/2021</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 08/01/2022</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 08/01/2027</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial
No: IR1649045</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1649045</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146c.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of
ophthalmic conditions; drug delivery systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/24/2021</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 12/08/2022</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 12/08/2025</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN) <BR></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: IR1649045 <BR></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1649045 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146part2b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Republic of Korea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10: <BR></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for
treatment of ophthalmic conditions; drug delivery systems <BR><BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 11/24/2021 <BR>Reg Date: 10/23/2023 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 10/23/2026 <BR><BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SG-S</FONT> SIGHT SCIENCES DESIGN <BR></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: IR1649045 <BR>Reg. No: IR1649045 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146part2b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10: <BR></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for
treatment of ophthalmic conditions; drug delivery systems <BR><BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 11/24/2021 <BR>Reg Date: 04/14/2023 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><BR>For Renewal, see Madrid Protocol Record</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 04/14/2028 <BR><BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN) <BR>Serial No: IR1649045 <BR>Reg. No: IR1649045 <BR></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146part2b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mexico</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10: <BR></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for
treatment of eye conditions; drug administration systems for the treatment of ophthalmic conditions <BR><BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 11/24/2021 <BR>Reg Date: 11/29/2022 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deadline to File Use Affidavit: 10/12/2025</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 11/29/2025 <BR><BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES (S SIGHT SCIENCES DESIGN) <BR>Serial No: IR1649045 <BR>Reg. No: IR1649045 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g715146part2b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10: <BR></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for
treatment of ophthalmic conditions; drug delivery systems for treatment of ophthalmic conditions <BR><BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 04/11/2022 <BR>Reg Date: 08/02/2022 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 08/02/2027 <BR><BR></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: 97/132,509</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No.: 6,946,535</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States of America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: Medical devices for treatment of ophthalmic conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered <BR>App Date: 11/18/2021 <BR>Reg Date: 01/10/2023 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8 &amp; 15 Due: 01/10/2029</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX <BR>Serial No: 925794775 <BR>Reg. No: 925794775 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered <BR>App Date: 02/18/2022 <BR>Reg Date: 05/23/2023 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 05/23/2028 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 05/23/2033 <BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX <BR>Serial No: 90/890,290 <BR>Reg. No: <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States of America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allowed - Intent to Use <BR>App Date: 08/18/2021 <BR>Reg Date: <BR></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Statement of Use Due/EOT4: 05/10/2024 <BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX <BR>Serial No: 925794775 <BR>Reg. No: 925794775 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered <BR>App Date: 02/18/2022 <BR>Reg Date: 05/23/2023 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 05/23/2028 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 05/23/2033 <BR></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX <BR>Serial No: Pending <BR>Reg. No: IR1651448 <BR>Sight Sciences, Inc.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Australia Canada <BR>European Union <BR>United Kingdom <BR>Japan <BR>Republic of Korea <BR>Mexico <BR>Singapore <BR><BR>See specific country below for current
status.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered <BR>App Date: 02/18/2022 <BR>Reg Date: 02/18/2022 <BR></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 02/18/2032 <BR><BR></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TEARCARE MGX <BR>Serial No: IR1651448 <BR>Reg. No: IR1651448 <BR><BR>Sight Sciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 02/18/2022 <BR>Reg Date: 06/07/2022 <BR></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record <BR></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 06/07/2025 <BR></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TEARCARE MGX <BR>Serial No: IR1651448 <BR>Reg. No: IR1651448 <BR><BR>Sight Sciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">European Union</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 02/18/2022 <BR>Reg Date: 08/10/2022 <BR></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record <BR></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 08/10/2027 <BR></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: IR1651448</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1651448</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions <BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 02/18/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 01/05/2023</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to
Cancellation If Not Used: 01/05/2026</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 02/18/2032 <BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: IR1651448</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1651448</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mexico</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions <BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) App Date: 02/18/2022 Reg Date: 11/30/2022</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deadline to file Affidavit of Use: 11/03/2025</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 11/30/2025 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: IR1651448</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1651448</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Republic of Korea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions <BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) App Date: 02/18/2022 Reg Date: 09/07/2023</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 09/07/2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serial No: IR1651448</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. No: IR1651448</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions <BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) App Date: 02/18/2022 Reg Date: 04/21/2023</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 04/21/2028</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX <BR>Serial No: IR1651448 <BR>Reg. No: TMA1,206,658 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 02/18/2022 <BR>Reg Date: 11/01/2023 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 11/01/2026 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 02/18/2032 <BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEARCARE MGX <BR>Serial No: IR1651448 <BR>Reg. No: IR1651448 <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;10: <BR>Medical devices for the treatment of ophthalmological conditions <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid) <BR>App Date: 02/18/2022 <BR>Reg Date: 06/21/2022 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 06/21/2027 <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 02/18/2032 <BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DELIVERING THE POWER OF SIGHT <BR>Serial No: 90/892,482 <BR>Reg. No: <BR></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States of America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05: <BR>Pharmaceuticals and diagnostic preparations for the treatment of ophthalmic conditions; drug delivery systems comprised of
topically-applied liquids, ointments, creams, and gels for the delivery of ophthalmic pharmaceuticals and preparations <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10: <BR>Medical devices for treatment of ophthalmic conditions; drug delivery systems comprised of devices for the delivery of ophthalmic
pharmaceuticals and preparations via injection and implants, sold without medication <BR></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allowed - Intent to Use <BR>App Date: 08/19/2021 <BR>Reg Date:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Statement of Use Due EOT2: 06/27/2024 <BR><BR><BR></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DELIVERING THE POWER OF SIGHT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(EXPRESSION REGISTRATION)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 925795593</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: 925795593</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App&nbsp;Date:&nbsp;02/18/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 08/02/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewals N/A</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DELIVERING THE POWER OF SIGHT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1670155</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1670155</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Union</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mexico</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">See specific country below for current status.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceuticals&nbsp;and&nbsp;diagnostic preparations for the treatment of ophthalmic conditions</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of ophthalmic conditions; drug delivery systems for treatment of ophthalmic conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 02/18/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 02/18/2022</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 02/18/2032</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DELIVERING THE POWER OF SIGHT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1670155</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1670155</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceuticals and diagnostic
preparations for the treatment of ophthalmic conditions</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of ophthalmic conditions; drug delivery apparatus and devices for treatment of ophthalmic conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 02/18/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 10/31/2022</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 10/31/2025</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DELIVERING THE POWER OF SIGHT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1670155</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1670155</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">European Union</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceuticals and diagnostic
preparations for the treatment of ophthalmic conditions</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of ophthalmic conditions; drug delivery systems for treatment of ophthalmic conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 02/18/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 02/08/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 02/08/2028</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DELIVERING THE POWER OF SIGHT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1670155</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1670155</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceuticals and diagnostic
preparations for the treatment of ophthalmic conditions</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of ophthalmic conditions; drug delivery devices for treatment of ophthalmic conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 02/18/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 09/15/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 09/15/2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DELIVERING THE POWER OF SIGHT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1670155</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1670155</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mexico</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;05:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceuticals and diagnostic
preparations for the treatment of ophthalmic conditions</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for treatment of ophthalmic conditions; drug delivery systems for treatment of ophthalmic conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 02/18/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 02/09/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 02/09/2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OMNI ERGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 3020220175777</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: 302022017577</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Germany</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/02/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 11/02/2022</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 11/02/2027</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 11/02/2032</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OMNI ERGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 018788086</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: 018788086</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">European Union</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/02/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 03/14/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 03/14/2028</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 11/02/2032</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OMNI ERGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: UK00003845240</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: UK00003845240</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/02/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 01/27/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 01/27/2028</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 11/02/2032</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OMNI ERGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 140902022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: 793018</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/01/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 02/09/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 05/09/2028</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 11/01/2032</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 97/452,747</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: 7,250,681</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye; excluding medical guidewires</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 06/10/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 12/19/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8&amp;15 Due: 12/19/2029</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1704800</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brazil</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Union</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Republic of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korea</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">See specific country below for current status.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/23/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 11/23/2022</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 11/23/2032</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1704800</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/23/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 04/17/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 04/17/2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 11/23/2022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 11/23/2022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1704800</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Union</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/23/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 05/22/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 05/22/2028</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Republic of Korea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 11/23/2022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1704800</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/23/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 10/19/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 10/19/2028</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Refusal Received</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:
11/23/2022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisional Refusal</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Response Due:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">04/12/2024:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">information from local associate
pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SION</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1704800</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1704800</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices, namely, manual
surgical instruments for performing anterior segment surgery in the eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/23/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 06/15/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 06/15/2028</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">US-SMARTHEAT</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 97/520,248</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allowed - Intent to Use</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:
07/26/2022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: <B></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Statement of Use Due/EOT2: 05/23/2024 </B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTHEAT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1714511</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1714511</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">See specific country below for current status.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 01/26/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 01/26/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 01/26/2033</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTHEAT</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1714511</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 01/26/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 12/07/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation if Not Used: 12/07/2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 97/688,968</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: 7,264,154</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 11/22/2022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 1/2/2024</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8&amp;15 Due: 01/02/2030</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1733694</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australia</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brazil</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Union</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Republic of Korea</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mexico</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">See specific country below for current status.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 05/09/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 05/09/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 05/09/2033</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1733694</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 05/09/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 08/28/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 08/28/2026</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1733694</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Union</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 05/09/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 10/26/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 10/26/2028</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mexico</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Republic of Korea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTLIDS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733694</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1733694</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kingdom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 05/09/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 11/16/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 11/16/2028</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 97/688,973</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allowed - Intent to Use</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:
11/22/2022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: <B></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Statement of Use Due/EOT2: 05/23/2024</B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1733707</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brazil</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Republic of Korea</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mexico</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">See specific country below for current status.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 05/09/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 05/09/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 05/09/2033</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mexico</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Republic of Korea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 05/09/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMARTCABLE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1733707</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1733707</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kingdom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered (Madrid)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 05/09/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 08/29/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Renewal, see Madrid Protocol Record</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Vulnerable to Cancellation If Not Used: 08/29/2028</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 97/588,332</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: 7,080,717</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g715146g0123151836895.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 09/12/2022</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 06/13/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8 &amp; 15 Due: 06/13/2029</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 97/796,894</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g715146g0123151837239.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Published &#150; Intent to Use</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:
02/15/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Opposition Period Expires: 01/18/2024</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No: IR1750784</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g715146g0123151837570.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Protocol</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australia</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brazil</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Union</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Republic of Korea</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mexico</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">See specific country below for current status.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date: 08/11/2023</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: 08/11/2023</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Renewal Due: 08/11/2033</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g715146g0123151837570.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brazil</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g0123151838258.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g0123151838615.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">European Union</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Refusal Received</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:
08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date: <B></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Response to Provisional Refusal Pending</B> <B>(Due 12/12/2023)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g715146g0123151838966.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g715146g0123151839367.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mexico</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g0123151839367.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Republic of Korea</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g715146g0123151839367.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext &#150; Pending Protection</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:
08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Opposition Period Expires: 12/10/2023</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEARCARE MGX LOGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: IR1750784</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g715146g0123151839367.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid Ext - Provisional Refusal Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App
Date: 08/11/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Examination Pending</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCOR</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serial No: 98/112,350</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reg. No:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;10:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Medical devices for the
treatment of ophthalmological conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Published - Intent to Use</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">App Date:
08/01/2023</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg Date:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opposition Period</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expires: 01/18/2024</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Filing Deadline: 02/01/2024</B></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title/Mark</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Registration<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Registration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Case</B><br><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Country</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">07777368.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2034937</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/11/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Switzerland</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">07777368.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2034937</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/11/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Germany</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">07777368.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2034937</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/11/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EP<BR>Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European<BR>Patent&nbsp;Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">07777368.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2034937</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/11/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Spain</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">07777368.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2034937</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/11/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">France</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">07777368.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2034937</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/11/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United<BR>Kingdom</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">07777368.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2034937</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/11/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Italy</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">2009-518132</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5520600</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/11/2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/475,523</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/26/2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7,909,789</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/22/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/695,053</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/27/2010</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8,287,482</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/16/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">2014-152575</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/31/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6113118</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/24/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/025,112</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/10/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9,370,443</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/21/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/445,816</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/12/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9,486,361</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/8/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15/182,165</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/14/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10,314,742</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/11/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11740372.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/3/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2531138</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/30/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EP<BR>Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European<BR>Patent Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">2012-552089</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/3/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5856569</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/18/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Japan</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/020,706</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/3/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8,529,622</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9/10/2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/245,811</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9/26/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8,439,972</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/14/2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14/012,963</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/28/2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8,876,898</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/4/2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2012374034</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2012374034</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/1/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2878271</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Canada</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12871982.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2844200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EP<BR>Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European<BR>Patent Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/644,748</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9,095,412</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/4/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EP<BR>Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European<BR>Patent Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Belgium</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Switzerland</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Germany</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Spain</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">France</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United<BR>Kingdom</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ireland</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Italy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Netherlands</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Norway</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16155079.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3047823</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Sweden</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/644,758</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9,216,109</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/22/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/644,769</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9,855,167</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/2/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2021205065</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2021205065</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/22/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13/644,780</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8,894,603</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/25/2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2023200129</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14/539,648</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/12/2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9,895,258</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/20/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14/816,822</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/3/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10,179,066</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/15/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14/973,620</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/17/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Response<BR>Filed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">2017-505632</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6652961</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/28/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2021240226</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Allowed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3209383</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Canada</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14/675,580</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10,299,958</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/28/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15/340,911</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/1/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10,398,597</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9/3/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11740372.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/3/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2531138</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/30/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Germany</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11740372.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/3/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2531138</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/30/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">France</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11740372.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/3/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2531138</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/30/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United<BR>Kingdom</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15/683,652</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/22/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10,406,030</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9/10/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/866,429</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/15/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2015390071</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2015390071</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/21/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2980713</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2980713</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/3/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Canada</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">201580079974.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">ZL<BR>201580079974</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/2/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">China</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15888007.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3277236</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EP<BR>Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European<BR>Patent Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15/854,126</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/26/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10,888,453</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/12/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2018200231</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2018200231</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/14/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18109217.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1249726</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2/25/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Hong Kong</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16/189,882</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/13/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10,857,027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/8/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16/397,733</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/29/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,090,188</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/17/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">2021-183077</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7348253</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9/11/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/397,817</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/9/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,872,158</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/16/2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">2023-145205</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16/413,466</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/15/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,389,328</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/19/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16/526,832</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/30/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,865,041</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/9/2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16/532,260</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,166,847</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/9/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/498,626</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/11/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2020-9776</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6977073</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/12/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2020202716</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2020202716</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/29/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">23190417.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European<BR>Patent Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">63/117,393</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/23/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Application<BR>Filed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/533,408</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,471,324</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/18/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/033,408</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,504,270</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/22/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/553,671</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,389,327</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/19/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States<BR>of America</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/827,485</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/27/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Allowed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/827,494</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/27/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,617,679</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/4/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18/197,679</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/15/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18/130,353</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/3/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18/130,354</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/3/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/990,589</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/18/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11,857,460</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1/2/2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AU2021381495</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3199736</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Canada</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">202180090923.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">China</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21895840.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European<BR>Patent&nbsp;Office</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2023-530994</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/534,348</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/534,349</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11,419,886</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/23/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/868,696</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/19/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11,554,134</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">1/17/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">18/088,347</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/23/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Allowed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR DEVICES, SYSTEMS, AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">22812314.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/27/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">European<BR>Patent&nbsp;Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR DEVICES, SYSTEMS, AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/827,573</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/27/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR DEVICES, SYSTEMS, AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PCT/<BR>US2022/03/1457</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/27/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Patent<BR>Cooperation<BR>Treaty</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEVICES AND METHODS FOR INTRAOCULAR TISSUE MANIPULATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">18/122,108</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/15/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United&nbsp;States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEVICES AND METHODS FOR INTRAOCULAR TISSUE MANIPULATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PCT/<BR>US2023/015327</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/15/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Patent<BR>Cooperation<BR>Treaty</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEVICES AND METHODS FOR INTRAOCULAR TISSUE MANIPULATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">18/122,109</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/15/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11,877,954</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">1/23/2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12871982.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2844200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12871982.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2844200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Germany</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12871982.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2844200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Spain</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12871982.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2844200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">France</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12871982.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2844200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United<BR>Kingdom</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12871982.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2844200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Italy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">202110189856.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">China</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/239,263</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11,116,660</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/14/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">42022047529.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Hong Kong</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/239,270</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11,344,447</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/31/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTRAOCULAR DEVICES, SYSTEMS, AND METHODS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">63/194,824</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5/28/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Application<BR>Filed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">21179625.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">European<BR>Patent Office</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15888007.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3277236</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">France</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15888007.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3277236</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Germany</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15888007.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3277236</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Italy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15888007.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3277236</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Spain</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15888007.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3277236</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULAR DELIVERY SYSTEMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15888007.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/31/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3277236</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United<BR>Kingdom</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BIO-ERODIBLE OCULAR IMPLANTS FOR TREATMENT OF CONDITIONS OF THE EYE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">63/428,389</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/28/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">United States<BR>of America</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Serial&nbsp;#</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Publication&nbsp;#</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Publication<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;#</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issue<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BRAZIL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">BR 11 2014<BR>016505 0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2423</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/13/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">112014016505-0</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/18/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CHINA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2012800711619</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CN 104334129 A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/4/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ZL<BR>2012800711619</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/19/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CHINA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2017107693584</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CN 107510545 A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/26/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ZL<BR>2017107693584</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/19/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CHINA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">202210615213x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CN 115068202A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/20/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">GERMANY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12864218.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">60 2012 061 539.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/26/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EUROPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12864218.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2800543</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/12/2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2800543</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/26/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">NAT PHASE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">SPAIN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12864218.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2800543</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/26/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">FRANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12864218.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2800543</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/26/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED KINGDOM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12864218.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2800543</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/26/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">ITALY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12864218.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">502019000077339</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/26/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JAPAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2014-551238</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2015-503417</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/2/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6747770</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/11/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JAPAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2018-193884</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6768761</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/25/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JAPAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2020-158988</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2020-499386</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/17/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JAPAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2022-125366</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PENDING</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>APPARATUS<BR>AND<BR>METHODS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">13/343,407</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">1/4/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2013-0172790-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/4/2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9,724,230</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/8/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WIPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PCT/<BR>US2012/059384</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/9/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">WO 2013/103413 A1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/11/2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">NAT PHASE</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">13/645,985</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/5/2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2013-0172829-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/4/2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9,510,972</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/6/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>FOR DRY<BR>EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">14/967,116</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/11/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2016-0106576-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/21/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10,973,680</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/13/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15/364,070</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/29/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2017-0079834-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9,844,459</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/19/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">METHODS<BR>FOR<BR>IMPROVING<BR>CONTACT<BR>LENS<BR>COMFORT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15/369,176</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/5/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2017-0079840-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9,642,743</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/9/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15/442,003</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/24/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2017-0165106-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/15/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10,052,226</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/21/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>APPARATUS<BR>AND<BR>METHODS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15/639,850</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/30/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2017-0304110-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/26/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10,772,758</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/15/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">16/059,281</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/9/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2018-0344512-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/6/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10,925,765</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/23/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>APPARATUS<BR>AND<BR>METHODS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">16/988,495</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/7/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2020-0405534-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/31/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">DRY EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/166,619</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/3/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2021-0177647-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/17/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>FOR DRY<BR>EYE<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/169,038</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/5/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2021-0177648-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/17/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">COMBINATION<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">15/374,426</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/9/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2017-0087009-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/30/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11,285,040</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/29/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ISSUED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WIPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">COMBINATION<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PCT/<BR>US2016/065876</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/9/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">WO 2017/100608</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/15/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">ABANDONED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">COMBINATION<BR>IN<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">17/651,357</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/16/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2022-168136-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/2/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BRAZIL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">FORCEPS<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">BR<BR>112021004614 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/4/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2629</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/25/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CHINA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">FORCEPS<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2019800742977</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/4/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CN 112996466</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/18/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EUROPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">FORCEPS<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">19860871.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/4/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3833310</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/16/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JAPAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">FORCEPS<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2021-513382</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/4/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PENDING</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">FORCEPS<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">16/127,870</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/11/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2020-0078211-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/12/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WIPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">FORCEPS<BR>TREATMENT<BR>SYSTEMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PCT/<BR>US2019/049440</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">9/4/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">WO 2020/055634</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3/19/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">NAT PHASE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">TREATMENT<BR>APPARATUS<BR>AND<BR>METHODS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">16/523,078</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/26/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2021-0022914-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">1/28/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BRAZIL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>WITH<BR>IMAGING<BR>SYSTEM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">BR<BR>112022002061.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/4/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2674</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/5/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CHINA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>WITH<BR>IMAGING<BR>SYSTEM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2020800668613</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/4/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CN 114513982 A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/17/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EUROPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>WITH<BR>IMAGING<BR>SYSTEM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">20850894.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/4/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3998933</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/25/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JAPAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>WITH<BR>IMAGING<BR>SYSTEM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2022-505537</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/4/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PENDING</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>WITH<BR>IMAGING<BR>SYSTEM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">16/984,997</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/4/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">US-2021-0052216-A1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/25/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WIPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>WITH<BR>IMAGING<BR>SYSTEM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PCT/<BR>US2020/044886</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/4/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">WO 2021/026154</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2/11/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">PUBLISHED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">FORCEPS FOR<BR>DRY EYE<BR>TREATMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">62/266,483</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/11/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">EXPIRED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">UNITED STATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">CONTROLLER<BR>WITH<BR>IMAGING<BR>SYSTEM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">62/882,792</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">EXPIRED</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BORROWER&#146;S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPLIANCE CERTIFICATE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hercules Capital,
Inc. (as &#147;<U>Agent</U>&#148;) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to that
certain Loan and Security Agreement dated January 22, 2024 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as
the &#147;<U>Loan Agreement</U>&#148;) by and among Hercules Capital, Inc. (&#147;<U>Agent</U>&#148;), the several banks and other financial institutions or entities from time to time party thereto (collectively, &#147;<U>Lender</U>&#148;) and SIGHT
SCIENCES, INC., a Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Loan Agreement (together with
Company, individually or collectively, as the context may require, &#147;<U>Borrower</U>&#148;). All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned is an Officer of Company, knowledgeable of all Company financial matters, and is authorized, on behalf of Company, to provide
certification of information regarding Company; hereby certifies, on behalf of Company, that in accordance with the terms and conditions of the Loan Agreement, Company is in compliance for the period ending ___________ of all covenants, conditions
and terms and hereby reaffirms that all representations and warranties contained therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such
representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties. The undersigned further certifies that
no Default or Event of Default exists as of the date hereof. The undersigned further certifies that any financial materials delivered with this Compliance Certificate are prepared in accordance with GAAP (except for the absence of footnotes with
respect to unaudited financial statement and subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments) and are consistent from one period to the next except as explained below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REPORTING REQUIREMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REQUIRED</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHECK IF ATTACHED</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interim Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quarterly within 45 days</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FYE within 90 days</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACCOUNTS OF BORROWER AND ITS SUBSIDIARIES AND AFFILIATES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby also confirms, on behalf of Company, that the below disclosed accounts represent all depository accounts and securities accounts
presently open in the name of each Borrower or Borrower&#146;s Subsidiary/Affiliate, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each new account that has been opened since delivery
of the previous Compliance Certificate is designated below with a &#147;*&#148;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Depository<BR>AC #</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Financial<BR>Institution</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Account<BR>Type<BR>(Depository&nbsp;/<BR>Securities)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Last<BR>Month<BR>Ending<BR>Account<BR>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Purpose&nbsp;of<BR>Account</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>BORROWER Name/Address:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="21" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUBSIDIARY Name/Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="21" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name of Test</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Required Level</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Actual Level</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">In Compliance Y/N?</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minimum Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minimum Net Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ADDITIONAL DISCLOSURES </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MATERIAL CONTINGENCIES: The undersigned hereby also confirms that a report detailing any material contingencies
(including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, as certified by Borrower&#146;s chief executive officer or chief financial
officer, is attached hereto as Annex I.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INSURANCE POLICIES OF BORROWER AND ITS SUBSIDIARIES </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[The undersigned hereby also confirms that since delivery of the previous Compliance Certificate, neither
Borrower nor any of its Subsidiaries has entered into or amended any insurance policy required pursuant to Section&nbsp;6.1 of the Loan Agreement.]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[Since delivery of the previous Compliance Certificate, Borrower and/or one or more of its Subsidiaries have
entered into new, or amended existing, insurance policies required pursuant to Section&nbsp;6.1 of the Loan Agreement. Attached hereto are copies of such new or amended insurance policies and updated insurance certificates with respect to such
policies, as required to be delivered pursuant to Section&nbsp;6.2 of the Loan Agreement.]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INTELLECTUAL PROPERTY </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[The following claim(s) have been made to a Loan Party that material part(s) of the Intellectual Property
violates the rights of a third party: [&nbsp;&nbsp;&nbsp;&nbsp;]]<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ORGANIZATIONAL STATUS </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[Each Loan Party&#146;s present name, former names (if any), locations, place of formation, tax identification
number, organizational identification number and other information are attached hereto.]<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CAPITALIZATION AND SUBSIDIARIES </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[Attached hereto is a true, correct and complete list of each Subsidiary, substantially in the form of Schedule
5.14 to the Loan Agreement.]<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include in Compliance Certificates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if neither Borrower nor any of its Subsidiaries has entered into or amended any insurance policies
since delivery of the previous Compliance Certificate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if Borrower or any of its Subsidiaries has entered into or amended any insurance policies since
delivery of the previous Compliance Certificate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Include if any claim(s) have been made to any Loan Party that any material part of the Intellectual Property
violates the rights of any third party. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attach updated Exhibit B if updates to organizational status are needed pursuant to Section&nbsp;5.1 of the
Loan Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attach updated Schedule 5.14 if updates are needed. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very Truly Yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SIGHT SCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF JOINDER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Joinder Agreement (the &#147;<U>Joinder Agreement</U>&#148;) is made and dated as of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ], 20[&nbsp;&nbsp;&nbsp;&nbsp; ], and is entered into by and between__________________., a ___________ corporation (&#147;<U>Subsidiary</U>&#148;), and HERCULES CAPITAL, INC.,
a Maryland corporation (as &#147;<U>Agent</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Subsidiary&#146;s Affiliate, SIGHT SCIENCES, INC., a Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has
delivered a Joinder Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Agreement (together with Company, individually or collectively, as the context may require, &#147;<U>Existing Borrower</U>&#148;) has
entered into that certain Loan and Security Agreement dated January&nbsp;22, 2024, with the several banks and other financial institutions or entities from time to time party thereto as lender (collectively, &#147;<U>Lenders</U>&#148;), each other
Borrower that is party thereto, and Agent, (as may be amended, supplemented or otherwise modified from time to time, the &#147;<U>Loan Agreement</U>&#148;), together with the other agreements executed and delivered in connection therewith; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Existing Borrower&#146;s execution of the Loan
Agreement and the other agreements executed and delivered in connection therewith. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, Subsidiary and Agent agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms
not defined herein shall have the meaning provided in the Loan Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement
the same as if it were Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that (a)&nbsp;with respect to (i)<U>&nbsp;Section</U><U></U><U>&nbsp;5.1</U> of the Loan Agreement, Subsidiary
represents that it is an entity duly organized, legally existing and in good standing under the laws of [ ], (b) neither Agent nor Lenders shall have any duties, responsibilities or obligations to Subsidiary arising under or related to the Loan
Agreement or the other Loan Documents other than as described in the immediately following sentence herein, (c)&nbsp;that if Subsidiary is covered by Existing Borrower&#146;s insurance, Subsidiary shall not be required to maintain separate insurance
or comply with the provisions of Sections 6.1 and 6.2 of the Loan Agreement, and (d)&nbsp;that as long as Existing Borrower satisfies the requirements of Section&nbsp;7.1 of the Loan Agreement, Subsidiary shall not have to provide Agent separate
Financial Statements. To the extent that Agent or Lenders has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other Loan Documents, those duties, responsibilities or obligations shall flow only to
Existing Borrower and not to Subsidiary or any other Person or entity. By way of example (and not an exclusive list): (i) Agent&#146;s providing notice to Existing Borrower in accordance with the Loan Agreement or as otherwise agreed among Existing
Borrower, Agent and Lenders shall be deemed provided to Subsidiary; (ii)&nbsp;Lenders&#146; providing an Advance to Existing Borrower shall be deemed an Advance to Subsidiary; and (iii)&nbsp;Subsidiary shall have no right to request an Advance or
make any other demand on Lenders. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Subsidiary agrees not to certificate its equity securities without Agent&#146;s prior written consent (except
to the extent certificated prior to the date of this Joinder Agreement), which consent may be conditioned on the delivery of such equity securities to Agent in order to perfect Agent&#146;s security interest in such equity securities.]
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subsidiary acknowledges that it benefits, both directly and indirectly, from the Loan Agreement, and hereby
waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee for the benefit of creditors, receiver, bankruptcy trustee or itself as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debtor-in-possession</FONT></FONT> under any bankruptcy proceeding) to the fullest extent provided by law, any and all claims, rights or defenses to the enforcement of this Joinder
Agreement on the basis that (a)&nbsp;it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b)&nbsp;its obligations under this Joinder Agreement are avoidable as a fraudulent conveyance.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or
otherwise) of all the Secured Obligations, Subsidiary grants to Agent a security interest in all of Subsidiary&#146;s right, title, and interest in and to the Collateral. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Joinder Agreement shall be governed by, and construed and enforced in accordance with, the laws of the
State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE TO JOINDER AGREEMENT] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SUBSIDIARY: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">_________________________________. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone: ___________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">email: ____________</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGENT: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HERCULES CAPITAL,
INC. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:____________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:__________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: ___________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">400 Hamilton Ave., Suite 310</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">email: legal@htgc.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-289-3060</FONT></FONT></P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF WARRANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Attached] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACH DEBIT AUTHORIZATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hercules Capital, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[If SBA: Hercules Technology III, L.P.]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Re: Loan and Security Agreement dated January 22, 2024 (the &#147;<U>Agreement</U>&#148;) by and among SIGHT SCIENCES, INC., a Delaware
corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Agreement (together with Company, individually or collectively,
as the context may require, &#147;<U>Borrower</U>&#148;), Hercules Capital, Inc., as administrative agent and collateral agent (&#147;<U>Agent</U>&#148;) and the lenders party thereto (collectively, the &#147;<U>Lenders</U>&#148;) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the above referenced Agreement,
Borrower hereby authorizes Agent or Lenders to initiate debit entries for (i)&nbsp;the periodic payments due under the Agreement and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(ii)&nbsp;out-of-pocket</FONT></FONT> legal fees
and costs incurred by Agent or Lenders pursuant to <U>Section</U><U></U><U>&nbsp;11.12</U> of the Agreement to Borrower&#146;s account indicated below. Borrower authorizes the depository institution named below to debit to such account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[IF FILED PUBLICLY, ACCOUNT INFO REDACTED FOR SECURITY PURPOSES] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DEPOSITORY NAME</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BRANCH</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">STATE AND ZIP CODE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TRANSIT/ABA NUMBER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ACCOUNT NUMBER</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This authority will remain in full force and effect so long as any amounts are due under the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">________________________________________________ </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company, on
behalf of each Borrower) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By: ____________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: __________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: ___________________________________</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[RESERVED] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">J-1</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF U.S. TAX COMPLIANCE CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the Loan and Security Agreement dated as of January 22, 2024 (as amended, supplemented or otherwise modified from
time to time, the &#147;<U>Loan Agreement</U>&#148;) by and among SIGHT SCIENCES, INC., a Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Loan Agreement (together with Company, individually or collectively, as the context may require, &#147;<U>Borrower</U>&#148;), the several banks and other financial institutions
or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#147;<U>Lenders</U>&#148;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself
and Lenders (in such capacity, the &#147;<U>Agent</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the
undersigned hereby certifies that (i)&nbsp;it is the sole record and beneficial owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii)&nbsp;it is not a
&#147;bank&#148; within the meaning of Section&nbsp;881(c)(3)(A) of the Code, (iii)&nbsp;it is not a <FONT STYLE="white-space:nowrap">&#147;10-percent</FONT> shareholder&#148; of Borrower within the meaning of Section&nbsp;871(h)(3)(B) of the Code
and (iv)&nbsp;it is not a &#147;controlled foreign corporation&#148; related to Borrower as described in Section&nbsp;881(c)(3)(C) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned has furnished Agent and Borrower with a certificate of its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Person status on
IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E.</FONT></FONT> By executing this certificate, the undersigned agrees that (1)&nbsp;if the information
provided in this certificate changes, the undersigned shall promptly so inform Borrower and Agent, and (2)&nbsp;the undersigned shall have at all times furnished Borrower and Agent with a properly completed and currently effective certificate in
either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: _____________ ___, 20___</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">[NAME OF LENDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">J-2</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF U.S. TAX COMPLIANCE CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the Loan and Security Agreement dated as of January 22, 2024 (as amended, supplemented or otherwise modified from
time to time, the &#147;<U>Loan Agreement</U>&#148;) by and among SIGHT SCIENCES, INC., a Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Loan Agreement (together with Company, individually or collectively, as the context may require, &#147;<U>Borrower</U>&#148;), the several banks and other financial institutions
or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#147;<U>Lenders</U>&#148;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself
and Lenders (in such capacity, the &#147;<U>Agent</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the
undersigned hereby certifies that (i)&nbsp;it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii)&nbsp;it is not a &#147;bank&#148; within the meaning of Section&nbsp;881(c)(3)(A)
of the Code, (iii)&nbsp;it is not a <FONT STYLE="white-space:nowrap">&#147;10-percent</FONT> shareholder&#148; of Borrower within the meaning of Section&nbsp;871(h)(3)(B) of the Code and (iv)&nbsp;it is not a &#147;controlled foreign
corporation&#148; related to Borrower as described in Section&nbsp;881(c)(3)(C) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned has furnished its
participating Lender with a certificate of its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Person status on IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E.</FONT></FONT> By executing this certificate, the undersigned agrees that (1)&nbsp;if the information provided in this certificate changes, the undersigned shall promptly so
inform such Lender in writing, and (2)&nbsp;the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the
undersigned, or in either of the two calendar years preceding such payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, terms defined in the Loan
Agreement and used herein shall have the meanings given to them in the Loan Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: _____________ ___, 20___</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">[NAME OF PARTICIPANT]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">J-3</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF U.S. TAX COMPLIANCE CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the Loan and Security Agreement dated as of January 22, 2024 (as amended, supplemented or otherwise modified from
time to time, the &#147;<U>Loan Agreement</U>&#148;) by and among SIGHT SCIENCES, INC., a Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Loan Agreement (together with Company, individually or collectively, as the context may require, &#147;<U>Borrower</U>&#148;), the several banks and other financial institutions
or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#147;<U>Lenders</U>&#148;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself
and Lenders (in such capacity, the &#147;<U>Agent</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the
undersigned hereby certifies that (i)&nbsp;it is the sole record owner of the participation in respect of which it is providing this certificate, (ii)&nbsp;its direct or indirect partners/members are the sole beneficial owners of such participation,
(iii)&nbsp;with respect to such participation, neither the undersigned nor any of its direct or indirect partners/members is a &#147;bank&#148; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or
business within the meaning of Section&nbsp;881(c)(3)(A) of the Code, (iv)&nbsp;none of its direct or indirect partners/members is a <FONT STYLE="white-space:nowrap">&#147;10-percent</FONT> shareholder&#148; of Borrower within the meaning of
Section&nbsp;871(h)(3)(B) of the Code and (v)&nbsp;none of its direct or indirect partners/members is a &#147;controlled foreign corporation&#148; related to Borrower as described in Section&nbsp;881(c)(3)(C) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned has furnished its participating Lender with IRS Form <FONT STYLE="white-space:nowrap">W-8IMY</FONT> accompanied by one of the
following forms from each of its partners/members that is claiming the portfolio interest exemption: (i)&nbsp;an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or (ii)&nbsp;an IRS Form <FONT STYLE="white-space:nowrap">W-8IMY</FONT> accompanied by an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> from each of such partner&#146;s/member&#146;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned
agrees that (1)&nbsp;if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender and (2)&nbsp;the undersigned shall have at all times furnished such Lender with a properly completed and currently
effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: _____________ ___, 20___</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">[NAME OF PARTICIPANT]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">J-4</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF U.S. TAX COMPLIANCE CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the Loan and Security Agreement dated as of January 22, 2024 (as amended, supplemented or otherwise modified from
time to time, the &#147;<U>Loan Agreement</U>&#148;) by and among SIGHT SCIENCES, INC., a Delaware corporation (&#147;<U>Company</U>&#148;), and each other Person that has delivered a Joinder Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.13</U> from time to time party to the Loan Agreement (together with Company, individually or collectively, as the context may require, &#147;<U>Borrower</U>&#148;), the several banks and other financial institutions
or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#147;<U>Lenders</U>&#148;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself
and Lenders (in such capacity, the &#147;<U>Agent</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the
undersigned hereby certifies that (i)&nbsp;it is the sole record owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii)&nbsp;its direct or indirect partners/members
are the sole beneficial owners of such Loan(s) (as well as any promissory note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Loan Agreement or any other Loan Document, neither the undersigned nor any of
its direct or indirect partners/members is a &#147;bank&#148; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section&nbsp;881(c)(3)(A) of the Code, (iv)&nbsp;none of
its direct or indirect partners/members is a <FONT STYLE="white-space:nowrap">&#147;10-percent</FONT> shareholder&#148; of Borrower within the meaning of Section&nbsp;871(h)(3)(B) of the Code and (v)&nbsp;none of its direct or indirect
partners/members is a &#147;controlled foreign corporation&#148; related to Borrower as described in Section&nbsp;881(c)(3)(C) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned has furnished Agent and Borrower with IRS Form <FONT STYLE="white-space:nowrap">W-8IMY</FONT> accompanied by one of the
following forms from each of its partners/members that is claiming the portfolio interest exemption: (i)&nbsp;an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or (ii)&nbsp;an IRS Form <FONT STYLE="white-space:nowrap">W-8IMY</FONT> accompanied by an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> from each of such partner&#146;s/member&#146;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned
agrees that (1)&nbsp;if the information provided in this certificate changes, the undersigned shall promptly so inform Borrower and Agent, and (2)&nbsp;the undersigned shall have at all times furnished Borrower and Agent with a properly completed
and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: _____________ ___, 20___</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">[NAME OF LENDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BORROWER&#146;S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Bank Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Account Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Account&nbsp;Type</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Branch Address</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Name of<BR>Company/Subsidiary<BR>holding Account</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lockbox<BR>Account (used<BR>for Customer<BR>Remittances)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">530 Lytton Avenue, Suite 101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA
94301-1539</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight&nbsp;Sciences,&nbsp;Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***] </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Checking<BR>Account</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">530 Lytton Avenue, Suite 101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA
94301-1539</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight Sciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Interest-Bearing</FONT><BR>Account</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">530 Lytton Avenue, Suite 101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA
94301-1539</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight Sciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ZBA Payroll<BR>Account</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">530 Lytton Avenue, Suite 101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA
94301-1539</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight Sciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Account used to<BR>deposit funds<BR>from Fidelity<BR>related to stock<BR>matters</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">530 Lytton Avenue, Suite 101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA
94301-1539</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight Sciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">London</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">UK (GBP)<BR>Account<BR>primarily set up<BR>for Customer<BR>Remittances</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 King Edward Street, London,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EC1A 1HQ</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">UK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight Sciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank of America<BR></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Europe DAC,<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Frankfurt Branch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Germany<BR>(EUR) Account<BR>primarily set up<BR>for Customer<BR>Remittances</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taunusanlage <FONT STYLE="white-space:nowrap">9-10</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">60329 Frankfurt</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Germany</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight Sciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank of America</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">London</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">UK (GBP)<BR>Checking<BR>Account</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 King Edward Street, London,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EC1A 1HQ</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">UK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight Sciences,<BR>UK, LTD</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank of America</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Europe DAC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Frankfurt Branch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Germany&nbsp;(EUR)<BR>Checking<BR>Account</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taunusanlage <FONT STYLE="white-space:nowrap">9-10</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">60329 Frankfurt</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Germany</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight&nbsp;Sciences<BR>GmbH</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERRILL PRIVATE WEALTH MANAGEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment<BR>Account</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2049 CENTURY PARK E STE</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1200 CENTURY CITY
CA</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">90067</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sight&nbsp;Sciences,&nbsp;Inc.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1 &#150; Commitments </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>LENDERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TRANCHE 1<BR>COMMITMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TRANCHE 2<BR>COMMITMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TRANCHE 3<BR>COMMITMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hercules Capital, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hercules Private Credit Fund 1 L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">/</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hercules Private Global Venture Growth Fund I L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">/</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL COMMITMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1 &#150; Subsidiaries </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Entity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction of Organization/Incorporation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences UK, LTD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">England and Wales</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Germany</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1A &#150; Existing Permitted Indebtedness </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1B &#150; Existing Permitted Investments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1C &#150; Existing Permitted Liens </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.3 &#150; Consents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.8 &#150; Tax Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.9 &#150; Intellectual Property Claims </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.11 &#150; Borrower Products </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;16, 2021, the Company filed suit in the U.S. District Court for the District of Delaware (C.A. No. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1:21-cv-01317)</FONT></FONT> alleging that Ivantis, Inc. (&#147;Ivantis&#148;) directly and indirectly infringes the Company&#146;s U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 by making, using,
selling, and offering for sale the Hydrus<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Microstent. The Company&#146;s complaint seeks money damages and injunctive relief. On January&nbsp;24, 2022, Ivantis asserted counterclaims
requesting declaratory judgments that the Company&#146;s asserted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">patents-in-suit</FONT></FONT> are not infringed and/or are invalid. On August&nbsp;1, 2022, the Company filed an
amended complaint alleging that Alcon Inc., Alcon Vision, LLC and Alcon Research, LLC (collectively, &#147;Alcon&#148;) infringe the four originally asserted patents by making, using, selling, and offering for sale the Hydrus<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Microstent, and that all defendants also infringe U.S. Patent No.&nbsp;11,389,328. The defendants asserted counterclaims requesting declaratory judgments that the Company&#146;s asserted <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">patents-in-suit</FONT></FONT> are not infringed and/or are invalid. Ivantis and Alcon filed petitions with the U.S. Patent Office seeking <I>inter partes </I>review of U.S. Patent Nos.
8,287,482, 9,370,443, 9,486,361, and 10,314,742 (IPR2022-01529, IPR2022-01530, IPR2022-01533, IPR2022-01540), each of which the U.S. Patent Office denied for raising prior art reference and invalidity arguments that were cumulative of those
previously considered by the office. The Court entered a claim construction order September&nbsp;19, 2023.&nbsp;A <FONT STYLE="white-space:nowrap">five-day</FONT> jury trial is scheduled to commence on April&nbsp;8, 2024.&nbsp;The Company is
presently unable to predict the outcome of this lawsuit or to reasonably estimate the potential financial impact of the lawsuit on the Company, if any.</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.13 &#150; Employee Loans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.14 &#150; Subsidiaries </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Entity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction of Organization/Incorporation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences UK, LTD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">England and Wales</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Germany</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 7.23 &#150; Affiliate Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d715146dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g715146dsp118.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules
Capital </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Refinancing replaces prior senior credit facility </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MENLO PARK, Calif. - January 23, 2024 -</B> (GLOBE NEWSWIRE) &#151; Sight Sciences, Inc. (Nasdaq: SGHT) (&#147;Sight Sciences&#148;), an eyecare technology
company focused on developing and commercializing innovative technology intended to transform care and improve patients&#146; lives, today announced the closing of an up to $65&nbsp;million senior secured credit facility with Hercules Capital, Inc.
(NYSE: HTGC) (&#147;Hercules&#148;), a leader in customized debt financing for companies in life sciences and technology-related markets. The transaction included the immediate draw of $35&nbsp;million, the net proceeds of which the Company used to
pay off the principal amount of the Company&#146;s indebtedness to its previous secured lender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This new facility further strengthens our balance
sheet and enhances our ability to execute our strategic plan,&#148; said Ali Bauerlein, Chief Financial Officer of Sight Sciences. &#147;We are excited to partner with the Hercules team and are pleased to extend our cash runway and expand financial
flexibility through the support and confidence of a leading growth medtech lender like Hercules. We feel Hercules is an ideal partner for us moving forward as we scale our business over the coming years.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This capital commitment from Hercules aims to help Sight Sciences deliver on its important mission to transform the treatment of eye diseases by
treating the underlying causes,&#148; said Lake McGuire, Managing Director at Hercules Capital. &#147;We are proud to partner with the Sight Sciences team and provide them with improved financial flexibility.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Credit Facility Terms: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$35&nbsp;million funded at loan closing, with up to an additional $30&nbsp;million potentially available (subject
to certain conditions as described in the credit agreements </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">54-month</FONT> maturity, with interest-only period of 30 months, which can be
extended to 36 months subject to achievement of certain performance milestones </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The credit facility is secured by substantially all of
the Company&#146;s assets. Additional details regarding the Company&#146;s debt refinancing will be filed with the Securities and Exchange Commission on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> available at
investors.sightsciences.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Sight Sciences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions to transform care and improve patients&#146;
lives. Using minimally invasive or <FONT STYLE="white-space:nowrap">non-invasive</FONT> approaches to target the underlying causes of the world&#146;s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms
that enhance patient care and supplant conventional, outdated approaches. The Company&#146;s OMNI<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Surgical System is a MIGS technology indicated to reduce intraocular pressure in adult
patients with primary open-angle glaucoma (&#147;POAG&#148;), the world&#146;s leading cause of irreversible blindness. The Company&#146;s TearCare<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> System technology is 510(k) cleared for the
application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (&#147;MGD&#148;) when used in conjunction with manual expression of the meibomian glands, enabling office-based clearance of
gland obstructions by physicians to address the leading cause of dry eye disease. The Company&#146;s SION<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Surgical Instrument is a manually operated device used in ophthalmic surgical
procedures to excise trabecular meshwork. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit&nbsp;www.sightsciences.com. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OMNI, SION, and TearCare are registered trademarks of Sight Sciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> 2024 Sight Sciences. All rights reserved. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g715146dsp118.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the
meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such
forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor
provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements
herein include, without limitation, statements concerning the terms of the new secured credit facility with Hercules including the amount of available borrowings, and the Company&#146;s ability to expand its financial flexibility through the
utilization of the credit facility with Hercules. These statements often include words such as &#147;anticipate,&#148; &#147;expect,&#148; &#147;suggests,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;intend,&#148; &#147;estimates,&#148;
&#147;targets,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;may,&#148; &#147;will,&#148; &#147;forecast&#148; and other similar expressions. We base these forward-looking statements on our current
expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under
the circumstances at such time. Although management believes these forward-looking statements are based upon reasonable assumptions at the time they are made, management cannot guarantee their accuracy or completeness. Forward-looking statements are
subject to and involve risks, uncertainties and assumptions that may cause the Company&#146;s actual results, performance or achievements to be materially different from any future results, performance, or achievements predicted, assumed or implied
by such forward-looking statements. Some of the risks and uncertainties that may cause actual results to materially differ from those expressed or implied by these forward-looking statements are discussed under the caption &#147;Risk Factors&#148;
in the Company&#146;s filings with the SEC, as may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. Sight Sciences
undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>pr@SightSciences.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philip Taylor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilmartin Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">415.937.5406 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor.Relations@Sightsciences.com</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sght-20240122.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/24/2024 2:04:20 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:sght="http://www.sightsciences.com/20240122"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.sightsciences.com/20240122"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sght-20240122_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sght-20240122_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>sght-20240122_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/24/2024 2:04:20 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>sght-20240122_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/24/2024 2:04:20 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sght-20240122.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g715146dsp118.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146dsp118.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M;A*D(WA4^%V/-Q]&I/EJ4?BC?\3DXFT# _M]=5-]_P M/.]?;O\ G7I-5_\
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' 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g715146g0123144526750.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123144526750.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 ,@# 2(  A$! Q$!_\0
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M ]WHKG/"_CKP]XPB+:1?K)*!EK=_ED7_ (#_ %&:Z.@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^9O&^L:[\5OB))X6T5B-/M)
M6C5<X3Y3AY7_ !Z?AZUW&D_!OP/X5LXY_$MY%=7&,L]U,(X\^RYY'US7DO\
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M]99&4Y)]R:X_X'>$]:\)Z5K$.LV;6SSS1O&"<[@%(- '8_\ "NO!W_0N:?\
M]^A7BOPYMH+/]HK5[6VB6*"&2\2.-1@*H8@ 5](5XKX0\$^(--^..JZ_=V#1
MZ;/-=-',2,$.QV_G0![57SIJ?_)UL/\ U\P_^DZU]%UXK?>"?$$W[0D?B5+!
MCI*SQL9\C&!"%)_.@#VJBBB@ HHHH *.]% ZT ?/G@7XXC3)7T;Q1YDEO'(R
M17JC<RC/ <=_K7I%QX4^'WCR$7L=O8W)DY\ZV<*WZ?X5\_>$_"NF:SX_U;PQ
MKTSVEQ(9H[:8'&R=7Z8/4$ UMZA\$O'/AZY:719Q<H#\LEK.8W_$<4 >E3?L
M^^#Y)&9)+^,'HHER!^E<_P"(?V?]!M+*2XMO$#66Q<DW>-@^IZUQ4FG_ !B@
M+0>7KQ XRN6'YU)'\+?B7XFF U/[0L9QEKVXX'_ <_TH YGPYXVUKP%KCC3-
M1%U:Q2%'C#%H9E!ZCTSV-?5W@[4M+U[0EU[2XPB:FWGS+W$H 5@?<;<5XKKO
MPR\.?#OP!J=YK=XM[K-U"8;11P$D/0J.IQU)/:NT_9\AGC^&[O*&$<E](T6>
MZX4$CVR#0!ZM7FOBOXAZS!XP;PKX4T9=1U&"$37#2-A4! ./U7\Z]*KS#QA\
M.[G5O%TGB#POX@&F:\(E6>//##& 3CID =1VH V? WBS7]=N[[3]?\/3:;=6
M8!:4?ZM\] /?'-<_JGQ.UW4_$EYH_@C0QJ8L&*W-S(V$W#@@?CD?A3O _C+Q
M,?%]]X*\510MJ4-L9X;F'HPXZX]C^E5?V?7A3PUK-JWRZA'J3FX5OO\ W0!G
M\0WZT =+X'\<:AXDL-435-&FT[4=-)656!\MB > ?7CD55\&?$&]\3?#?5_$
MT]I#%<61G"1(Q*MY<8<9^I-=I/<VL]GJ$<$T3O$CB548$JVWO[UXW\)O^2!>
M)O\ >O/_ $0M %K1_B5\1M>TR+4=-\'P3VDN=DBR'!P<']173^(?&^N^&_A=
M'XCU#2HH=5$JI+:,QVKERHY^F#^-<;\'O#OBN70M$U6#Q((]%69F;3]O50Y#
M#..YR>M=3\>?^267?_7S#_Z%0!N>%_','BCP#)X@M547$$#F>#/W)44DCZ'J
M/8UG^'OB1%=?"X^,M:B2V1&D#1Q'.XARJ@9[DXKSF]CD^%]['J,*M_PC?B33
M1'.BC(@G,7!_,Y^A/I6/=I*W[,>E,H8Q)JI:;']W?(.?Q(H [1OBEX[_ +,'
MB$>#A_89(8'<=_EY^]_]>NC\=_$B[\->#-'UVPT[<^H3+']GNLJR91FY]\BN
MUL;O3_\ A'K6Z26%=/\ LR,KDC8$VC'X8KRS]H9Q-X-T5X9%(?4E*.IR/]6^
M#0!=M_&'Q0>YA6;P5$D3.H=O,/ SR:TO&?Q"U/3/%%OX6\,Z2-1U=XO.D#MA
M42M/P5X?\4Z+<W4GB'Q$-5BEC41(%QY9!Y/05C^./A\VO^*8M;T'7O[+\0PP
M!2N[[Z#(!(ZCTZ8H T/!/BWQ)J^K7FD^(O#DFGW%L@D\]>8V!Z#ZG^E=U7D_
M@WQCXIL/'R^"/%Z0374L!EM[J'^( $\X[$*WITKUB@ HHHH **** /'?BK\(
MY_$-\?$?AQA%JH ::$-M\TCHRGLW\ZX2P^,'CSP<_P#9VO6!NC%QB\C,<G_?
M7?\ *OIVJU[IUEJ47E7UG;W4?]V:,./UH \)A_:5/E_O_#GSX_@N>/Y5E:G^
MT3X@O$:/2])M;5FX#LQE8?AQ7M<GPV\&2R%W\.6&XG)PF/T%:&G>$O#ND$-8
M:)80,.CK NX?B>: /G70?A]XT^)VLQZIXCFNH;$G+7%R,$KZ1I_];%?2^DZ7
M9Z)I5MIEA$(K6VC$<:#L!_7O5RB@ KSKQ/\ "I=8\12Z_I&OWVD:C, )FB8L
MKX&/48^G2O1:* .'\%?#:V\)ZE=:O<ZE<ZIJ]RGEO=7'4+G. ,GT'?M6;X@^
M$<-]X@GUS0=;N]#O+G_CX%N/ED/<X!&,UZ510!QG@SX=6/@ZQOUCO+B\O[\8
MN;N8\MP>V??ZTSPM\/(O#'@74O#":@\Z7QF)G,>TIYB!.F><8S7;44 >/V?P
M1U#3K5+6S\=ZG;P)G;'%&549Y/ >NDU#X<2:I\.AX3O==N)W\X2M?2IN=L/N
M P3^'6N\HH Y[6?"-EKW@S_A&[XEX?LZ1+*%^964 *X]\C^E4?#_ ,/]/TCP
M"?"-[)_:%D_F;V9-I.YMW')P0>A]JZ^B@#Q\_ R3RO[.'B_4_P"Q-V?L6.WI
MUQ^GX5TWBWX96/B7PGI?AZVO)-/M=.D5XF"^8<!2N.2/7.:[JB@#RA/A!K22
M*Q^(.KD*0<$'G_Q^M7Q9\+(O$&O#7].UJ]TG5BH1Y8F+!@!@<9&/Y>U>A44
M<'X.^&4'AK6YM=O]5N=7U>1/+6XN./+4]<#)YKO*** "BBB@!**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g715146g0123151836895.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123151836895.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, $P# 2(  A$! Q$!_\0
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MM:SC9*/P[CW&:ZB@04444 %%%<G\2?$3^&/ U_?0OMNI (+<^COP#^ R?PH
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0^0JS10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g715146g0123151837239.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123151837239.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y $D# 2(  A$! Q$!_\0
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M![GU/?Z_05W XX%+10 4444 %%%% !1110!PWB#X>_;/%EAXHT*[73-6@?\
M?MLRERG=6 [XXS7<<^U+10!P^C>/)&\;:AX4UZVCL;Z-M]BX;Y+J(]"">_M]
M?2NXKBOB+X!A\:Z5&]O+]EUBS.^RNE."K==I(YP?T/-<-X7^,-YX?OO^$;^(
M-M+:WD!V"]V\,.Q8#_T(<&@#VZBJNGZG8ZK:I<V%W#<P.,J\3A@?RJU0 444
M4 %%17%S!:PM-<3)%&HRSNP  KR3QE\;K2WE.C^#XCJNJRGRTEC4M&C'TQ]\
M_3CWH ZOQOX\_P"$<N;'2-*MEU#7K^14@M-V JYY9B.@KH,:]ZV/YM_A7%_#
M7X?W>BRS>)?$LQN_$EZ,NSG=Y"G^$>_KCZ"O2: "N;\7^!M#\;6'V?5K;,J
MB*YCXDB^A]/8\5T=% 'S/JOPD\>>"+M[SPK?SWEOG.;-RDN/]J//S?AFLV+X
MS_$30)!;:D$DD3JE]:%'_3;7U57+^._^1?>@#PX?M'>)=O.E::6]</\ XU1N
M/CKX\U63R+&.UA=^%6VMB[?ADG^59%U_R%&_WJ]_^&/_ "#7^@H \>LOA_\
M$WXAS)+KMU=VUFQ!+W[E!_P&(=_P'UKVSP/\,-!\#1"2UC-UJ###WDP&[Z*/
0X1].?>NTH[4 +1244 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g715146g0123151837570.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123151837570.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" %8# 2(  A$! Q$!_\0
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M*/15[)ZGO^M=+X&^ VE:')%?^()4U.^4AEA _<1GZ'EOQX]J]@5510J@*H&
M .!0 V&&.WA2&&-8XHU"HBC 4#H!13Z* "BBB@ J.:&*XB:*:))(V&&5U!!_
M T44 >/_ !*\-:#;$O!HFFQ.5R6CM44GIZ"O(K73[)K[:UG;E=PX,2X_E110
J!] ^ O#6@II_VA=$TU9P>)!:)N'XXS7?@ # &!110 M%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g715146g0123151838258.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123151838258.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ %$# 2(  A$! Q$!_\0
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6[U;551550%51@ #  IU "4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g715146g0123151838615.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123151838615.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( %P# 2(  A$! Q$!_\0
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MO -UK$</BCP\7A\0:<-P,7#3(.<#_:';U'%'PV^+UCXHBCTO662RUQ/D*O\
M*LY'=?0^U>I5X]\3_@U%XA>37/#@6VU<'?)"#M2<^H/\+?H: /8:*^7/#WQB
M\6^"+HZ1XAM9+V. [&BN<I-'C_:[_C^=>P:!\:O!FMHJR:A_9\YZQW@V8_X%
M]W]: /0Z*J6NIV%]&)+2]MYT/1HY P/Y5:W+_>'YT +136DC499U ]S6%JWC
M?PSH:DZCK=E"1_ 906/T4<F@#?JAJ^LZ=H.G27^IW<=M;1C+.YQ^ ]3[5X_X
MG_:)TRV1X?#EC)>3=!/<#9&/?'4_I7"Z-X>\;?&;5UOM6NI8]+1OFG==L2#N
M(U[G_)- '07^MZQ\<O%*:)I:RV?ABU</<2$<L ?O-[GLOX_3W[2],M-&TNVT
MVPA$5K;1B.-!V _K5'PSX8TOPEHT6F:5 (X4Y=C]Z1N[,>YK9H **** .>\4
M>"/#_C&V\K6+!)7482=/EE3Z-_0Y%>'^)/V=-5MG:7P]J,-[%GB&Y_=R#\?N
MG]*** //+WP%XVT&0M+H6IQ%3_K((V<?]])D53.H^+;<[&O=;C(XVF64?UHH
MH 5;7QAK.(UAUN]R>%VRR?XUTFB_!3QOK#J9--%A$3S)>.$Q_P !Y;]*** /
M7?"7P!T#1GCNM;F;5KI>?+(V0@_3JWXG'M7K4,,5O"D,$:11(-J(BA54>@ Z
*444 24444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g715146g0123151838966.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123151838966.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% %D# 2(  A$! Q$!_\0
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M4'M/-.]H$;S)WSW9CD*?S/TKV#0_A=X-\/JOV30[:65?^6UTOG.??+9Q^ %
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M/?J?TH K?"KX;MX2M)-7UAOM'B*^&Z>1VW&$'DH#W)/+'N?ISZ3110 4444
M(RJZE64,K#!!&017 >(?@QX+\0.\IT\Z?<-DF6Q;R\G_ '<%?THHH \L\4?
M6#1(O/M_$,CQGHDEH"?S#C^5>;R>$]EQY7VW/OY7_P!>BB@#NO"OP23Q$5:3
M7VA3&2JVF3^>_P#I7JF@? GP;HS)+=03ZI,O.;M_DS_N+@?GFBB@#TBWMX+2
:!+>VACAA082.- JJ/0 <"I:** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g715146g0123151839367.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g0123151839367.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, &$# 2(  A$! Q$!_\0
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M.:SNX4FMYD*21N,A@>HKYL\5^$?$?P?\0'Q!X7GF?2)&Z_>"#^Y*.X]#_(T
M?35%>4^"_CGH&OI':ZPRZ5J!P#YA_=.?9NWT->IQ313QK)#(LB,,AE.0: 'T
M444 %%%% !12%@HRQ 'J37GWC'XQ>&?"J20QW U#4%X%O;MG!_VFZ#^= '::
MOK%AH6F3:AJ5REO:PKN9W/Z#U/M7ANG-??&_QZMY<Q20^$]*DW+$W24]@?5C
MW]!7-V</C#XY^(@UU(UMHT#_ #E01#"/0?WG_P \"OI'0-!T_P -:+;Z5ID
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g715146g715146c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g715146c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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5 4 % !0 =Z "@ H * #..^* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g715146g715146part2b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g715146g715146part2b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MP!E_\<+']* /0=$\2:+XCMVGT;4[>]C3&_RGR4STW#J/QH U* "@ H * "@
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MBY\2]7^']SI4>F6EG.MXDC/]I5C@J5QC:P]30!Z1IER][I5G=2!0\T*2,%Z
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MZG)_]""#\: .#^'GCSPK\.OAL+G+7NO7TDCR6R !E*G:BLV/E7&&YR?F; -
M&!KWQZ\8:M^[L7@TF'/_ "[IN<_5FS^@% '.6VL_$/5AY]IJ/B*[5B?FAEG=
M??&#B@"5/&WQ#\,W \_6-8MI&'"7I9@<>BR B@#T#P_^T-<2LEEXKTB"XLY1
MY<LUN,':1@YC.0WN 1W^E &!\$WBB^,(CLI&-H\=PJ'D;DP2N<_0'F@#ZIH
MS/$?F?\ ",:MY.?-^QR[,>NPXH ^</@%K&A:7XLNX]5DBAO+J-8[.64<!LG<
MN[^$GC'3.,=P" ?3MQ;6][;M!<PQSPN,,DBAE8>X- &;X=\,:1X4L'LM'LTM
MH7D,CXY+$GN>IQT'H* /$?VEO^/WPY_USG_FE 'K=_K9\.?"\ZPJ!Y+335=%
M;H7V *#[9(H \0^"O@^/QGXDOO$VNR&[%G,'\N0!A/,V3E\]AUQZD=A@@'TN
M$54"!0$ QC'&* .*M_A3X7M_&LOB@68-PQ#);[5\B-QC]X%Q][(S]3GKS0!R
M?[1W_(C:9_V$5_\ 1;T ==\(O^25:!_UQ;_T-J .UH ^8/!O_)SL_P#V$[__
M -!FH ^GBJGJ : /$?VDE \/:'@ ?Z4__H- '>_"M5_X5?X?)4?\>WI[F@#L
M0H7H * %H Q?%>BV7B3PY=:'?RB.._7RD/&0X^92,]2"N?PH ^-O$_A75O"&
ML2:;JUL8Y%/R2*#Y<H_O(Q'S#G\.AP: /7_AY\0OAAH.G1QR:-)IE]@&6>6(
MW)9L8R'Y8#V  YH ]/MOBWX#N(5>/Q';*IX D5T(_!@#0!J6_C#PCK"&*+7M
M+N0>L9N4)/\ P$F@#GO%'P<\(^*(Y)XK1=.O'0[)[,!5SV)0?*WZ$^M 'FWP
M[\!:WX&^,6G0:I"K0RPS^3<1',<F$/?L?8T ?1=  1D8- 'BWCCX V.JS3:A
MX:N5L;N1B[VTO^H)/]W RGTY'TH \\FT7XI_#%EN8'O5LH^K6\GGVX _O)R
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MO/L=.GE2VB\I%\L"9E R "> !R30!S%_XB^*&N?$3Q%HOA;5HU@TZ8XCDB@
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M,?> +-QU(X' ]2 1^!_ >J^&O'_BG7;V:U>UU::22!8G8NH:4N-P*@#@]B:
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140222415979616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001531177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 22,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sight Sciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">80-0625749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4040 Campbell Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">266-1144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGHT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d715146d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sght-20240122.xsd" xlink:type="simple"/>
    <context id="duration_2024-01-22_to_2024-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001531177</identifier>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-01-22_to_2024-01-22">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-01-22_to_2024-01-22"
      id="Hidden_dei_EntityCentralIndexKey">0001531177</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-01-22_to_2024-01-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-01-22_to_2024-01-22">2024-01-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-01-22_to_2024-01-22">Sight Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-01-22_to_2024-01-22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-01-22_to_2024-01-22">001-40587</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-01-22_to_2024-01-22">80-0625749</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-01-22_to_2024-01-22">4040 Campbell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-01-22_to_2024-01-22">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-01-22_to_2024-01-22">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-01-22_to_2024-01-22">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-01-22_to_2024-01-22">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-01-22_to_2024-01-22">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-01-22_to_2024-01-22">266-1144</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-01-22_to_2024-01-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-01-22_to_2024-01-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-01-22_to_2024-01-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-01-22_to_2024-01-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-01-22_to_2024-01-22">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-01-22_to_2024-01-22">SGHT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-01-22_to_2024-01-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-01-22_to_2024-01-22">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-01-22_to_2024-01-22">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>21
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7QQN.(.WTS6 ^RNE[/N)V_U7'V_&_P)02P,$%     @ [X W6)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ [X W6 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #O@#=83.^C/^\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #O@#=8F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .^
M-UBE !,L>P0  ,@1   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #O@#=8GZ ;\+$"  #B#   #0
M        @ &_#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .^ -UB7BKL<
MP    !,"   +              "  9L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( .^ -U@<.&7J/P$  #P"   /              "  800  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #O@#=8)!Z;HJT   #X 0  &@
M    @ 'P$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #O@#=899!YDAD!  #/ P  $P              @ '5$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"   ?%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d715146d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d715146d8k.htm">d715146d8k.htm</File>
    <File>sght-20240122.xsd</File>
    <File>sght-20240122_lab.xml</File>
    <File>sght-20240122_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>26
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d715146d8k.htm": {
   "nsprefix": "sght",
   "nsuri": "http://www.sightsciences.com/20240122",
   "dts": {
    "inline": {
     "local": [
      "d715146d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "sght-20240122.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sght-20240122_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sght-20240122_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-01-22_to_2024-01-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d715146d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-01-22_to_2024-01-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d715146d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sightsciences.com//20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>27
<FILENAME>0001193125-24-012979-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-012979-xbrl.zip
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MGUZQB^/SLXNKU>N;\T3IA(<QBR-V*3SD.(.PYB:+%&MNK?L;JX<RZK-X*!#
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MH6+I\<!BU^RX=*2=IW6/>1S,Y;=,3PC_6-B5&S+F U'M*<&_8*(38O\.OXZ
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M,2YH=&WLO6MSVU:6+OR=5?P/J,QD2NR"%4F^)+'3J9(E.=:,;T>2)Z??J?D
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M+S^\_Q5_^^G9(*:WILGH(BKJB[2,WJ5E!<_4%TD=74 CQ^DTNZ1F)-%_%CA
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MZ(KV5PPXYF-2SS"6&FNHDM6J,8(RL^&B3IU4YG$(T94Z*A+:#T=#&FV:%H>
MV2A$V>+0?XEA%M0PJ(U#],+C6+K>C3EBKYT;-P<+CNP,%S&N7]P1-,#W8,'J
MSGM>%!_:B[9Y5^B_<B'X+*WX#MBVA4",06[!QJT0B:032VH/RAPQLF,^AV$,
M"QQQ?&HB7JDZ^0AO@(61DQN%7H7N%)!5^*:.=JUHD (P2B<2R1V/"^_ 08%C
M@[M09 4]XS4&AY]D*4B[&20K3'6):^N\3&:\6$%8@V2EM8Y#A2AMWCUH#R89
M"3?RIV?Y?5H'Z+L5Y 8LWO<Y^G?+C-3&@Z2Z:(LSYTN0 #=L;5'OY!Q;V'>
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MIX7BPS_J)QU$#LC(FH@X!],\G62D;1":@#O9[VV%SLL3C"U%U\:LJ-\/'FK
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M:@)B3Q%T8@TR-CNM,C!)*3Z/*( @?[;CGH124DL86UX(K$1/Q663@!)39XJ
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MB&QVH*1 $[ Z\*PE0/D\R4RFFH"HTTQP _PK)SV)*FFC8WR.-//"&,B2)J5
M6UAZX31Q8(2).'ERX2YD-S)^7(FKW0]VC[8#^V:14@G8K,I=:<:ZG(R7YV2I
MPE*<,7C6W^^,'7L_:4XE!YC05=OFLYQFK/J([87YOY,JK7D/L>0RD1\X7!@2
MAJ94KG^2"P'SVX@#QZ4_Q)0(.$W9SZ3O)8?=/":EBW2PB;HH.!Q5LJ3%TZ Q
M0C&G<%#:AO FQIROB/#@:#''IKK7,I"Q2M!GP \(8KXHW4.+,FU_Q(/J"'Y!
M0IF,R3\6.<<^RA1&;=+1/'9P-*>P-+^Q5X<C,H[^#Z-GDJA<FZN2I*Q3/\$P
M)/,<@M*% M+0 L";CA$R?TGNKW=E@<X',K8;$1ZP"*I"-)SV(MZ@-&OR/;;<
M"NNA!SAPPLW;@;V)UN@=?C,85$X'\L;]V$;L5 VU<*.2Z>3X=+\SQG0$>E^Q
M3%']J=42.L[)UO$D1(YNY5%(MZ)<&I9%9%X6L\7TG+VV>-#2.;V-]O.F%A%%
M1: Y:ZTD.6(\4[,:2II!AIQDWB&M9A-*6%P,'#F7<U$/+)#%YOPC1V;7<G5>
M_'E*CE07I U/3Y$$.=97Z([#V6(1]!+V2<KKLTJ^\-2$DK23%#JJN/S!0O,J
MYLD2,P!B_0<F/0G!D&X)73Y7:%U[$%W=[TGDE=+L"@^-E>OJ)_+Y9S?.X-)O
M5@ZW'G#LBT,U&95P]!#^PXX"30TZ9LD>(^ ;/U#!P*9C$UN!_^0/:+ #4TZ'
M8K0<$8..Y>YSYK"Q&:^W4?Z9EL6#83+%V53C! ZGX4)B!MZD#ACW6I\"21_,
MGGT'A\?=E!1\4)'W+^/=+E,;S+2F)839<"0W*1].9P+,87[:\V1<UT!*E*K+
M166ZEU8P9U>!!T'+@(P7(U+__5"DS14L"\KM=F\T\(+=FC2?T.53Y$CLN#+_
M2XHX\+*2W.%^+T^QN :VB=)(1Z@V$+U2*Y9J7/H9,4+FJ6$95OSPI8O6B212
M1XP)._DD,1O^95&VT>.E/>:=,E89O8P]IU -GS$2-^EBO+<BK S1[S5($/8>
M"2O&U^MO?OS-WWPG*_3%8;?Z0XC'%YK%=%@NSJ-]4YB'X[-!,1U6:NIBDQI-
M>Q]U('"LT\2CO+$O'6Z734H/I%5IM1\4*3QRIDLACF$&&13!E&W#=70PS>@:
M5\S-D,,;ZCAQ2>")#&<I,Q0E[2PT]O/E%9. VMH,L61M,-YRC)%HQV0PH8)$
MA"N:TZD16V]\3)H*G4_RIC"FJNC 4JSFF,QJ 9\@5QB-([EYS#&-S+'#90MD
MPVZ#L+/<C<UZ'[M;U#G^33J V2(G8 '\HD1:?AC.W7MC\V\D;$#O/]4>(=3/
M;)8).3 QG" J&"3U(B;<!\[UN4)PT%@O%_R6C%&FR/E;$PT$G)8N$*%XABU;
M#R"-0/H-5)"QUY<CM; 84(?_F)8C!@2E2CL6>WY,_,,[=<34*YC=LU'$;$+.
M$&'QPT;"BA-" 39U^CT_(-H@Z:VM9^!1I"!Q1QD97,R3T=! 38Y:( #BKI\(
MFZNIS+X=&UV"#.PH6BD5+;?WQ!"_HPI*1V[%H:8DDO=L=CM)&SJ.(@>/;EJ_
ME/5/NO/8('\X',=P4?08<T;V2.EZDQ$M/V=NTWA@P<$A&"*I+5#4DO9T&A""
M*9FE]$P'95O:Q;/L:),M9C/@6=[DV%MS8$T:\W1*@'N]D[D3>%F-A=I5C-^Q
M9OW-%PA!K%)&R.$Z]!4Z'/%-A62$#GL*TF"<.NB[>X%PRQ:>O"EH2S!QUR/A
M*%5 0C$V(:^FX$:TN[=#R:'5((209S-C5CLOQCKD)OJ#L7A5@8Q!Q-K@()P@
MQ*63W@G00%JF!+$=<7P$SE(B6L=78467(;1B4::-,5%17UE[GX@DV)')6-_"
M[A9O=L-]G?F!)IQMK*LR-;.#51[ H&>EURB,#'Y$VUU2Q:GGQK%)QKA8J!C'
MP8Q'S:F1/9XB 3>\B%@RR?@W7#>:URLND*BZ2--.&D3BWXN;2S(9_['@BEX5
MU99!YU)UD7 2M$?'T8@W%S6O>74 D;"1>7!Y V8R&;GIX_'V$@]Q3HDE/M-F
M07XN]SGZ0#)-7=8'SIVZ)58#=&'!+&SST44-6IZK+8K&8W:9!K_;-65'(4CY
MK"EA6#YV@]I 86Z-"Z2;AM.BDDW&A!12],UC*0T$5 >>PHJ:2]/.GL%WI(9"
MD8@D!174WC?B[;DP6Z(37[K1W(]C+#(!F_E%,A) !*S8\W8BQ1E5%WTIPJTC
M6OM0ZH+&WLT&2U=I-K4J9'LS0;?7E@M^M+V[]<? IV-LQ,[MC%YUJDIS']P*
MDYB,X*,%QLB=T%IL)34%P7\?4//Y8K3Q9HB\ )MA,8LU#.[SN#/?= * F%0)
M*L3KP.!-IS@O>J*+8/*$3(1\JD4,K''L& ?-8T5IA@-=9BE#M< R,+2$<:"\
MT]]>3(0=,JACV6T2[+2?41)H#UH)4!-K:,C9!\A,\&*P"'.)'0[?Z:_7N_?D
MFW?OCN2$J2"G93T[V;B,':7GB8=5/^OWSE!WA79^J)Y%[Y#1&WY53#O\BU7;
M"NL)B+Z =)0Y[5#L7_4ANBKHX>979%_(*8EF.A?Y0@0-^56"'1ZS/I:G5\@X
M(E8]I_4T7XRI"5AJN6TKVZ FF.T%X0<"WLDV-[5L/-)[4XD!5E2SKY5"G>43
MU+$D<V<2=4Z""Q%W-9/ZA>W8[$G<U>QV 9Y.]_%-'X[&JO=V<&#U>\,4S)8T
M;],,2E'=OY31^LM[&?R@2$_45:.G->;. 2#8+_(8M2+W!""O3)6%O%"P-HZ$
M KC[/?W15&MVD'*.91O\K635J:475 BFTW+.='!B\=W>A2$IOX0^08P6]"U+
M+[F@!#%DX/.OLRD,&5J\Q\>;W39:1WE]2;TF91CI$\8]V0'+<0":-9!60ZBW
M#J S$$>DL..UJM!2P+9(2!FZ=(D&8FB3D89<N8)#,ZIDT:A^9VH!QQN=E9/3
M6Q![G++W9I,-_L\B([//2<KVGG=\^\8=*GD;A$5%H!S#"8(B5I5WB^(IYA'6
MUUD^/V[O/N2JF FM-K!'11RP=QS^:+5Z30G.]0GO+S:=\-[*US-&52NK+Q:=
MR/_M]"7]R6_&[K-QJK=-G))?FLV\06,32:\ZAP%KTR'')GI@F,F.<"L@M(@N
M.HXNEG/L\LAE5*B!%]EZJ7$;:!NCOWJTF TQ6$<QETLR,AE].R*7@+J6P(8S
MQ".*]X0NH6FI65#.<81&L*W 316B0CX18R"K2U<).>3\Q>!2,C536E.%*%C&
MK/+:=&[%<;!W4J%J[ XCDA'MO)_L3<XUR/Q.02DE=R7S6%,,[@O G,!RCGRG
MNX:DJ1C)>=@%AAE1VR#W,YR]M)ZDL-K^P4L-?:I;@'X6Z)8PHQKQ'#-I>$L"
MQF1>O3\XB%XP(SDLPE-7PT1"P!H&\FW GW]G*E+^\CO:4\U>W%3/]NM0J*=U
MK+SL[H!@K8A"22RDWS-%HAK)4BC3,1Q^.P5=U?)VG4Y5W3>\-?H]0F2N)-M7
M!YD[7S?8WM=P^*2P4EEIDU7<R=@2LL%'#3)X['63Z\!ILN390@ZK<U<Q>9R@
M[$4Y#+-[E>)9AFJ"W.2B94T#6^I"D]J+C7(5@)R:H^8,>O2W'FL#X)SE6NU+
MA%B#N3%V-/V='8(]5DNM#4/5+/6<>/#DG?T>O#3@KL A@[L"WG:,J' H:6V/
MV$$B 9TW^Z>'^_\'^;!C7^J):2&FPC^F$/G@)1F%A)1L1FD[8I<=%/X^$("F
M"Q;J6$GMY4$T QLO8[8>Y&USVC^A? M4];F4(&&.&>-"L4'+W'G#[BOE_XK7
MR,!X2L"T,6M,"T]5];[D(&)V]#6C&, N"5<$GR$\M8NO11,%P]$7/'\0_UW!
M$-?Z![1EZ/86)M:@5N2R>EH.95N'3PB,&][D43(=29*!,/U^O7[@'[_Y@>_H
M+( 6HJL!U+@4(Y!'%%7H0*3,],Y$[I10!.:+/041D1D1T<6I'ZO.3+5:? F7
MCG(LNM%=ID.6*H]_FI4:#J4:N+:@2+.>"+,=9[9AZA,)P$$%[@ZN:$51[)7:
M35=,L!::HRIHM*%[5-XI_^5]93+36".T(.4<,IO'X8R]").,QAV9?*L:JAVW
M/3?Y=$49!:XX)C86X1G>5VM)/FDZ)T7B_9L$\_I%N]+53(:5FMP!79;2K#"<
M -66((JG\VG29;5^!?.*8E30T26E'^=<AI&B^!5Z1G&11"NV56R(PI4BC5>'
MYN)L5"UD>J4SS)Z@5;Q/REV;F.A%-H'E\#J;3O4 ?E/\ '+0!-D?4XR=XNP;
M[-*U\(PW1?[@,*LDB57A&1W+2KO.16P9I'E]GM(UK_\!C,4)*@3H 0NC'\.E
MN--]F$,=W2[*$81(WA27IACX+A4#WWNX2=,;B]NN=JT>.F0OMOZLI,J@R^@M
M(6SQ)T7L[_-)(7;UICL$PJ]J^Q%:I>I0+KL:PH<^!_*-0)_Y. O+7U?T;FA^
M1C7%4E\A.'#%7E?G^,F3Z 6:PR?I^7;TZ.>='W^.MK!4_':T]U@JQ&N2FK?Z
MIU*91TLLU[ZX260J?FE#31M;1!Q\"I94T(2#M3[3%2YJR>-K"3P:_=SH@;.J
M.&5K>=^.U3T2=GC!7ZGIG#6X<2HPLZ-V.=$EDGB8R$SKL>M+AZ[.Y?9'YI:%
MQ>FO VGR:,VW@YH-65T%$:OKWX^6?;_7#,?[XH^N[B;ZB"1'LQ1'48 :J(L-
MGD!!^>M.:>@J10?E4XS U\727=[E,!T9N?^$Q7[$1.N:V3Q<!@=(P$:B.NA*
M#A)V88_% _(2E%)X!L1<= K:%2C>1;2[N[WWX_;>P\UG58:QEDZE\$:$BEW;
MV,%6O(<GT>!.5E%RI>>6HL0)N6AP+(0U3'.FEG),([XI7QW!H@!^.H%#BOJ>
M\S (V:%8-2#.<'R+7#-N<)^ZA/U5J6DF,"U.&J%+9%^ZS<BR!4L);5<KA9'6
M. CP1<10=3<-7L'MN*$) TM7'/G7L)&[.*ZEI*-4*"\-NM^F/'DK$#S]'I,S
M!/)IG6R"HY,J'YO[OEY'UD_?'%EWMK [$#^=1ZX@EJ1(8R<BZNDZ;?/)BI[(
M3S@,3Q]]'_;LT6U[MI4-6I[S^6(((@OV1@Z29.1PA F>5<5T86##&@YYG8YA
M3Y9ID*-]F;(YE; 6L?5Z_Z#BXKO]'GVBND@=:)'=?/C,*V*P."@D8'-HW?#P
MEE<'A_ 67^W]=38JBP?'^66")"G1;]-D 4(%LZS+\Q1,O:W7Q[^=#A@1/::D
M'A"F;Z%)&%<@+:8HG5E+/RABGSTM=+_KWTB;A6F>HTRK>(P+HBXITUF!69DI
M:KQ<. 651?'23)=$L\V<=NTWP@C/Z,=IH[%*A=]2U=Z^?G-,_:2'3I<5$HUA
M"= J'7LZ;&ZAB+O1!SCS*9++)Q<I!>IO:!3,<^1R#(W+5N(D&8"WYK3YDU9R
M-F!BJ2)7K7W+-YA#P&3_>^3G0+%\O,9SANB+BOJ?B^F21^+A+BF\C_%=SGX:
MF:K7.+$$W8I=.(0CVEV94E10XG_^]K>__2]BD C(IFDAW-"IBT%USC .]NGQ
MVS?^PG$SQT:-M7.BVI'<*QYMVLE:SN^GG>\;";[7-Y_+7,*VIE1TM"%@"3V@
M&I5<[M(E3\R*JGZ (=$<:S-0C!W?#_](2BYJ2;<*G:%ST%<.G<#(3UJ#_AAW
M9W='^QJ\([N;UH&ZP*$K@_<^C\HLR550VM9:S5-9JSN\5I_>@PTY6(60O4<2
MXUK\@=WGT2VV>;A/;D+<6V4?>1^I"_>^;:=/E5S0:Q)=\35RZRQ-R@,\%/GV
M#3I4/*&301!W6OH68>Q3_3#(N!C1R= QKN%6-ESGU=,U7?[3-BWI>BZ?V^>(
M<OX:]DN*F_/:CZ98E]FD@&,2LH7<:HTZK73;8I@C@[O!*?=L\R,!0Z$>1S/+
M1)@&RW;$=>LH$$S0"J1N,6L!)IFM=DWO+GSI"X;S").X4[B4RI[BRM/E RZ>
M$9)-)(UAHY\:M%W.OR-5=M'&7C+O.VEXU"/S#,R+WD/+\V8P;*'T(IBP#W];
M_ZQC%)ZEY;G/?AHK.8;IR19=X[BO_Y5A4B1:%N5E=DDY)$23,K@/RR,;P.Z^
MR0*AV*NY@0K;*#+AVO >-IE<C>C/TZ.!J1/Y)6Z<;6F5YD))HCR]PD7E>+I7
MK;(M9W-P;9SF<J'/$4_.7!-=;[5B!@V^Z78=9($*^'QX+X[ITK-[H#I<#G#C
M*O*K,?U)KBDO2C$@(7\$CK/7J2GOHAE2+M()C<18<#5(TX51\<5X$Y"P1+>S
MBO(\#BJ@C5>WDE:0I0)!" [NUC+6M$Q:O++06B(,I@_Y?C2WL=-/R0@YOD(V
MALC_;NRP^8:27Z5:2<2GRNE'NSZH42./3.GH/FIU6:7LE+?8A"Z^WMICJS(M
M_;$IT;G;?PR.%@?T]B//3A ?>5&Z_<928&"@X==7R$T7P?ZSK];E^?,WE^>=
M2KS+05.Q(&$56!(:YD-G&-4'(.D]R28U&!V@)NP^=HF?I2'Z1>+0I0"K'^DM
M@J@V\4(UT)H';FPIY)N'<9!7C1N1Y2C^ZP\&57E3*<N=C$6[;ZX</0B]5JB5
MSURPE9F%R=@T"410OW<!.ZPHR=;I-,@H#<D]BH/(ZDUL2MB4+?VZR=[CX0R#
MAC>G.]75(,N:6:\Z@1S9!:.27;G0R9$GMG8V#/HNH5?U=?2ONVM:S&:RGQ>V
M>?$(; MM7U9*N??+JF8X_,29R!&;R(&OCW')]T!MN 25 >M61=D,G;VP$*:H
MYJ)\$;8-QPYN.]Z=)QW=+DV:"Z-O6FV^5#=MM9CIM!&S<YO0C(8!X;P%$E.#
M^AIN>ER1"P/(YY6#KZ34 7QI8)+QF3_6Y#OB-J)(+X\88VBINF;[DJU5&(;M
M?8C6$COZXI'=U-"H42UFG%M$!>9=+1!6M6*WV9F%S%KC[8H&Q+=$B1!*D>-J
M%0?J%!HFG$L0FTJ8J$D0_Y<HV\X>/0,#5N&7'G.YZS&7/N\ ^CUMV#@EO+58
MS"FA5!P YGH5HJ9?\!'1];G'C<]YWGCS,I^:T.\1+_>*^C,;=B:MHP.\'P[;
M8)%:_+KF[_G4;3Q<DLO"59;T56\DV!1PI86S$2(6.+5-\6[WP;1O# 1!;DR>
M4(!<<DZ_,6-PV2Q!DQC3RQ>P+W:)X_H>'#]9JV<P=[!'0011U:DU?&:/=1/:
MM*F$TY0ID;*2# &VBS)R,E>C,AO2>/1[G\:G3_9^+/O$A31)  3]&!<IJYVF
MDN^HJ%S]7BQ8,V=/<U5,:BH =TU&/&MLZK=J??(^3.=E8S91RS(DGP4QS(E"
M< /JSJVUW)VHO^_M&.T\H/!L3\EMOLP5%[KKK4N9!U=')%B ?,[BQ&-Z"\_]
MVSSM.DC\.6*6[3V8Q=8D4JXB%GY"A07,@05Z49) DU".%])2JG#OA9OG/G00
MA,[I8LCSWSP&[T7[H($A!>TUM4$\U:PN59=@:D5BL%+1!//3="!53?H]R4B%
M5P]3T,DFW>&1P,D?%#X)U_Y-Q?C]&'8,-I$$7N0Z-@T1\MD=M1/2[YD9N0=J
MQL?&SK^E&&MF=:U:>]#M*_;/&*8D/DNY9H.2C(#)!"=@350G M4W)$Y9#O9T
M(F5XFXF3@0%4Z-EIGIF#*9XM9@BS+*)I07R;#5.IXPCA,4&?QL>1J3?IG\&_
M%CD9;'+<F^@"$K@9%A9D,X.V$5VO51!BK1BF;=6(.X&\EM$R34QY^LY6NH^P
MIZ7CCC#;'%HB)@L;N?Y#7Z\#=G?GFP?V3N5%4UQ(#$.8!KJYE)M:&,B"Z]2P
M-L<ZV7[S>0K:L7"DSPVNQS.PA]0!]@QM2[8UHGOWM@)N[6%V-\;]UD<,_N'2
MT5RFIED5L.W9P_S*E=WPUB]?:Q#@=3^D1O,- $5("\Z,2ARRXG>M.53_?4]/
MES#Q"K]Z(Q+R]M<L?*'9\T][)739O=,#R39YD']$1<:2Q);I1,F6-$-$*&-%
MN<.:P-5J]V#<0._2QI7:2IA*/M.ZD7PZCM"C+\Y$1Q3@.$:Q;,.,2O!Z)#('
M7T#?A1Y75&60GD&6A8!,*(A2>SXE"BYP98]8@PM_F"PF6QFN:&WBU0?^AO&:
M+?/JOOKHM'TW\DQ1@=25KJGG]\8U-4"1B6_]D#*L<$P9B*$M)L826@R&#@\6
MM)2R27TX_+IL*5?&B9G3@A+TN%58/S/N$-(#7>*#1B.MTUN?%OSY%/EB";64
M1!)&L^CK:\7?_H,]5\OA!M+RG;^=6BGXLE,\)9-RS*+\/Y+9_%F_]ZXH#-&V
M2_K%[[PNBK'+,>"UAHXD(24U9Q32&F&%*LQ82$ C\(.6%R:ZNWKH4&X%XT8H
MH+L;N[6'Y<U'+_J<P=,CU>2[58PZII("OI9;Y*IT,&Y. &-F# (3N&TIB@5,
MJE2_=]NYR;R/B68GRTTY&R[/PEO5%_ EE4'+OUHA19R-'3C8)O+=?),MHC"[
MSR=D< +RKH,549"[C6FF,W-%OO&6KY<=LG"[<[/-%6@L5PYQ2/F_JE%M6LS)
M1F?N@\\E8U>7QEJY%#KQ@ME8#Z]_K>8<T_":FM)8\D:3PQE6"L.PF-:)5/MU
M[]'(CZ@7E&=ON!=,E2,#;Q+"[4)3VG%#B ?!QH5-&:6F@[A3M3U%,*/;+<PM
MTV%[_/C8VQY48! .3F@$[I&F4@8;J16)QYPI#<''Q*E@ZQ*50N]#A[;$^L\%
MULHT5[)2S0S= S?59:ARN+J?'8Y1IT11Q8:\FJ3E/>A!HP.&Y1Q53ZM@#+2^
MRDH^4E]UACFS;.D6XJX?+6!#S;2B&O*(9HJH03+JM*ZG+K<'15;^_Q9-C[,Z
ML80K-:OF% + -L31JO=+M'5UL*4I;=7JOP=BZ;*AU8:>#>;'Y8DAP2$Y\W/8
M)NCX*XME,G7L;9($SVYY:Y0AS-V-';G>_>A=712D)Z/,V)]@E57&3EX?NFJ;
M:AD1B2/<2M8.=H\L"4;(.^ %BD+R2-JNM[W_(HE6YP%\Q2[#W6\NP[L/;:W>
M65AB09T(E\7T4N%+>5HS\R=ZR@5P'J3T"-DR*+YY"F>HQUXQE(O+3S'EH%<:
MI*XM"2ZG0 0P2G*Z.S#ZQ%5\<"J*$CA87B?]@MSE<633)#<$4RWVG\IRX:RB
MP>GW' _./3C'LK73^33:VO>TQ$B>DRAK.E5)T'&"$2^$*8870+>4(W7-BSG2
M[I_+^_FY[NF-H=<Y;,3;3'1G;4RG1]YJME?,;_/TZ^(Y<HM$RR$38S\8=,\^
M-?C8\F!C:,G-D@QID]?M4[S<?V;$TB\_Z!YG%9&%, X26IH'(Z&2F[E$:5 M
MN5V^ UGRYS4R)["VG#%H6O-@?.V/RG(G>XQV8M(E#.P94RY3(G,>+MF4V_SF
MAJ'%BBEUA#:%5)_%/!\$Q)PC'<>4X=>KMNLZ%:\A]O'I&_G>J78P\FJH9\0E
MHC&-W^@B+Z;%N7 1CI&PJYBK<NLO>XY7C3GK92F4/D>N=;]@D%1 -@&=)Z'R
MSB4* DBNLM]ZV]*L,2'G^.2H>ML2O <[\6/'04!0(1S=SNSE^Z#G4Z#$>%&Z
M3&@RCIT;@(6@"Q58W-,*^[EQ9]SOV7$2OUH#7!.JURY-:L(P'?8O'%$=[3!5
M<HWGP9X4';ZY8+V1M+]*IYC_LKOG?6R8L"*9"Z$L=;'%YK X88<<,/T>UPE<
ME@6E 5>UM9"05!B+)]X$GA>0BF24CR"YH?0]@H W6H)IOURJ11*!3 6]3$!5
M849),VOD43LQXKK)?L9VW<9%^7H]C3-A\G'AT&9@XZ;G!>C6*+I,I7%2%]0S
M3.XCUA.",M*-.BC73^<]..L^R:<4-5Q*FQ5EE^MFV-0$]AC!=O$E]9P79=O)
MH0X=YYDG!DDR22S&]R;;MQ7Q9^&$;U=5M7WLK<!YWXNA7[N[5J,R.D(0Q/<?
MY*;-W7*#LT)!ZQ\]9IU94PFT[K+YFZAU^U6.']\3H +Y Y*Q*R-F1]$RF778
M.?W>;0R=>Y%N0\D#]S.&SQ0'-H6F6:_A*_;J[7WSZMTY5H(7T&?"/_J]W0./
M_]@TFXKTB="WR4<*/*9:Q:6J'/DVJZ_LH,$?,=>3*C+2U6EZ2<X'"=^C,%NF
M=1!I*1$7S#G-,.65J!U8"!MV(QX*:"280DOBSD0PEU?$8Y:73J=5LGK09<98
MIZQ&AT.5EI>I*2MNT%7>#U5\Z#R9D$/L'ARVJ*GQO+!S#H=MFF0S=NZE<-.8
M=!S%EL&,P(R5=591Q8)9BF6LLA$6+TC*,B/_(&9?X5F2TLU3>,6T* ,,Z33[
MD&H.Z^?$MCCL-N,,8AQ6T&HB7Z::P=>,8&]-+7DLDJ6'0*!N476LJ'LP2VZ2
M JWQC\7X7.H#C=-1R5Y:*G- 5B\5P'6.O%%6CA8SI@BH1':(-N#SD,@0;ECL
M_1X.#L7Z-R]'+B6[W-.KB?G$ 4"CYRDHY1KE^:E[ <,9^KVKHOP0E)E#.UI(
M(Q8Y^Z>E]K D%&#. U,_:&',-EJ:RRPP6(5S87@!&J UMBI#]'4M+ V%KS"$
M-#N>+TD3&#! NE03<\A[9!P1>F<0?@L'?)93PD?PR5(IT+6=C/9V&1)_4O.0
M,V-!)!4V3F[?&2Y_1IX<G1R?[N.+TOPR*PL]+>C6 8?/"=]>E UXN_TV,OBM
M'9LH&)K[L 7<40I2SB6^4G];J:^937W53"!"K7AWHHNQ,.Q+1MJM8*?*-@UW
MC=Y1Z6%S?@0VF3>W6#5Q+,29#9K?T,;:O!PV>HS-O&@.S7U.A\0@#TT9EH9P
M'!,TPS*3M'.&\@=7QARQ+]'NR&8R26>6]8#=&C?,3\%O<;2ZQIH I2@%5 Q<
M"7KTBQZQX[@SV//&C2WNP6'UT2^5?L\9@@Q2T;P!XIN-$BX%S2 7D7&)U$NL
MN4 J5A+W M,(5GY?-%[4CJ\<18"&UH3MA#R*XG!U.%#X!V+\B99RO+@7OA\K
MVVQVH2 .G)"QVAN2YVDR?SLC\:9#@O5XVV,2;86N>5^[D!4-GW?82#)T3=9%
M'63WS U['$-_[P-\E.,W[BPFN#;7ML75IZ4D)]<'%Z%##XK)1,.*;75(WH7Y
M)@4,O*I@BC!QV=0. >JV#P+T\ CG2# _6%"L1DXTK=HR+(L/3+T_R4JV9X)7
M(F8U=54_"V;J%Y-4F^F"*#04;(7>CWG"C*2DTBKO:(A"Y\?8]G\6.=,.,_L?
M@>.@M==-V;4W\)3!M#ZX2I8RLW:"W9C!N3@;EFQGP-(I4Z-Z.&,-;'!<4[C\
MK[7^G(0/4XM=Z-?D/<'KDXRUS\MDNJ#SQN6<N-JIK)PR:9&V["OVQSW\YH^[
M^W 6)B^YDXGBQNXLLC:+UW?91G$J;[]'FGN@\[8C#:OHQ&R UEF93FQV:*#A
MKF-=+I:L>%<AO)''2M^X&=S^#*M"= 2^'S996/H]'U7:;&ADX-58?QZ9JKW>
MZEVPV.FF#?(3W'"+;#YF9@(_XM+S\M*!THP"(^)35$K"RN,0A)9Z[%&!YE%V
M+M'AC>HX9CK%3M,)L:2>9S@V64ZU*26H9&&3%FNRP!(/;/%MMS!;";/R6KL=
ME7:$''S#98M'ZB] ,R)!/^_MBQO>#N<F[-##O$3S%;N9M716-4+).%3]WB>A
M(LT1WW(BP"E?AR[X^S"@6</A2G-.ZBG&HL_)U>3DA1;&P!!#Q9C'5%CP5^*1
M.A;[C: =]Z*PRL?LXTV\(,X;6Y'S5)+D.:_&)=#KK@W..\.D)"N4;ZJ7<[33
M#/&</V"K+F[Z+3YQX>&R6)P3D[W,KS^(DR%H_JWP $[2JL;/IXG432,B/,^5
M+I5P%0&M9P:KQ+:*J@OLT0L(I7"Q4J(AQ,T,#@>WV/ID%G5H&J<YZKBF8TJ
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M(_^#^-.ZCKX*S!MG7FQ6JICN7(+)JMZ4=Y2?T#DRDKI P&?)$>^@/R:<"[M
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M!M,6'K KP^"8_ZSG'BUQ$_86!:;M+W.A2)5MY(:3W>,%)8U_VR0.81 =%G&
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M\9O-JE!JIK076\Q"S'A#0,TD?,4-?"C-\"?(7+&5W":M'&[02Y<DM]_K3 Y
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MG$1'PE3%>F$\I8(A)-@ S]'?I[2HM>VQ>R1FC$KG6)C9_];7(*?3G9@I9F.
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M>(D*2F#HH6'IMZNX!F:SG&!SEO.NN!W<!*H "T:4^[28+6IIX,9S9EC64*.
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M:*/F(V%.N&X[8[$ F^+DRG"\,UY]6HCV,$LOQ)]A]C@:MS:=K.1FI<.*JE,
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M8+JUH;@)M1Q4D;5_:=*R]*YCG8!B4;9)G#'N]VZ;^W\/-Z4)%7X:TT\L2<X
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M@D4%H!X*,W<INL79Z ))GL$0K_+*7$O$X]E($NO"*NIZ 3=&A(GE=6$>%7Z
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MG;$+'B7EC3@(838Y!3;;W$UXT %J%X;^.0(A(QY[*[D&8KY4]@FC*^S.JN$
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M(<!8CC( 80'T9B+ 0.(1B+05=+/IMQ\H9!"D<J>,%+:J$KXJFHR+RJI]\*<
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MH'-T2:'/X(I+S00UN,3V3W$D_<>@>T,A14@>M&WX3CL&781&4>^- D??=BT
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M'PYE6K!+NJ-IGU/4?Z"9NB S)>S$5A#4D/KK]O=2211^8=MJW!G<U3K1I15
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MGX0:7B@F1H"^U-Y54 2P XQB(#A-FYW5LY6$;,L@WFC)4P %,1VT]JKVK23
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M&:2D#J"*2Q":[_T$>U S!<O_<[*/Q/SX2*QL2BG -U "?3O\%4/V):[8MWG
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MN!_O/+LCPYWLZ43^9XU5'EYF8,7=#-+<M?_T_2?OJUKX%X^?/7KQ\MFCYT\
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MIC%VIU?W&$DZ0*-4G "N.-((UL."1%FPW9^S)MCYC] _HNFG;CFD",%+31?
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M-:^U.G&?<B'U>04ZOO##4SG$]TL08K$$U$W>5AJ6@P#V-NH_DL[G$&2MW+]
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M-3.-R$E%=BFUD$]Y#-15XCNIJW<8%TK&A>OJX\(2I^I(]X8VK!QA0MU.;&B
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M9JS$='ZKXZ)BV?1NTXL0:@(Q\;*%+AM,I\(@$&:I5'6O9D'\P,+<B"LOP3^
M&]1H-IV^#$,(J3>=RBP )7DX#&5?83'N) BODAK$9-]_^Y .(D-+;QA0]@\M
M^L-"-'0GNT$2IX-T!>"*RM<I-JP8C'Q_L);AS/H1S<4[Q3:MVGEPXT,@ZOYU
M@F0-N4@<6BU5@C0K+4%@4QK6NWDL29ID#JF)-O< B67BR/;6_4!"?;=G>+=H
MH@"<\%$^+P["V\MY/,5\!I4 ,]%3(*-Y!3<U[^E"]G2KFGM:2QYB_7IP,X?R
M^W>4-61XJ&&7@H8A(/*-Z\C8R5"8_B2#MK> _(H\SC%X!FR]*4WY*W6'A2B2
M*986_ZCC1.B'#>*9CAEE<W.R^6$DFI9(I<54G&B)&$-IM:/O"IXM/P1-;7LK
MXQE'S]A34AUSG/>P4B#\A<3%O*F?$V01TYYY6FJXTT(")N5#B;=V$R $B"]
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M7*KTBP'E$J7ZTR7Y@XZ/K"3WI^I-/%J(&X)/+]T*,M>2(M<\RK 8H I(WKU
M11/@508PIBM:[@GL05,,*AW1I^@AV%,6%;;HY&[YB&4)1*EHI>&^T0-0A$%:
M+DM)&\UCL6?]:[&!I_1TY9>:!UI]N<^?TH83\I+BDRV.3[X"S:%33<WA\+N8
MK)0B*GX@(P93<5@A-C!5N=R4T'XUDX"0>%H6W414([3,BVSF'RU*Q6QY3=9
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MIIH6)EU#X4]Q>'V#K<7($D7[S[S6-EH-8#[0XIE#8_@@,?T-HUS3<&JR3#E
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MPA15)?''/HF:E)P$G1ILB2A)W*-GZH6T%ZPBU9,RIXY 2VVJA)=: "V.)(P
M1@?Z/KZ/[("269OM3U1_Z)"2I)+\[5 ;/V86O@T3OW^%[?O7UB0QAR?_ <>/
M]H5,VH0T.G%,@E3+$Y7F9A99)M%.8%/&D:N*GLN["B3K7NY8O_M(J[P$B'[
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MXM/U24J6$K<^^OJ+=7YV\'_^[;KKMMU6Y]IQO:;XJ=?L]/KMO3\FUY!F)2
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MUW!>@[+Q^ $O.$5*7J EC/OF%)^U5B4>U/<?H6UK$%Z/K<_A"/Q[GP)_*'X
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MV^L7?>-FPX-F,JY;'S0AXY>ND259PA VZZ88:!AH*@$T7J/3;]M.NW"@$1I
M%XYMX=I%S_9Z7;O5*]QH=9V&VZF9.9RN^V2089"I(,BL8$*YK5VW[;6[[;J9
M4!W7;;INKP2EIP505/AXV81BT'D5H.,V&X[7MMWBI;GDF"O>(.G;S:YCMUIE
M&'WHD"G<Z&/%I@)?88S9(,:T6FV[5_S!:E$'W>+!JR\LIX[=[!0.7J[;Z#'&
M5 \=&&-JCC'MAMOS;+?3+EXK<%NEG%C7L9MNR^ZV"D>OCHPL%>YD9I"IP%<8
M9 R0.3O\LG]Q* '&0)URPDW=EM/L>GN%8XS7:)9B*GGMINLV"W>["'1I.J5@
MXII+S2RN,F.$J1#"K.("]G8A'P4"R*6X@,N"HG:OW6EW"M=(H)4!&E2%8_+:
M7,#O.3F3DS-?_$7O.3ES8WHK^/@=NUM\-E-9PJ)GM[V^W?&*]^O)H$3AL0.V
MC"OP%=9;-X<P'GKXBP_V42)F&1#3:O;M?K=PB&E+?R%#3+7 @2&FWA#3:@C;
MU^YW"C]7PGSLE7)@>W:OV[%[_3+\;ZV:58YPKC?CS(/-&0AB/AU^.?K;X=G?
MK?._GU\<?BT=6<"GU@3/?N''2=@:K5+2$\H;LM? R&'AD%4>LNS/@5][%#*$
M,(1L#$)ZW9[7+3Y9J"C\>/:$"U\QW>FOV-L>^&-_R$C 2+ ,"<JI#NMUW7[/
MVRN\B*L\!:+7:GG%E[1#VE$;^D(5?F=.#*C"5QA(UJ92N,U&IP79@<5[#\H"
ME;[M]-MVJ_@;]VC -0KQLT>5,:6"F-)QVVVGV]\KOHR]+$QI.BUA6I7@\^W+
M_JBLIE0)#!A2ZF#O,(R4#"/E*28?@]%U.&>:648,1@Q&C%7NS#T$&348-1@U
M'G=G[A/(B,&(P8CQ"#TCW:/K/5=%5;DJJLE5445<]/Y55D6Q1&")L,*=N=,:
MJY ,& P8CXRZ<S<UQ@[&#L:.Q]WY* [8Q<V(P8C!B+$J8J1[+#)>,%XP7C!>
M++WS<3"[H3CZE%&#48-1@U%C%=2(XA\^JQD,& P8#!BKW/G\1R V&0,& \:&
M*Q?;=:I<]-R.[3IET!-36UZN7:P6'C"JU!152J 0+P]5>NVV[78*[T[I-KR:
MD30QIC"F5 ]3A&+O>D[;*;YI5(G,;Z4-6:HJQ9-N,_<;@\C+!1&EF/3JP_[4
MLWO]EMUQBO?N2/ZG^C'3LFK"J%(E5 &?H^>(LU]=<^?9<RY\T4HBE60M@_%@
MTWC@MAKM9M_NE$ 'Y\HFVH7+[+Y0,]JV5[P?&(;+#I#JX0&C2OU0I>=V[%[Q
M-G^/.H.5X%BQW6[?=CK%M^-NN&UNFET].&!0J1^H]+M-NU,\"30T>^T6 BO5
MLUW.@NDD&D\#.,:?P]&&P.(]LRY4F'6AV5^5=<%["D/!J[GH/;,NK$\<K-+3
MO+O;=MJ=IE=23_-FH^F6HHUV.FVOWRF^[PMUI"M>@*ZMISDKG:QTKC^4WW(\
MKW"[L##PJ)[.N3\:13\X*L]X\/+PH.DY_6:O\ #W"P8#[LC&2/ 2D<!M-3K=
MMMTN/C^G-+/"=6ROW[?[Q4?.VK+7-3NYJX4'C"J%-Z>7D((_8X/ZBU\/SPX_
MGYR5 C+M1K/EV'VW>%^ 2QV9BX]W.7:SW[/;_<++$_H4^V.,J18Z,,84CC%G
MAU_V+PXEOI2MQ[C0\+WK[16N;GAT7@N'+J_==-UF&0E+3:<42.1V" PF#"8,
M)A4'$^;%9BQA+&$L*<[R8<ILAI7*P4J[T>DU[4Z[A-QDXF0IGI?!L5M.QW::
MA;N:^PW789]*]="!,:;>&--M]#H=NU5\E667J@F>7UCQ:@+%C!>,%_?@Q3_^
M^M>__K,,#) WYIO6YZ;ON53AY90JU+%M(S>(?)&I0I#+T^P[3K=PCU-IJ4+E
M#1D,3ABS5_B=F0^,-<87#"+]GCB-U<T\7M-X!7PT:\:<SJG*#!T;US]Z0I;W
M^]W67G4+F;(W_J\OX*XQ!U_\T+V::2('-^&8H82A9*U=6]J]'IS O?I4.C2]
M;M=K%@YUG8;;*04P#D\!ZGZ)_?&L>,PXG,?1)/#'\(A3?R8^M4ZNKD).]6$<
MV5SU5+O1:[=LM_BZ:B =[)05AA= :+?:Q1LU1)58)T6$PVH,*]6#%2#O]!S'
M:Y;AMBRK\T)90VXWW%;-Z%[8T<H8LFD,<7NNT_?<[E[AB;SE%79[K7ZW>%7*
MHZX+=>K<\FLTOK9^BV0:$0,( \@& *33<'M]82L4?FZ@:+M9"D,YV#;MKNUX
MQ5M-7J-NI'-LVS"L5!)6FOVNW6T6[GX05D*_E"H U[6=OF.[O<+QJD>,S>PQ
MJ1@>,*K4#%56H-'UW%VWUW2ZW;K1Z':;K9Y7O+>VWW#=FJ6@,(TNH\Q&=9<N
MZBZ]XH,RO4:_%#U J"Z]KF>[Q7/EN3*(S+TLJP4'#"HU Y555)?FKMMJ>TZ[
MZJK+LT=6^-1**L=D381!@PLO^:8Q%U[6JO"RY7'A91$7O7^5A9<585/N-%IN
MTVX5W^2S75:33V&&-GM]N^D5;H9V&VZ_9L%]-D-9HZP#R+2]CMUK%GZPNI(&
ML R0Z77:MM,JH>-<GUU=U4,'QIAZTXL)B&EZMM<I/*>FURA-C7$[ A1;Q:<7
MN24% !AB*O 5AIC-,1BV^CV[4T)]EB/#Y\\^L:_&9\Z P8!1O? ;Y/3N]KO=
M^A!*=,1HG6[QU9LU+-_D,!R#QZ;!0_R_;AG]YTHKU"QKR%W*OZX3?G"A)F/(
MQC&DZ?:=5AF%FH5AR*LQ49ACAO%A*3Y\/CG[*A#BXNCD.!V0$7^P+LX.Q5^.
M?Q%+=?SIB+YS\AE"--;AWP_+P(U.L^&Z7;O9+\,2\)J%%#M6#SCV)Y-1./!G
M882'_',X8L\HXPBG#/)--Y<RR%#P6J%@<W5,[6;3;CG%FQQ>6=R2KFNWNJ[=
M+#X+ T(Y/<XAJQXB,*[4#U><<G"E+SF<"D\5$;#2=EJVURWASM1(DV&E8H#
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MKUF>6[3']!'U_,KK@_7?CTY/7IP">WIPT8"G?#L'>&TX;6$V5]X]NN3^OY]
M37*SX4(8JFGME^6F[%(PY_FH6UF%.*>XZ#T71E>X,+K#A='UNHCU$2Z,KKVA
M67(&8;/1:;7M?J^LE ^AC[3K8U7VO/Z+L2K;KF/WNV6MN]!C,:.Q+)<LFY5L
M5M8/Q \$8)P)/?3P#* ;VD(+6(<?-X#LK4:_T[7=TDXH!&A+;5-?%+1W!+0[
MG7:WLRYH%\#NEHF-".Q-N],KRV78HFX2W&"AAE]A<']A&GJ[T>RT;*>TM&D
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MI1-U?3D^#DOOS]#T248N;F_D8KDX;^1BZ36Q=_*EE;\DY9PLY)QW5HDU<^?
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M+NL<%]"Y\^[S[)5P1U0XZF O<!\H&QC25SXG9J# 2IO6HV6&0%!#7.GT^L'
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M,, Q7YQQ'OJBP9UT3^QPQ ?ZO<\D$AAZUW4# $H8$<=J6+L!;A L9^CH(;
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MG++O[>S[O9V3QY(59=_;V?>FS\FML5O%WFI?4Y8K:;C:!@"5ABO9]Y;VO6D
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MB;23/H;O<I.4. ;,*9=B):598T[X3*F!?]7AZ@,O.I:N\&LY.Y<QLYYM&>Q
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M@<5#QC61(=@!F6 Q,9I$;H:1NGDLU\>,I:NGQO,ZE<.2V3R%\B.B=<S#%7J
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MH)A8(H)&2%J$4IE0J8!+</G8:C0ZT=<=MON911=VM;!5)&LF50$<@JHTBR;
M:7%6_<16,^$\L(*!+!?.72F"<9I.2I;^,/]Y< U4!2S\=KHAKY.'+HS%$A=&
M;9T\>R%>+0J8*E'@<I/G6WI"E)6QK4:.[IZ#_F]@YHC7!B9#_X,9Y<5U'+I[
M'\YK0\&O%L%YN#'.PN#3QC@$UA/N!O%5<)T_@RG]L$!*.AR 5?#_8&+/GZGG
MDE=I]V\_TY]GWH?^P>CPEV?;6UM_U\/M@IG:&SR(7^F>J-=B?[<AX0E?G^/U
M?KOU'UN;6UO;: .(%%H@RT<^YS,["W,8'S!L3=2HVB6LX\+#^>RP"$)Q-8F!
M5^.G'U(4'5FDF31)LTFPB HX$_1Z$B'P/[*X@/4CAT4V:P]1#@R^'E0E?#G<
M$'X&B9.<,Y<-0'"FV3EPQ_^C<^BC(.77R#=X2Q[!.@99NT4Z:$",>7.%%^#'
M!]U$5_[4MO$_7FYNO_S97R)U:DR#5@54Q&P*"F-(RCK,&W:+A%-.$KZB@?]U
MEN(H^F<)JL$PB.OK@'.8Q&F.\A F$'COP^P<*+%WB>L LV8B4MJ,I?<JW<H#
M5:JBRB*AHBE(1,^J4\ZB:K&(@=6#TN&S%IWC56D,A@F^?1+D%^K^]T'V*2SP
M4DOVK91Q#[NHC>.SEI?MA(3U%;'NW,7E#<B-8)^'88'[@.J*6!5:66FW,E#$
MHHRMB5UO+5IG$817D7F8L9T"-T:TK4E%&X4- [E*+[ ?1;J<K55M/\?#[7[U
M<FVZKH9D:2(]81J62O+"5DFJ7B_K\IKW1 T:'IX)Z0$)M5NS*%:T"<LB(Y_*
M9%CK9A4A2F88T*#E-MP41Z9T>?O]KV$%[2743-;BL$HA5DI(KMQ6LA)ZV8/"
MNTK+&)7;VK&H&!!UJL"+'+JX@EUDYE)Q@*1HZS)3<TQ]9L>++$HSM=?J2%=)
M E@U[@NZ$;PD$&W*(D$E!O"!-YH1-UX MG"V >_=F*1E0OH@61K*X)C3$:+M
M;[=@.]1^6 J\RYU(E-EKY3<L,>]$DA:\&WD!_!^%'/'T13D&!@3<YL:Q9_!%
M&"/MJ>%:QY)W7LE_H1-A7 ZML!-P!7VT6S4"J<V2**+)([:,(. A:!*N(HSF
MU83M#Q>:80"?Q+?3^)&STPUJ1<D+_%EV+,A@#)J3\^F;A2@J8M(4"M3NK26)
M@ZL<-*6LC/E\9>%Y&;/KA;G!VK4\>9K"%;B9-!A<P>L4#VGTV5O[4:X!S::X
MR(VMO&J.WIK,D6WM:WL^.;$N_*:,B9\YRZUW&R93\J6)UYDA?\+9V88PK/\
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M]D5YU5?DF-[$.7WR<R!CG!62)UI)F/3!ZG2,<+SZ2@3TK,Q(*JKTE$1[?;3
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M-JA\V_+#/4R6!L*%:^6TF )3#06HUJSR^4&AT5L6SLTD_5I%&)OZ/]3*WA%
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M&=X;A^<!2"]2#EG#$.-8)W-J5Y,N01YB6XE)J*,U%7@(9:IA!K-Q3ZJ.5!I
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MS99++^4UD4".0D?J5^"#4#)(/N=E!./!!EB,Z6&%R(5VFIQH#>J!U>=0C+K
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M%;&E-[]7:M:+ (.I2]-S4DXGZ7E"6=CDV::$;E2E(C3[V=:E\TY3QD>JK>-
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MZ"'%@GK_N^)/K=K=-_&4?5N/E^5*J[K<JBXYFS 5_R,2]G[QEG% S=/DYA=
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M?U5:&HL"<K$<[OQQ@V/G.ZY8_^-J ,Z;'_9/#C["EX>C]T=[_Q]02P,$%
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MQ8P,$V$S*];;CRS"*CB-24.^P#@'S- ",U@!$Z(OL>F\-O8 ]9;5'J#K%JX
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MD<FF.HQ\(KH\W$Z-3+29L](9YA8U,E**20N-**(!]/>X>Q@JA)?8)7#&[32
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M=LEE=%"7.SQ@'V'>G+'_[ .Y>.1O4$L! A0#%     @ [X W6#T;77%^'
M:Z<   X              ( !     &0W,34Q-#9D.&LN:'1M4$L! A0#%
M  @ [X W6!D? K$:DP$ F4\. !$              ( !JAP  &0W,34Q-#9D
M97@Q,#$N:'1M4$L! A0#%     @ [X W6&/9"5$%/P  344! !
M     ( !\Z\! &0W,34Q-#9D97@T,2YH=&U02P$"% ,4    " #O@#=8-@@"
MB7T.  #Y+   $0              @ $F[P$ 9#<Q-3$T-F1E>#DY,2YH=&U0
M2P$"% ,4    " #O@#=8%FS+3#P#  !;"P  $0              @ '2_0$
M<V=H="TR,#(T,#$R,BYX<V102P$"% ,4    " #O@#=83=;"DJ@&  "D20
M%0              @ $] 0( <V=H="TR,#(T,#$R,E]L86(N>&UL4$L! A0#
M%     @ [X W6'X..+O9!   "2X  !4              ( !& @" '-G:'0M
F,C R-# Q,C)?<')E+GAM;%!+!08     !P ' +T!   D#0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
